UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 20-F/A

(Amendment No.1)

 

(Mark One)

REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2023

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 

SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of event requiring this shell company report

 

For the transition period from                       to

 

Commission file number 001-41773

 

Adlai Nortye Ltd.
(Exact name of Registrant as specified in its charter)
 
Cayman Islands
(Jurisdiction of incorporation or organization)
 

c/o PO Box 309, Ugland House

Grand Cayman, KY1-1104

Cayman Islands

(Address of principal executive offices)
 

Yang Lu, Chief Executive Officer

Building 6 & 8, 1008 Xiangwang Street 

Yuhang District, Hangzhou 

Zhejiang Province, 311121 

The People’s Republic of China
Tel: +86-0571-2891-8385
 

Email: ir@adlainortye.com

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

 

Securities registered or to be registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
American Depositary Shares, each representing
three Class A Ordinary Shares, par value $0.0001 per share
  ANL   The Nasdaq Stock Market LLC
(The Nasdaq Global Market)

 

Securities registered or to be registered pursuant to Section 12(g) of the Act: None

 

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None

 

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report: 110,700,805 ordinary shares, consisting of 93,710,805 Class A ordinary shares, par value US$0.0001 per share, and 16,990,000 Class B ordinary shares, par value US$0.0001 per share, as of December 31, 2023.

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

☐ Yes ☒ No

 

 

 

 

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

☐ Yes ☒ No

 

Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐   Accelerated filer ☐   Non-accelerated filer Emerging growth company

 

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act.

 

The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

 

U.S. GAAP ☐   International Financial Reporting Standards as issued
by the International Accounting Standards Board
  Other ☐

 

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

☐ Item 17 ☐ Item 18

 

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).

☐ Yes No

 

(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)

 

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

☐ Yes ☐ No

 

Auditor Name   Auditor Location   Auditor Firm ID
Mazars USA LLP   New York, USA   339

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Amendment No. 1 to Form 20-F (the “Form 20-F/A”) amends our annual report on Form 20-F for the year ended December 31, 2023 (the “Original Form 20-F”), which was originally filed with the U.S. Securities and Exchange Commission on April 19, 2024. The purpose of this Form 20-F/A is to include in the Original Form 20-F (1) the Report of Independent Registered Public Accounting Firm (the “Auditor's Report”) dated April 13, 2023 in connection with the Company’s consolidated statements of operations and comprehensive loss, changes in shareholders’ equity and cash flows for the year ended December 31, 2021, and (2) the Company’s accompanying consolidated statements of operations and comprehensive loss, changes in shareholders’ equity and cash flows for the year ended December 31, 2021 and the related notes. This Form 20-F/A does not reflect events occurring after the filing of the Original Form 20-F and does not modify or update the disclosure therein in any way except as described above. No other changes have been made to the Original Form 20-F. The filing of this Form 20-F/A should not be understood to mean that any statements contained in the Original Form 20-F, as amended by this Form 20-F/A, are true or complete as of any date subsequent to the original filing date of the Original Form 20-F. Accordingly, this Form 20-F/A should be read in conjunction with the Original Form 20-F.

 

In addition, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is including new certifications by the Company’s principal executive officer and principal financial officer as exhibits to this Form 20-F/A pursuant to Rule 13a-14(a) of the Exchange Act.

 

 

 

 

PART I

 

ITEM 8. FINANCIAL INFORMATION

 

A. Consolidated Statements and Other Financial Information

 

See “Item 18. Financial Statements.”

 

Legal Proceedings

 

We may be subject to legal proceedings, investigations, and claims arising from the ordinary course of our business from time to time, and we may also initiate legal proceedings in order to protect our intellectual property and other rights. Currently, we are not a party to any actual or threatened legal or administrative proceedings which would have a material and adverse impact on our business, financial condition, or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

 

Dividend Policy

 

Our board of directors has discretion as to whether and when to distribute dividends, subject to certain requirements of Cayman Islands law. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. Under Cayman Islands law, a Cayman Islands exempted company may pay a dividend out of either profit, retained earnings or share premium, provided that in no circumstances may a dividend be paid if that would result in the company being unable to pay its debts as they fall due in the ordinary course of business. Even if our board of directors decides to pay dividends, the form, frequency, and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions, and other factors that the Board may deem relevant.

 

We are a holding company incorporated in the Cayman Islands. For our cash requirements, including any payment of dividends to our shareholders, we rely upon payments from our operating entities. PRC regulations may restrict the ability of our PRC subsidiaries to pay dividends to us. See “Item 4. Information on the Company—B. Business Overview—Regulation— Regulations relating to foreign exchange control.” and “Item 4. Information on the Company—B. Business Overview—Regulation— PRC laws and regulations — Regulations relating to dividend distribution.”

 

If we pay any dividends on our ordinary shares, we will pay those dividends which are payable in respect of the Class A ordinary shares underlying the ADSs to the depositary, as the registered holder of such Class A ordinary shares, and the depositary then will pay such amounts to the ADS holders in proportion to the Class A ordinary shares underlying the ADSs held by such ADS holders, subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. Cash dividends on our ordinary shares, if any, will be paid in U.S. Dollars.

 

B. Significant Changes

 

Except as disclosed elsewhere in this annual report, we have not experienced any significant changes since the date of our audited consolidated financial statements included in this annual report.

 

1

 

 

PART III

 

ITEM 17. FINANCIAL STATEMENTS

 

We have elected to provide financial statements pursuant to Item 18.

 

ITEM 18.   FINANCIAL STATEMENTS

 

The consolidated financial statements and the related notes required by Item 18 are included in this annual report, beginning on page F-1. The reports of Mazars USA LLP, the Company’s independent registered accounting firm with respect to the referenced financial statements, are included on pages F-2 and F-3.

 

ITEM 19. EXHIBITS

 

Exhibit    
Number   Description of Document
     
12.1   Principal Executive Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
12.2   Principal Financial Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
13.1   Principal Executive Officer Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
13.2   Principal Financial Officer Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS   XBRL Instance Document
     
101.SCH   XBRL Taxonomy Extension Schema Document
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   XBRL Taxonomy Extension Definitions Linkbase Document
     
101.LAB   XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

2

 

 

SIGNATURES

 

The registrant hereby certifies that it meets all of the requirements for filing on this Form 20-F/A and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

 

  Adlai Nortye Ltd.
     
  By: /s/ Yang Lu
    Name: Yang Lu
    Title: Chief Executive Officer
       
Date: February 14, 2025    

 

3

 

 

ADLAI NORTYE LTD.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

    Page
Report of Independent Registered Public Accounting Firm (Mazars USA LLP, New York, NY, PCAOB ID: 339)   F-2
Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2021, 2022 and 2023   F-4
Consolidated Statements of Financial Position as of December 31, 2022 and 2023   F-5
Consolidated Statements of Changes in Shareholders’ Equity for the Years Ended December 31, 2021, 2022 and 2023   F-6
Consolidated Statements of Cash Flows for the Years Ended December 31, 2021, 2022 and 2023   F-7
Notes to the Consolidated Financial Statements for the Years Ended December 31, 2021, 2022 and 2023   F-8

 

F-1

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and
Shareholders of Adlai Nortye Ltd.

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated statements of financial position of Adlai Nortye Ltd. (the “Company”) as of December 31, 2022 and 2023, and the related consolidated statements of operations and comprehensive loss, changes in shareholders’ equity, and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”).

 

In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2022 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with International Financial Reporting Standards (IFRS) and its related interpretations as issued by the International Accounting Standards Board.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

/s/ Mazars USA LLP

 

We have served as the Company’s auditor since 2022. 

 

New York, New York 

April 19, 2024

F-2

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated statements of operations and comprehensive loss, changes in shareholders’ equity and cash flows of Adlai Nortye Ltd. (the “Company”), for the year ended December 31, 2021, and the related notes (collectively referred to as the “financial statement”). In our opinion, the consolidated financial statement presents fairly, in all material respects, the results of its operations and its cash flow for the year ended December 31, 2021, in conformity with International Financial Reporting Standards (IFRS) and its related interpretations as issued by the International Accounting Standards Board.

 

Basis for Opinion

 

This financial statement is the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement is free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statement, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

/s/ Mazars USA LLP

 

We have served as the Company’s auditor since 2022. 

 

New York, New York 

April 13, 2023

 

F-3

 

 

ADLAI NORTYE LTD.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE

LOSS FOR THE YEARS ENDED DECEMBER 31, 2021, 2022 AND 2023

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

      Year ended December 31, 
   Notes  2021   2022   2023 
      $’000   $’000   $’000 
REVENUE  4   45,726    
    5,000 
Other operating income, net      183    259    890 
Administrative expenses      (12,450)   (13,039)   (15,289)
Research and development expenses      (42,105)   (54,490)   (58,152)
Total operating loss      (8,646)   (67,270)   (67,551)
Other income and gains      213    2,079    3,303 
Other expenses      (70)   (1,395)   (80)
Investment income      32    550    62 
Fair value gain on financial assets at fair value through profit or loss (“FVTPL”)      40    484    
 
Fair value (loss)/gain on financial liabilities at FVTPL  16   (46,910)   7,195    (39,171)
Finance costs  5   (1,337)   (433)   (791)
LOSS BEFORE TAX      (56,678)   (58,790)   (104,228)
Income tax expense  6   
    
    (643)
LOSS FOR THE YEAR      (56,678)   (58,790)   (104,871)
Attributable to:                  
Ordinary Equity Holders of the Parent      (56,678)   (58,790)   (104,871)
OTHER COMPREHENSIVE LOSS                  
Exchange differences on translation of the financial statements of subsidiaries      (94)   (3,157)   (82)
Other comprehensive loss for the year, net of tax      (94)   (3,157)   (82)
TOTAL COMPREHENSIVE LOSS FOR THE YEAR      (56,772)   (61,947)   (104,953)
Attributable to:                  
Ordinary Equity Holders of the Parent      (56,772)   (61,947)   (104,953)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT                  
Basic and diluted                  
Loss for the year ($ per share)  8   (2.23)   (2.31)   (2.42)
Weighted average common shares outstanding  8   25,440,000    25,440,000    43,342,068 

 

The accompanying notes are an integral part of the Consolidated Financial Statements

 

F-4

 

 

ADLAI NORTYE LTD.

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

AS OF DECEMBER 31, 2022 AND 2023

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

      Year ended December 31, 
   Notes  2022   2023 
      $’000   $’000 
ASSETS           
Current assets           
Cash and cash equivalents      42,758    91,492 
Financial assets at FVTPL  12   21,287    7 
Prepayments, other receivables and other assets  11   2,258    2,696 
Short-term investments at amortized cost  13   
    7,000 
Total current assets      66,303    101,195 
Non-current assets             
Property, plant and equipment  9   3,713    2,646 
Right-of-use assets  10(a)   2,162    1,154 
Other intangible assets      89    63 
Prepayments, other receivables and other assets  11   327    282 
Long-term investments at amortized cost  13   
    24,849 
Total non-current assets      6,291    28,994 
Total assets      72,594    130,189 
LIABILITIES             
Current liabilities             
Trade payables      13,098    14,348 
Other payables and accruals  14   3,877    4,890 
Interest-bearing bank borrowings  15   4,307    30,357 
Lease liabilities  10(b)   1,001    722 
Financial liabilities at FVTPL  16   290,368    
 
Total current liabilities      312,651    50,317 
Non-current liabilities             
Lease liabilities  10(b)   1,236    469 
Total non-current liabilities      1,236    469 
Total liabilities      313,887    50,786 
SHAREHOLDERS’ (DEFICIT)/ EQUITY             
Ordinary shares (par value of $0.0001 per share; 442,456,586 shares authorized; 40,440,000 shares issued and outstanding as of December 31, 2022; and nil outstanding as of December 31, 2023)
  17   4    
 
Class A Ordinary shares (par value of $0.0001 per share; nil outstanding as of December 31,2022; and 93,710,805 shares outstanding as of December 31, 2023)  17        9 
Class B Ordinary shares (par value of $0.0001 per share; nil outstanding as of December 31,2022; and 16,990,000 shares outstanding as of December 31, 2023)  17        2 
Series A convertible preferred shares (par value of US$0.0001 per share; 14,560,000 and nil shares authorized, issued and outstanding as of December 31, 2022 and 2023, respectively)      10,980    
 
Additional paid-in capital  18   6,415    438,707 
Share option reserve  18   13,688    18,018 
Exchange fluctuation reserve  18   (4,159)   (4,241)
Accumulated deficit  18   (268,221)   (373,092)
Total shareholders’ (deficit)/equity      (241,293)   79,403 
Total liabilities and shareholders’ (deficit)/equity      72,594    130,189 

 

The accompanying notes are an integral part of the Consolidated Financial Statements

 

F-5

 

 

ADLAI NORTYE LTD.

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

FOR THE YEARS ENDED DECEMBER 31, 2021, 2022 AND 2023

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

   Attributable to owners of the parent 
           Series A                 
       Additional   convertible   Share   Exchange         
   Ordinary   paid-in   preferred   option   fluctuation   Accumulated   Total 
   Shares   capital   shares   reserve   reserve   losses   deficits 
   $’000   $’000   $’000   $’000   $’000   $’000   $’000 
   (note 17)   (note 18)       (note 18)   (note 18)         
At January 1, 2021   3    6,416    10,980    4,220    (908)   (152,753)   (132,042)
Loss for the year       
    
    
    
    (56,678)   (56,678)
Other comprehensive income for the year:                                   
Exchange differences on translation of the financial statements of subsidiaries   
    
    
    
    (94)       (94)
Issuance of shares for the trust arrangement under the Share Incentive Plan   1    (1)   
    
    
         
Share-based compensation   
    
    
    3,386    
        3,386 
At December 31, 2021   4    6,415    10,980    7,606    (1,002)   (209,431)   (185,428)
At January 1, 2022   4    6,415    10,980    7,606    (1,002)   (209,431)   (185,428)
Loss for the year       
    
    
    
    (58,790)   (58,790)
Other comprehensive income for the year:                                   
Exchange differences on translation of the financial statements of subsidiaries   
    
    
    
    (3,157)       (3,157)
Share-based compensation   
    
    
    6,082    
        6,082 
At December 31, 2022   4    6,415    10,980    13,688    (4,159)   (268,221)   (241,293)
At January 1, 2023   4    6,415    10,980    13,688    (4,159)   (268,221)   (241,293)
Loss for the year       
    
    
    
    (104,871)   (104,871)
Other comprehensive income for the year                                   
Exchange differences on translation of the financial statements of subsidiaries   
    
    
    
    (82)       (82)
Issuance of ordinary shares   1    91,779    
    
    
        91,780 
Conversion of Financial liabilities at FVTPL   5    329,534         
    
        329,539 
Conversion of Series A convertible preferred shares   1    10,979    (10,980)                   
Share-based compensation   
    
    
    4,330    
        4,330 
At December 31, 2023   11    438,707    
    18,018    (4,241)   (373,092)   79,403 

 

The accompanying notes are an integral part of the Consolidated Financial Statements

 

F-6

 

 

ADLAI NORTYE LTD.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED DECEMBER 31, 2021, 2022 AND 2023

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

       Year ended December 31, 
   Notes   2021   2022   2023 
       $’000   $’000   $’000 
CASH FLOWS FROM OPERATING ACTIVITIES                
Net Loss   5    (56,678)   (58,790)   (104,871)
Adjustments for:                    
Finance costs        1,337    433    791 
Investment income        (32)   (550)   (62)
Fair value (gain)/loss on financial liabilities at FVTPL   16    46,910    (7,195)   39,171 
Fair value gain on financial assets at FVTPL        (40)   (484)   
 
Loss/(gain) on disposal of items of property, plant and equipment        5    (7)   
 
Depreciation of property, plant and equipment   9    861    931    1,213 
Amortization of intangible assets        16    20    25 
Depreciation of right-of-use assets   10(a)    951    1,090    984 
Equity-settled share-based payment expenses   19    3,386    6,082    4,330 
(Increase)/Decrease in prepayments, other receivables and other assets        (419)   4,346    (436)
(Increase)/Decrease in non-current assets        (157)   128    45 
Increase in current assets        (390)   
    
 
Increase in trade payables        600    10,117    1,252 
Increase in other payables and accruals        619    656    906 
Decrease in advances from customers        (3)   
    
 
Net cash flows used in operating activities        (3,034)   (43,223)   (56,652)
CASH FLOWS FROM INVESTING ACTIVITIES                    
Purchases of property, plant and equipment        (1,018)   (1,249)   (200)
Purchases of intangible assets        (102)   (19)   
 
Proceeds from disposal of items of property, plant and equipment        
    17    1 
Purchases of financial assets at FVTPL        (81,234)   (58,980)   (7)
Disposal of financial assets at FVTPL        27,465    88,057    21,039 
Purchases of investments at amortized cost        
    
    (31,849)
Received investment income of financial assets at FVTPL        32    550    62 
Net cash flows provided/(used in) from investing activities        (54,857)   28,376    (10,954)
CASH FLOWS FROM FINANCING ACTIVITIES                    
Proceeds from issuance of ordinary shares        97,370    
    91,780 
Addition of bank borrowings        12,411    7,897    50,234 
Bank borrowings interest paid        (427)   (292)   (602)
Repayment of bank borrowings        (10,430)   (13,315)   (24,069)
Transaction costs for issuance of convertible redeemable preferred shares        (758)          
Payment for lease liabilities        (966)   (1,070)   (1,103)
Net cash flows (used in)/from financing activities        97,200    (6,780)   116,240 
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS        39,309    (21,627)   48,634 
Cash and cash equivalents at beginning of year        24,261    64,131    42,758 
Effect of foreign exchange rate changes, net        561    254    100 
CASH AND CASH EQUIVALENTS AT END OF YEAR        64,131    42,758    91,492 

 

The accompanying notes are an integral part of the Consolidated Financial Statements

 

F-7

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

1.CORPORATE AND GROUP INFORMATION

 

Adlai Nortye Ltd. (the “Company”) is a limited liability company incorporated in the Cayman Islands on 9 May 2018. The registered office of the Company is located at Harneys Fiduciary (Cayman) Limited, 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman, KY1-1002, Cayman Islands.

 

The Company is an investing holding company. The Company’s subsidiaries were involved in the research and development of pharmaceutical products.

 

As of the date of this report, the Company had direct and indirect interests in its subsidiaries, all of which are private limited liability companies, the particulars of which are set out below:

 

            Percentage   
            of equity   
      Date and place of  Issued ordinary  attributable to   
      incorporation / registration  share/  the Company   
Name  Notes  and place of operations  registered capital  Direct  Indirect  Principal activities
Alpine Bioscience Ltd. (“Alpine BVI”)     British Virgin Islands 8 January 2018  One share of par value $1  100%    Investment holding
Adlai Nortye USA Inc (“Adlai US”)     The United States 30 January 2018  10,000 shares of par value $0.0001 each    100%  Clinical studies and testing, and technology development and transfer
Adlai Nortye (Switzerland) AG (“Adlai Swiss”)     Switzerland 21 June 2022  100 shares of par value CHF1’000 each    100%  Investment holding
Adlai Nortye PTE.LTD (“Adlai SGP”)     Singapore 22 April 2022  Two shars of par value $1    100%  Investment holding
Adlai Nortye (HK) Limited (“Adlai HK”)     Hong Kong 24 April 2018  HKD 0.001    100%  Investment holding

Hangzhou Adlai Nortye Biopharma Co., Ltd* (“Adlai Hangzhou”)

     the People’s Republic of China (“PRC”)/Mainland China 14 September 2004  RMB 200,000    100%  Product research and development, technology transfer and consulting services business

Shanghai Adlai Nortye Biopharma Co., Ltd* (“Adlai Shanghai”)

     the People’s Republic of China (“PRC”)/Mainland China 22 December 2021  RMB 10,000    100%  Product research and development, technology transfer and consulting services business

Hangzhou Tangchuang Weilai Technolegy Co., Ltd (“Hangzhou Tangchuang”)

     the People’s Republic of China (“PRC”)/Mainland China 2 November 2022  RMB 10,000    100%  Product research and development, technology transfer and consulting services business

 

 

*The English name of the subsidiary registered in the PRC represents the best efforts made by management of the Company to translate its Chinese name as the subsidiary does not have an official English name.

 

F-8

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.1BASIS OF PRESENTATION

 

The consolidated financial statements of the Group include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.

 

2.2BASIS OF PREPARATION

 

As of December 31, 2023, the Group’s balance of cash and cash equivalents was $91,492 and short-term investments of $7,000 and the Group had net current assets of $50,878. Management has evaluated the sufficiency of its working capital and concluded that the Group’s available cash and cash equivalents and short-term investments will be sufficient to support its continuous operations and to meet its payment obligations when liabilities fall due within the next twelve months from the date of issuance of these consolidated financial statements. Accordingly, management continues to prepare the Group’s consolidated financial statements on going concern basis.

 

The Consolidated Financial Statements have been prepared in accordance with International Financial Reporting Standards (“IFRSs”), which comprise all standards and interpretations approved by the International Accounting Standards Board (the “IASB”). All IFRSs effective for the accounting period commencing from January 1, 2020, together with the relevant transitional provisions, have been early adopted by the Group in the preparation of the Consolidated Financial Statements throughout the Relevant Periods and in the period covered by the Interim Comparative Financial Information.

 

Recently issued accounting pronouncements:

 

In 2016, the IASB issued IFRS 16, which increases lease transparency and comparability among organizations. Under the new standard, lessees will be required to recognize all assets and liabilities arising from leases on the balance sheet, with the exception of leases with a term of 12 months or less, which permits a lessee to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. IFRS 16 is effective for fiscal years beginning after January 1, 2019. The Company adopted the new lease accounting standard as of January 1, 2019. Adoption of this update increased the amounts of total assets and total liabilities on the Company’s consolidated financial position, and did not have a material impact on the Company’s consolidated results of operations and cash flows.

 

The Consolidated Financial Statements have been prepared under the historical cost convention except for certain financial liabilities which have been measured at fair value at the end of each of the Relevant Periods.

 

2.3ISSUED BUT NOT YET EFFECTIVE IFRSs

 

The Group has not applied the following new and revised IFRSs that have been issued but are not yet effective in the Consolidated Financial Statements.

 

      Effective for
accounting year
beginning on or after
Amendments to IAS 1  Classification of Liabilities as current and non-current  January 1, 2024
Amendments to IFRS 16  Lease Liability in a Sale and Leaseback  January 1, 2024
Amendments to IAS 1  Non-current Liabilities with Covenants  January 1, 2024
Amendments to IAS 28 and IFRS 10  Sale or contribution of assets between an investor and its associate or joint venture  To be determined

 

The Group is in the process of making an assessment of the impact of these new and revised IFRSs upon initial application. So far, the Group expects that these standards will not have a significant effect on the Group’s financial performance and financial position.

 

F-9

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Subsidiaries

 

A subsidiary is an entity (including a structured entity), directly or indirectly, controlled by the Company. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee (i.e., existing rights that give the Group the current ability to direct the relevant activities of the investee). When the Company has, directly or indirectly, less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

 

(a)contractual arrangements with other vote holders of the investee;

 

(b)rights arising from other contractual arrangements; and

 

(c)the Group’s voting rights and potential voting rights.

 

The financial statements of subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. The results of subsidiaries are consolidated from the date on which the Group obtains control, and continue to be consolidated until the date that such control ceases.

 

Profit or loss and each component of other comprehensive income are attributed to the owners of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

 

Fair value measurement

 

The Group measures certain financial instruments at fair value at the end of each of the Relevant Periods. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability, or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or most advantageous market must be accessible by the Group. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

 

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

 

F-10

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

All assets and liabilities for which fair value is measured or disclosed in the Consolidated Financial Statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

 

Level 1 based on quoted prices (unadjusted) in active markets for identical assets or liabilities

 

Level 2 based on valuation techniques for which the lowest level input that is significant to the fair value measurement is observable, either directly or indirectly

 

Level 3 based on valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

 

For assets and liabilities that are recognized in the Consolidated Financial Statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each of the Relevant Periods.

 

Impairment of non-financial assets

 

Where an indication of impairment exists, or when annual impairment testing for an asset is required (other than financial assets), the asset’s recoverable amount is estimated. An asset’s recoverable amount is the higher of the asset or cash-generating unit’s value in use and its fair value less cost of disposal, and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case the recoverable amount is determined for the cash-generating unit to which the asset belongs.

 

An impairment loss is recognized only if the carrying amount of an asset exceeds its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An impairment loss is charged to profit or loss in the period in which it arises in those expense categories consistent with the function of the impaired asset.

 

An assessment is made at the end of each of the Relevant Periods as to whether there is an indication that previously recognized impairment losses may no longer exist or may have decreased. If such an indication exists, the recoverable amount is estimated. A previously recognized impairment loss of an asset other than goodwill is reversed only if there has been a change in the estimates used to determine the recoverable amount of that asset, but not to an amount higher than the carrying amount that would have been determined (net of any depreciation/amortization) had no impairment loss been recognized for the asset in prior years. A reversal of such an impairment loss is credited to profit or loss in the period in which it arises.

 

Related parties

 

A party is considered to be related to the Group if:

 

(a)the party is a person or a close member of that person’s family and that person

 

(i)has control or joint control over the Group;

 

(ii)has significant influence over the Group; or

 

(iii)is a member of the key management personnel of the Group or of a parent of the Group;

 

or

 

F-11

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

(b)the party is an entity where any of the following conditions applies:

 

(i)the entity and the Group are members of the same group;

 

(ii)one entity is an associate or joint venture of the other entity (or of a parent, subsidiary or fellow subsidiary of the other entity);

 

(iii)the entity and the Group are joint ventures of the same third party;

 

(iv)one entity is a joint venture of a third entity and the other entity is an associate of the third entity;

 

(v)the entity is a post-employment benefit plan for the benefit of employees of either the Group or an entity related to the Group; and the sponsoring employers of the post-employment benefit plan;

 

(vi)the entity is controlled or jointly controlled by a person identified in(a);

 

(vii)a person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity); and

 

(viii)the entity, or any member of a group of which it is a part, provides key management personnel services to the Group or to the parent of the Group.

 

Property, plant and equipment and depreciation

 

Property, plant and equipment, other than construction in progress, are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property, plant and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.

 

Expenditure incurred after items of property, plant and equipment have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalized in the carrying amount of the asset as a replacement. Where significant parts of property, plant and equipment are required to be replaced at intervals, the Group recognizes such parts as individual assets with specific useful lives and depreciates them accordingly.

 

Depreciation is calculated on the straight-line basis to write off the cost of each item of property, plant and equipment to its residual value over its estimated useful life. The principal annual rates used for this purpose are as follows:

 

Plant and machinery   10% to 19%
Office equipment   19% to 20%
Motor vehicles   19%
Electronic equipment   19% to 20%
Leasehold improvements   The shorter of remaining lease terms or estimated useful lives

 

Where parts of an item of property, plant and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately. Residual values, useful lives and the depreciation method are reviewed, and adjusted if appropriate, at least at the end of each of the Relevant Periods.

 

F-12

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

An item of property, plant and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on disposal or retirement recognized in the statement of profit or loss and other comprehensive income in the year the asset is derecognized is the difference between the net sales proceeds and the carrying amount of the relevant asset.

 

Construction in progress is reclassified to the appropriate category of property, plant and equipment when completed and ready for use.

 

Other intangible assets (other than goodwill)

 

Other intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is the fair value at the date of acquisition. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are subsequently amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least at the end of each of the Relevant Periods.

 

Computer software

 

Computer software is stated at cost less any impairment losses and amortized on a straight-line basis over its estimated useful life of 5 years.

 

The estimated useful life of software is determined by considering the period of the economic benefits to the Group, as well as by referring to industry practice.

 

Research and development costs

 

All research costs are charged to expense as incurred.

 

Expenditure incurred on projects to develop new products is capitalized and deferred only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the project and the Group’s ability to measure reliably the expenditure during the development. Product development expenditure which does not meet these criteria is expensed when incurred.

 

Leases

 

The Group assesses at contract inception whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

 

Group as a lessee

 

The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

 

F-13

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

(a)Right-of-use assets

 

Right-of-use assets are recognized at the commencement date of the lease (the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and any impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease terms and the estimated useful lives of the assets as follows:

 

Offices  2 to 5 years
Office equipment  2 to 5 years

 

If ownership of the leased asset transfers to the Group by the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset.

 

(b)Lease liabilities

 

Lease liabilities are recognized at the commencement date of the lease at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for termination of a lease, if the lease term reflects the Group exercising the option to terminate the lease. Variable lease payments that do not depend on an index or a rate are recognized as an expense in the period in which the event or condition that triggers the payment occurs.

 

In calculating the present value of lease payments, the Group uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in lease payments (e.g., a change to future lease payments resulting from a change in an index or rate) or a change in assessment of an option to purchase the underlying asset.

 

(c)Short-term leases and leases of low-value assets

 

The Group applies the short-term lease recognition exemption to its short-term leases of office equipment (that is those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the recognition exemption for leases of low-value assets to leases of office equipment that are considered to be of low value.

 

Lease payments on short-term leases and leases of low-value assets are recognized as an expense on a straight-line basis over the lease term.

 

Financial assets

 

Initial recognition and measurement

 

Financial assets are classified, at initial recognition, as subsequently measured at amortized cost, fair value through other comprehensive income, and fair value through profit or loss.

 

F-14

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and the Group’s business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient of not adjusting the effect of a significant financing component, the Group initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs.

 

In order for a financial asset to be classified and measured at amortized cost or fair value through other comprehensive income, it needs to give rise to cash flows that are solely payments of principal and interest (“SPPI”) on the principal amount outstanding. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss, irrespective of the business model.

 

The Group’s business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Financial assets classified and measured at amortized cost are held within a business model with the objective to hold financial assets in order to collect contractual cash flows, while financial assets classified and measured at fair value through other comprehensive income are held within a business model with the objective of both holding to collect contractual cash flows and selling. Financial assets which are not held within the aforementioned business models are classified and measured at fair value through profit or loss.

 

All regular way purchases and sales of financial assets are recognized on the trade date, that is, the date that the Group commits to purchase or sell the asset. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the period generally established by regulation or convention in the marketplace.

 

Subsequent measurement

 

The subsequent measurement of financial assets depends on their classification as follows:

 

Financial assets at amortized cost (debt instruments)

 

Financial assets at amortized cost are subsequently measured using the effective interest method and are subject to impairment. Gains and losses are recognized in the statement of profit or loss and other comprehensive income when the asset is derecognized, modified or impaired.

 

Financial assets at fair value through profit or loss

 

Financial assets at fair value through profit or loss are carried in the statement of financial position at fair value with net changes in fair value recognized in the statement of profit or loss and other comprehensive income.

 

This category includes derivative instruments and equity investments which the Group has not irrevocably elected to classify at fair value through other comprehensive income. Dividends on equity investments classified as financial assets at fair value through profit or loss are also recognized as other income in the statement of profit or loss and other comprehensive income when the right of payment has been established, it is probable that the economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably.

 

F-15

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

A derivative embedded in a hybrid contract, with a financial liability or non-financial host, is separated from the host and accounted for as a separate derivative if the economic characteristics and risks are not closely related to the host; a separate instrument with the same terms as the embedded derivative would meet the definition of a derivative; and the hybrid contract is not measured at fair value through profit or loss. Embedded derivatives are measured at fair value with changes in fair value recognized in the statement of profit or loss and other comprehensive income. Reassessment only occurs if there is either a change in the terms of the contract that significantly modifies the cash flows that would otherwise be required or a reclassification of a financial asset out of the fair value through profit or loss category.

 

A derivative embedded within a hybrid contract containing a financial asset host is not accounted for separately. The financial asset host together with the embedded derivative is required to be classified in its entirety as a financial asset at fair value through profit or loss.

 

Derecognition of financial assets

 

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Group’s consolidated statement of financial position) when:

 

the rights to receive cash flows from the asset have expired; or

 

the Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a “pass-through” arrangement; and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

 

When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if, and to what extent, it has retained the risk and rewards of ownership of the asset. When it has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the Group continues to recognize the transferred asset to the extent of the Group’s continuing involvement. In that case, the Group also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

 

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Group could be required to repay.

 

Impairment of financial assets

 

The Group recognizes an allowance for expected credit losses (“ECLs”) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

 

General approach

 

ECLs are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12 months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

 

F-16

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

At the end of each of the Relevant Periods, the Group assesses whether the credit risk on a financial instrument has increased significantly since initial recognition. When making the assessment, the Group compares the risk of a default occurring on the financial instrument as of the reporting date with the risk of a default occurring on the financial instrument as of the date of initial recognition and considers reasonable and supportable information that is available without undue cost or effort, including historical and forward-looking information.

 

The Group considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Group may also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

 

Financial assets at amortized cost are subject to impairment under the general approach and they are classified within the following stages for measurement of ECLs except for trade receivables and contract assets which apply the simplified approach as detailed below.

 

Stage 1 Financial instruments for which credit risk has not increased significantly since initial recognition and for which the loss allowance is measured at an amount equal to 12-month ECLs
     
Stage 2  — Financial instruments for which credit risk has increased significantly since initial recognition but that are not credit-impaired financial assets and for which the loss allowance is measured at an amount equal to lifetime ECLs
     
Stage 3  — Financial assets that are credit-impaired at the reporting date (but that are not purchased or originated credit-impaired) and for which the loss allowance is measured at an amount equal to lifetime ECLs

 

Simplified approach

 

For trade receivables that do not contain a significant financing component or when the Group applies the practical expedient of not adjusting the effect of a significant financing component, the Group applies the simplified approach in calculating ECLs. Under the simplified approach, the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at the end of each of the Relevant Periods.

 

Financial liabilities

 

Initial recognition and measurement

 

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, as appropriate.

 

All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

 

The Group’s financial liabilities include trade and other payables, derivative financial instruments, interest-bearing bank and other borrowings and certain financial instruments designated at FVTPL.

 

F-17

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Subsequent measurement

 

The subsequent measurement of financial liabilities depends on their classification as follows:

 

Financial liabilities at fair value through profit or loss

 

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss.

 

Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Group that are not designated as hedging instruments in hedge relationships as defined by IFRS 9. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments. Gains or losses on liabilities held for trading are recognized in the statement of profit or loss. The net fair value gain or loss recognized in the statement of profit or loss does not include any interest charged on these financial liabilities.

 

Financial liabilities designated upon initial recognition as at fair value through profit or loss are designated at the initial date of recognition, and only if the criteria in IFRS 9 are satisfied. Gains or losses on liabilities designated at fair value through profit or loss are recognized in the statement of profit or loss, except for the gains or losses arising from the Group’s own credit risk which are presented in other comprehensive income with no subsequent reclassification to the statement of profit or loss. The net fair value gain or loss recognized in the statement of profit or loss does not include any interest charged on these financial liabilities.

 

The company assessed the contract characteristics of each series of convertible redeemable preferred shares to determine whether they should be classified as equity instruments or financial liabilities. The Series B, C, and D Preferred Shares and Series B Convertible Loans were classified as financial liabilities measured at fair value through profit or loss. The decision was based on the presence of a redemption feature and a conversion option with a price adjustment feature, which are considered financial liabilities under IAS 32.

 

The company also determined that the Series B Convertible Loans are a hybrid instrument that includes a non-derivative host contract and embedded derivatives, which should be accounted for at fair value through profit or loss.

 

Financial liabilities at amortized cost (loans and borrowings)

 

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost, using the effective interest rate method unless the effect of discounting would be immaterial, in which case they are stated at cost. Gains and losses are recognized in the statement of profit or loss and other comprehensive income when the liabilities are derecognized as well as through the effective interest rate amortization process.

 

Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortization is included in finance costs in the statement of profit or loss and other comprehensive income.

 

Derecognition of financial liabilities

 

A financial liability is derecognized when the obligation under the liability is discharged or cancelled, or expires.

 

F-18

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and a recognition of a new liability, and the difference between the respective carrying amounts is recognized in the statement of profit or loss and other comprehensive income.

 

Derivative financial instruments

 

Initial recognition and subsequent measurement

 

The Group uses derivative financial instruments, such as warrants. Such derivative financial instruments are initially recognized at fair value on the date on which a derivative contract is entered into and are subsequently remeasured at fair value. Derivatives are carried as assets when the fair value is positive and as liabilities when the fair value is negative.

 

Any gains or losses arising from changes in fair value of derivatives are taken directly to profit or loss.

 

Current versus non-current classification

 

Derivative instruments that are not designated as effective hedging instruments are classified as current or non-current or separated into current and non-current portions based on an assessment of the facts and circumstances (i.e., the underlying contracted cash flows):

 

Where the Group expects to hold a derivative as an economic hedge (and does not apply hedge accounting) for a period beyond 12 months after the end of the reporting period, the derivative is classified as non-current (or separated into current and non-current portions) consistently with the classification of the underlying item.

 

Embedded derivatives that are not closely related to the host contract are classified consistently with the cash flows of the host contract.

 

Derivative instruments that are designated as, and are effective hedging instruments, are classified consistently with the classification of the underlying hedged item. The derivative instruments are separated into current portions and non-current portions only if a reliable allocation can be made.

 

Cash and cash equivalents

 

For the purpose of the consolidated statement of cash flows, cash and cash equivalents comprise cash on hand and demand deposits, and short term highly liquid investments that are readily convertible into known amounts of cash, are subject to an insignificant risk of changes in value, and have a short maturity of generally within three months when acquired.

 

For the purpose of the consolidated statement of financial position, cash and cash equivalents comprise cash on hand and at banks, including term deposits, and assets similar in nature to cash, which are not restricted as to use.

 

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents at high-quality and accredited financial institutions in amounts that could exceed the $250,000 maximum amount insured by the Federal Deposit Insurance Corporation (FDIC). The Company does not believe that its cash and cash equivalents are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

 

F-19

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Provisions

 

A provision is recognized when a present obligation (legal or constructive) has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation.

 

When the effect of discounting is material, the amount recognized for a provision is the present value at the end of the reporting period of the future expenditures expected to be required to settle the obligation. The increase in the discounted present value amount arising from the passage of time is included in finance costs in the statement of profit or loss and other comprehensive income.

 

Income tax

 

Income tax comprises current and deferred tax. Income tax relating to items recognized outside profit or loss is recognized outside profit or loss, either in other comprehensive income or directly in equity.

 

Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period, taking into consideration interpretations and practices prevailing in the countries in which the Group operates.

 

Deferred tax is provided, using the liability method, on all temporary differences at the end of the reporting period between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

 

Deferred tax liabilities are recognized for all taxable temporary differences, except:

 

when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and

 

in respect of taxable temporary differences associated with investments in subsidiaries, associates and joint ventures, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

 

Deferred tax assets are recognized for all deductible temporary differences, the carryforward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carryforward of unused tax credits and unused tax losses can be utilized, except:

 

when the deferred tax asset relating to the deductible temporary differences arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and

 

in respect of deductible temporary differences associated with investments in subsidiaries, associates and joint ventures, deferred tax assets are only recognized to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.

 

F-20

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

The carrying amount of deferred tax assets is reviewed at the end of each of the Relevant Periods and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at the end of each of the Relevant Periods and are recognized to the extent that it has become probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be recovered.

 

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

 

Deferred tax assets and deferred tax liabilities are offset if and only if the Group has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities which intend either to settle current tax liabilities and assets on a net basis, or to realise the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

 

In compliance with IFRIC 23, accruals for risk on income tax are part of the income tax within the statements of operations and comprehensive loss and income tax payable within the statements of financial position.

 

Government grants

 

Government grants are recognized at their fair value where there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed.

 

Revenue recognition

 

Sales of intellectual property

 

Revenue from sales of intellectual property is recognized when control of the intellectual property is transferred to the customers at an amount that reflects the consideration to which the Group expects to be entitled in exchange for the intellectual property.

 

When the consideration of sales of intellectual property includes a variable amount, the amount of consideration is estimated to which the Group will be entitled in exchange for transferring the intellectual property to the customer. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved.

 

Milestone payments and sales-based royalties represent a form of variable consideration which is included in the transaction price to the extent that it is highly probable that a significant reversal of accumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. When the Group cannot conclude that it is highly probable that a significant revenue reversal of cumulative revenue under the contract will not occur, the Group constrains the related variable consideration resulting in its exclusion from the transaction price.

 

As part of the accounting for this arrangement, the Group must use significant judgement to determine: (a) the performance obligations; and (b) the method to estimate variable consideration.

 

At contract inception, the Group assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.

 

F-21

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

The Group uses judgement to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. If a milestone or other variable consideration relates specifically to the Group’s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Group generally allocates that milestone amount entirely to that performance obligation once it is highly probable that a significant revenue reversal would not occur.

 

The Group recognizes revenue only when it satisfies a performance obligation by transferring control of the promised goods or services. The transfer of control can occur over time or at a point in time. A performance obligation is satisfied over time if it meets one of the following criteria:

 

The counterparty simultaneously receives and consumes the benefits provided by the Group’s performance as the Group performs; or

 

The Group’s performance creates or enhances an asset that the counterparty controls as the asset is created or enhanced

 

The Group’s performance does not create an asset with an alternative use to the Group and the Group has an enforceable right to payment for performance completed to date.

 

The portion of the transaction price that is allocated to performance obligations satisfied at a point in time is recognized as revenue when control of the goods or services is transferred to the counterparty. If the performance obligation is satisfied over time, the portion of the transaction price allocated to that performance obligation is recognized as revenue as the performance obligation is satisfied. The Group adopts an appropriate method of measuring progress for purposes of recognizing revenue. The Group evaluates the measure of progress at the end of each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

 

Upfront fees

 

Upfront payment is allocated to the performance obligations based on the Group’s best estimate of their relative stand-alone selling prices. The Group recognizes revenues from non-refundable upfront fees at a point in time when the transfer of control of the intellectual property to the counterparty occurs and the counterpary is able to use and benefit from the intellectual property.

 

Milestone payments

 

At the inception of each arrangement that includes milestone payments, the Group evaluates whether the milestones are considered highly probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is highly probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Group, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are received. The Group evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgement involved in determining whether it is highly probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Group re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Milestone payments are allocated to performance obligations based on the Group’s best estimate of their relative stand-alone selling prices unless the criteria under IFRS 15.85 are met, in which case the milestone payments are allocated entirely to the performance obligation which the milestone payments are specifically related to.

 

F-22

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

The Group assessed that achievement of all the remaining contractual milestones is highly uncertain and the related milestone payments are not included in the transaction price. Milestones are achieved when the triggering event described in the related agreement occurs.

 

Sales royalties

 

The Group recognizes revenue for a sales-based royalty promised in exchange for the sales of intellectual property only when (or as) the later of the following events occurs:

 

(a)the subsequent sale occurs; and

 

(b)the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied.

 

Revenue from other sources

 

Rental income is recognized on a time proportion basis over the lease terms. Variable lease payments that do not depend on an index or a rate are recognized as income in the accounting period in which they are incurred.

 

Interest income

 

Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.

 

Share-based payments

 

The Company operates a share option scheme for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group’s operations. Employees (including directors) of the Group receive remuneration in the form of share-based payments, whereby employees render services as consideration for equity instruments (“equity-settled transactions”).

 

The cost of equity-settled transactions with employees for grants is measured by reference to the fair value at the date at which they are granted. The fair value is determined by an external valuer using a binomial model, further details of which are given in note 19 to the Consolidated Financial Statements.

 

The cost of equity-settled transactions is recognized in employee benefit expense, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled. The cumulative expense recognized for equity-settled transactions at the end of each of the Relevant Periods until the vesting date reflects the extent to which the vesting period has expired and the Group’s best estimate of the number of equity instruments that will ultimately vest. The charge or credit to the statement of profit or loss and other comprehensive income for a period represents the movement in the cumulative expense recognized as of the beginning and end of that period.

 

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group’s best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.

 

F-23

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Other employee benefits

 

Pension schemes

 

The employees of the Group’s subsidiaries who operate in Mainland China are required to participate in a central pension scheme operated by the local municipal government. These subsidiaries are required to contribute a certain percentage of their payroll costs to the central pension scheme. The contributions are charged to profit or loss as they become payable in accordance with the rules of the central pension scheme.

 

The subsidiary in the U.S. maintains multiple qualified contributory savings plans as allowed under Section 401(k) of the Internal Revenue Code in the U.S. These plans are defined contribution plans covering substantially all its qualifying employees and provide for voluntary contributions by employees, subject to certain limits. The contributions are made by both the employees and the employer. The employees’ contributions are primarily based on specified dollar amounts or percentages of employee compensation. The only obligation of the subsidiary in the U.S. with respect to the retirement benefits plans is to make the specified contributions under the plans.

 

Housing fund — Mainland China

 

The Group contributes on a monthly basis to a defined contribution housing fund plan operated by the local municipal government. Contributions to this plan by the Group are expensed as incurred.

 

Borrowing costs

 

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets (i.e., assets that necessarily take a substantial period of time to get ready for their intended use or sale) are capitalized as part of the cost of those assets. The capitalization of such borrowing costs ceases when the assets are substantially ready for their intended use or sale. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs capitalized. All other borrowing costs are expensed in the period in which they are incurred. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

 

Foreign currencies

 

These consolidated financial statements are presented in United States dollars (“$”), which is the Company’s functional currency. Each entity in the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency. Foreign currency transactions recorded by the entities in the Group are initially recorded using their respective functional currency rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency rates of exchange at the end of the reporting period. Differences arising on settlement or translation of monetary items are recognized in the statement of operations and comprehensive loss.

 

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured. The gain or loss arising on translation of a non-monetary item measured at fair value is treated in line with the recognition of the gain or loss on change in fair value of the item (i.e., translation difference on the item whose fair value gain or loss is recognized in other comprehensive income or profit or loss is also recognized in other comprehensive income or profit or loss, respectively).

 

F-24

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

In determining the exchange rate on initial recognition of the related asset, expense or income on the derecognition of a non-monetary asset or non-monetary liability relating to an advance consideration, the date of the initial transaction is the date on which the Group initially recognizes the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of the advance consideration.

 

The functional currencies of certain subsidiaries established in the PRC are currencies other than $. As of the end of the reporting period, the assets and liabilities of these entities are translated into $ at the exchange rates prevailing at the end of the reporting period and their statements of profit or loss and other comprehensive income are translated into $ at the weighted average exchange rates for the year.

 

The resulting exchange differences are recognized in other comprehensive income and accumulated in the exchange fluctuation reserve. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is recognized in the statement of profit or loss and other comprehensive income.

 

For the purpose of the consolidated statement of cash flows, the cash flows of the subsidiaries established in the PRC are translated into $ at the exchange rates at the dates of the cash flows. Frequently recurring cash flows of the subsidiaries established in the PRC which arise throughout the year are translated into $ at the weighted average exchange rates for the year.

 

3.SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES

 

Use of Estimates

 

The preparation of the Group’s Consolidated Financial Statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and their accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amounts of the assets or liabilities affected in the future.

 

Estimation uncertainty

 

The key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are described below.

 

Fair value of financial liabilities measured at FVTPL

 

The fair value of the financial liabilities, including convertible redeemable preferred shares, convertible loans, forwards and warrants, are measured at FVTPL and determined using the valuation techniques, including the discounted cash flow method and the back-solve method. Such valuation requires the Group to make estimates of the key assumptions including the risk-free interest rate, discount for lack of marketability (“DLOM”) and volatility, which are subject to uncertainty and might materially differ from the actual results. Further details are included in note 16 to the Consolidated Financial Statements.

 

Fair value of share-based payment

 

The fair value of the awarded shares is determined at the grant dates by the binomial option-pricing model. Significant estimates on assumptions, including the underlying equity value, discount rate, expected volatility, and dividend yield, are made by management. Further details are included in note 19 to the Consolidated Financial Statements.

 

F-25

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

3.SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES (continued)

 

The preparation of the consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reporting amounts of assets and liabilities, and disclosure of contingent assets and liabilities, as of the date of the consolidated financial statements, and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the valuation and accounting for financial liabilities at FVTPL and equity awards.

 

Impairment of non-financial assets (other than goodwill)

 

The Group assesses whether there are any indicators of impairment for all non-financial assets (including the right-of-use assets) at the end of each of the Relevant Periods. Other non-financial assets are tested for impairment when there are indicators that the carrying amounts may not be recoverable. An impairment exists when the carrying value of an asset or a cash-generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The calculation of the fair value less costs of disposal is based on available data from binding sales transactions in an arm’s length transaction of similar assets or observable market prices less incremental costs for disposing of the asset. When value-in-use calculations are undertaken, management must estimate the expected future cash flows from the asset or cash-generating unit and choose a suitable discount rate in order to calculate the present value of those cash flows.

 

Deferred tax assets

 

Deferred tax assets are recognized for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and level of future taxable profits together with future tax planning strategies. Further details are contained in note 6 to the Consolidated Financial Statements.

 

Uncertain tax positions

 

In assessing any uncertainty over income tax treatments, the Group considers whether it is probable that the relevant tax authority will accept the uncertain tax treatment used, or proposed to be used, by individual group entities in their income tax filings. If it is probable, the current and deferred taxes are determined consistently with the tax treatment in the income tax filings. If it is not probable that the relevant taxation authority will accept an uncertain tax treatment, the effect of each uncertainty is reflected by using either the most likely amount or the expected value.

 

The Group has evaluated the uncertain tax position of each of the companies within the Group as of December 31, 2022 and 2023, the Group did not have any significant unrecognized uncertain tax positions.

 

Leases — Estimating the incremental borrowing rate

 

The Group cannot readily determine the interest rate implicit in a lease, and therefore, it uses an incremental borrowing rate (“IBR”) to measure lease liabilities. The IBR is the rate of interest that the Group would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. The IBR therefore reflects what the Group “would have to pay”, which requires estimation when no observable rates are available (such as for subsidiaries that do not enter into financing transactions) or when it needs to be adjusted to reflect the terms and conditions of the lease (for example, when leases are not in the subsidiary’s functional currency). The Group estimates the IBR using observable inputs (such as market interest rates) when available and is required to make certain entity-specific estimates (such as the subsidiary’s stand-alone credit rating).

 

F-26

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

4.REVENUE

 

An analysis of revenue is as follows:

 

   2021   2022   2023 
   $’000   $’000   $’000 
Sales of intellectual property   45,726           
Sales of an exclusive option.   
    
    5,000 
Total   45,726    
    5,000 

 

Revenue of $5,000 for the year ended December 31, 2023 was derived from the option grant fee for the sale of an exclusive option to enter into a license agreement to further develop and commercialize products to a single customer, recognized at a point in time, and there was no further performance obligation to be performed.

 

The Group entered into a collaboration agreement with one customer in the year ended December 31,2021 for a list of patents and related research material, know-how, and research results generated through studies of the five products. The terms of the arrangement include: non-refundable upfront fees of RMB295,000 (approximately equivalent to $45,726), milestone payments for the achievement of specified certain development and sales targets and sales-based royalties.

 

Revenue of $45,726 for the year ended December 31, 2021 was derived from the upfront fee for the sale of intellectual property to a single customer, recognized at a point in time, and there was no further performance obligation to be performed.

 

5.FINANCE COSTS

 

An analysis of finance costs is as follows:

 

   Year ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
Transaction cost for issuance of the Group’s convertible redeemable preferred shares   758    
    
 
Interest expenses on bank and other borrowings   421    295    708 
Interest expenses on lease liabilities   158    138    83 
Total   1,337    433    791 

 

6.INCOME TAX

 

The company is subject to income tax on an entity basis on profit arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

 

Cayman Islands

 

Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gains.

 

The United States

 

The subsidiary incorporated in the United States (“U.S.”) is subject to U.S. federal income tax and New Jersey state income tax at the rates of 21% and 9%, respectively, during the Relevant Periods on the estimated assessable profits arising in the United States.

 

F-27

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

6.INCOME TAX (continued)

 

Mainland China

 

The provision for corporate income tax in Mainland China is based on the statutory rate of 25% of the assessable profits as determined in accordance with the PRC Corporate Income Tax Law, which was approved and became effective on January 1, 2008.

 

Pursuant to the relevant regulations on extension for expiries of unused tax losses of High and New Technology Enterprises and Small and Medium-sized Technological Enterprises issued in August 2018, the accumulated tax losses that did not expire from 2018 will have expiries extending from 5 years to 10 years from then on. Adlai Hangzhou qualified as a High and New Technology Enterprise during the years 2022-2024.

 

The income tax expense of the company for the Relevant Periods is analyzed as follows:

 

   Year ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
Current   
    
    643 
Deferred   
    
    
 
Total   
    
    643 

 

A reconciliation of the tax expense applicable to loss before tax at the statutory rate to the tax expense at the effective tax rate is as follows:

 

   Year ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
Loss before tax   (56,678)   (58,790)   (104,228)
Tax at the statutory tax rate (25%)   (14,169)   (14,698)   (26,057)
Foreign rate differential   13,240    2,933    14,711 
Expenses not deductible for tax   603    2,171    126 
Income not subject to tax   (2,890)   (4)   
 
Additional deductible allowance for qualified research and development costs   (1,109)   (1,681)   (2,338)
Unrecognized deferred tax assets   4,325    11,279    14,201 
Current income tax expense   
    
    643 
Tax charge at the Group’s effective rate   
    
    0.62%

 

F-28

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

6.INCOME TAX (continued)

 

Deferred tax

 

The Group considers positive and negative evidence to determine whether some portion or all of the deferred tax assets will be probable realized. Deferred tax assets have not been recognized in respect of these tax losses as they have been incurred in subsidiaries that were loss-making in the past and it is not probable that they will generate sufficient taxable income in the foreseeable future to utilize such tax losses.

 

   Year ended December 31 
   2022   2023 
   $’000   $’000 
Fixed assets   (13)   2 
Capitalized R&D   5,494    11,050 
Accrued and prepaid expenses   669    (101)
ROU Assets   (72)   5 
Advertising expenses in excess of deduction limit   14    11 
Allowance against receivables   
    3 
State tax   (1)   (1)
Stock options   1,075    883 
NOL   21,758    31,408 
Subtotal   28,923    43,260 
Unrecognized deferred tax assets   (28,923)   (43,260)
Total Deferred tax   
    
 

 

The Group has accumulated tax losses arising in Adlai Hangzhou in Mainland China of $83,103 and $102,647 as of December 31, 2022 and 2023, respectively, that will expire in five to ten years after the loss incurring year for offsetting against future taxable profits.

 

The Group also has accumulated tax losses in the U.S. of $46,201 and $54,168 as of December 31, 2022 and 2023, respectively, that can be carried forward indefinitely to offset against future taxable profits of the companies in which losses were incurred, subject to 80% taxable income limitation annually.

 

Uncertain Tax Position

 

The Company did not identify any significant unrecognized tax benefits for each of the periods presented. The Group did not incur any interest related to unrecognized tax benefits, did not recognize any penalties as income tax expense and also does not anticipate any significant change in unrecognized tax benefits within 12 months from December 31, 2023.

 

F-29

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

7.DIVIDENDS

 

No dividends have been declared and paid by the Company or the Group during the Relevant Periods.

 

8.LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

 

The calculation of the basic loss per share amount is based on the loss for the year attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 25,440,000, 25,440,000 and 43,342,068 in issue during the years ended December 31, 2021, 2022 and 2023, respectively.

 

The calculation of the basic loss per share amount is based on the loss for the years attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares in issue or deemed to be in issue during the year ended December 31, 2021, 2022 and 2023.

 

Basic loss per share is computed on the basis of the weighted average number of ordinary shares outstanding during the period of the financial statements.

 

Diluted loss per share of ordinary stock is computed on the basis of the weighted average number of shares of ordinary stock and dilutive securities (such as stock options and convertible securities) outstanding. As of December 31, 2021 the Company had 62,967,406 dilutive shares consisting of 57,543,414 relating to convertible preferred stock and 5,423,992 relating to options. As of December 31, 2022 the Company had 64,300,522 dilutive shares consisting of 57,543,414 relating to convertible preferred stock and 6,757,108 relating to options. As of December 31, 2023 the Company had 3,869,554 dilutive shares relating to options. Dilutive securities that have an anti-dilutive effect on diluted loss per share are excluded from the calculation.

 

No adjustment has been made to the basic loss per share amounts presented for the years ended December 31, 2021, 2022 and 2023 in respect of a dilution as the impact of the outstanding share options, restricted stock units and warrant liability had an anti-dilutive effect on the basic loss per share amounts presented.

 

9.PROPERTY, PLANT AND EQUIPMENT

 

   Leasehold   Plant and   Office   Motor   Electronic     
   improvements   machinery   equipment   vehicles   equipment   Total 
   $’000   $’000   $’000   $’000   $’000   $’000 
At January 1, 2022, net of accumulated depreciation   1,601    1,842    68    12    132    3,655 
Additions   710    360    
    168    11    1,249 
Depreciation provided during the year   (416)   (412)   (31)   (19)   (53)   (931)
Disposals   
    
    
    (10)   
    (10)
Exchange realignment   (121)   (117)   (4)   
    (8)   (250)
At December 31, 2022, net of accumulated depreciation   1,774    1,673    33    151    82    3,713 
As of December 31, 2022:                              
Cost   2,532    3,386    150    199    276    6,543 
Accumulated depreciation   (758)   (1,713)   (117)   (48)   (194)   (2,830)
Net carrying amount   1,774    1,673    33    151    82    3,713 

 

F-30

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

9.PROPERTY, PLANT AND EQUIPMENT (continued)

 

   Leasehold   Plant and   Office   Motor   Electronic     
   improvements   machinery   equipment   vehicles   equipment   Total 
   $’000   $’000   $’000   $’000   $’000   $’000 
At January 1, 2023, net of accumulated depreciation   1,774    1,673    33    151    82    3,713 
Additions   28    27    
    127    18    200 
Depreciation provided during the year   (700)   (416)   (20)   (43)   (34)   (1,213)
Disposals   
    
    
    
    (1)   (1)
Exchange realignment   (25)   (23)   
    (3)   (2)   (53)
At Dec 31, 2023, net of accumulated depreciation   1,077    1,261    13    232    63    2,646 
As of December 31, 2023                              
Cost   2,519    3,373    148    322    228    6,590 
Accumulated depreciation   (1,442)   (2,112)   (135)   (90)   (165)   (3,944)
Net carrying amount   1,077    1,261    13    232    63    2,646 

 

During the Relevant Periods, none of the Group’s property, plant and equipment were pledged.

 

There was no impairment for the Group’s property, plant and equipment during the Relevant Periods.

 

10.LEASES

 

The Group has lease contracts of properties and used in its operation with lease terms between 2 and 5 years.

 

(a)Right-of-use assets

 

The carrying amounts of the Group’s right-of-use assets and the movements during the Relevant Periods are as follows:

 

   Offices   Office
equipment
   Total 
   $’000   $’000   $’000 
As of January 1, 2022   2,725    209    2,934 
Additions   463    
    463 
Depreciation provided during the year   (961)   (129)   (1,090)
Exchange realignment   (141)   (4)   (145)
As of December 31, 2022   2,086    76    2,162 

 

   Offices   Office
equipment
   Total 
   $’000   $’000   $’000 
As of January 1, 2023   2,086    76    2,162 
Additions   
    
    
 
Depreciation provided during the year   (931)   (53)   (984)
Exchange realignment   (23)   (1)   (24)
As of December 31, 2023   1,132    22    1,154 

 

F-31

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

10.LEASES (continued)

 

(b)Lease liabilities

 

The carrying amount of lease liabilities and the movements during the Relevant Periods are as follows:

 

   Lease
liabilities
 
   $’000 
As of January 1, 2022   (2,888)
Additions   (463)
Accretion of interest recognized during the year   (133)
Payments   1,070 
Exchange realignment   177 
As of December 31, 2022   (2,237)
As of January 1, 2023   (2,237)
Additions   
 
Accretion of interest recognized during the year   (83)
Payments   1,103 
Exchange realignment   26 
As of December 31, 2023   (1,191)

 

   2022   2023 
   $’000   $’000 
Analyzed into:        
Current portion   1,001    722 
Non-current portion   1,236    469 
Total   2,237    1,191 

 

(c)The amounts recognized in profit or loss in relation to leases are as follows:

 

   Year ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
Interest on lease liabilities   158    133    83 
Depreciation charge of right-of-use assets   951    1,090    984 
Total amount recognized in profit or loss   1,109    1,223    1,067 

 

F-32

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

11.PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS

 

   As of December 31, 
   2022   2023 
   $’000   $’000 
Current:        
Prepayments (Note i)   1,912    2,337 
VAT deductible tax   100    135 
Deposits and other receivables   246    224 
    2,258    2,696 
Non-current:          
Deposits and other receivables   
    
 
Prepaid expenses   327    282 
    327    282 
Total   2,585    2,978 

 

 

Note i:

 

The amount represents prepayments for Contract Research Organizations (“CROs”) and deposit of property, plant and equipment not yet placed in use.

 

Other receivables had no historical default. The financial assets included in the above balances relate to receivables which were categorized in stage 1 at the end of each of the Relevant Periods. In calculating the expected credit loss rate, the Group considers the historical loss rate and adjusts for forward-looking factors and information. During the Relevant Periods, the Group estimated that the expected credit loss rate for other receivables and deposits was minimal.

 

The Group seeks to maintain strict control over its outstanding receivables to minimize credit risk. Long ageing balances are reviewed regularly by senior management. In view of the fact that the Group’s deposits and other receivables relate to a large number of diversified counterparties, there is no significant concentration of credit risk. The Group does not hold any collateral or other credit enhancements over its deposits and other receivable balances.

 

12.FINANCIAL ASSETS AT FVTPL

 

   As of December 31, 
   2022   2023 
   $’000   $’000 
Current:        
Wealth management product   21,287    7 
Total   21,287    7 

 

During the Relevant Periods, the Group used surplus capital to purchase dual currency structured deposit and wealth management product from domestic commercial banks, which preserved capital and liquidity.

 

The wealth management product held as of December 31, 2022 was an investment into a mutual fund whose portfolio included a mixture of fixed income assets, preferred shares and repos, which were redeemable every 3 months. The wealth management product held as of December 31, 2023 was an investment into a money market fund that invests in short-term debt instruments such as treasury bills, certain certificates of deposit, bonds, government gilts and commercial paper. The returns on all of the financial product was not guaranteed, hence their contractual cash flows did not qualify solely as payments of principal and interest. Therefore, those products were accounted at fair value through profit or loss. Further details are included in note 20(c) to the Unaudited Condensed Consolidated Financial Statements.

 

F-33

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

13.INVESTMENT AT AMORTIZED COST

 

   As of December 31, 
   2022   2023 
   $’000   $’000 
Short-term investments at amortized cost   
    7,000 
Long-term investments at amortized cost   
    24,849 
Total   
    31,849 

 

Short-term investment at amortized cost represent time deposits placed with banks with original maturities between three months and one year.

 

Long-term investment at amortized cost represent time deposits placed with banks with original maturities more than one year.

 

14.OTHER PAYABLES AND ACCRUALS

 

   As of December 31, 
   2022   2023 
   $’000   $’000 
Other payables and accruals (Note i)   255    303 
Tax payable   
 
    773 
Payroll and bonus payables   3,622    3,814 
Total   3,877    4,890 

 

 

Note i:

 

Other payables and accruals are unsecured, non-interest-bearing and repayable on demand. The fair values of other payables and accruals at the end of each of the Relevant Periods approximated to their corresponding carrying amounts.

 

F-34

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

15.INTEREST-BEARING BANK BORROWINGS

 

   As of December 31, 
   2022   2023 
   $’000   $’000 
Non-Revolving Facility, 5.22% interest, due March 22,2023, guaranteed (Note i)   1,436    
 
Non-Revolving Facility, 4.8% interest, due April 24,2023, guaranteed (Note ii)   2,871    
 
Non Revolving Facility, 4.2% interest, due March 26, 2024, guaranteed (Note iii)   
    2,824 
Non Revolving Facility, 4.0% interest, due September 17, 2024, guaranteed  (Note v)   
    1,412 
Non Revolving Facility, 4.0% interest, due September 18, 2024, guaranteed (Note v).   
    1,412 
Non Revolving Facility, 4.0% interest, due April 15, 2024, guaranteed (Note ii)   
    4,235 
Non Revolving Facility, 6.78% interest, due November 27, 2024, guaranteed  (Note vi)   
    3,000 
Non Revolving Facility, 6.0% interest, due November 14, 2024, guaranteed (Note vii).   
    10,650 
Non Revolving Facility, 6.3% interest, due December 26, 2024, guaranteed (Note vi).   
    4,000 
Non Revolving Facility, 4.0% interest, due December 25, 2024, guaranteed (Note iv)   
    2,824 
Total   4,307    30,357 

 

   Bank 
borrowings
   Total 
   $’000   $’000 
As of January 1, 2022   10,457    10,457 
Additions   7,897    7,897 
Repayments   (13,316)   (13,316)
Effect of foreign exchange rate changes   (731)   (731)
As of December 31, 2022   4,307    4,307 
Additions   50,234    50,234 
Repayments   (24,069)   (24,069)
Effect of foreign exchange rate changes   (115)   (115)
As of December 31, 2023   30,357    30,357 

 

All of the Group’s bank borrowings were obtained from third party financial institutions. As of December 31, 2022 and 2023, the Group’s credit facilities were $4,307 and $30,357, respectively, of which nil and nil was unused by the Group.

 

 

Notes:

 

(i)In March 2022, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 5.22% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. The non-revolving facility agreement was repaid at the maturity date of March 22, 2023.

 

(ii)In October 2022, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 20,000 and at an interest rate of 4.80% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. The non-revolving facility agreement was repaid at the maturity date of April 24, 2023.

 

In October 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 30,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors.

 

(iii)In March 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 20,000 and at an interest rate of 4.20% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. The non-revolving facility agreement was repaid at the maturity date of March 26, 2024. And in March 2024, Adlai Hangzhou repaid it at the maturity date.

 

(iv)In December 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 20,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors.

 

F-35

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

15.INTEREST-BEARING BANK BORROWINGS (continued)

 

(v)In September 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. And in March 2024, Adlai Hangzhou repaid it before the maturity date.

 

In September 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. And in March 2024, Adlai Hangzhou repaid it before the maturity date.

 

(vi)In November 2023, Adlai US entered into a non-revolving facility agreement for a facility amount of USD 3,000 and at an interest rate of 6.78% per annum, guaranteed by the company.

 

In December 2023, Adlai US entered into a non-revolving facility agreement for a facility amount of USD 4,000 and at an interest rate of 6.30% per annum, guaranteed by the company.

 

(vii)In December 2023, the company entered into a non-revolving facility agreement for a facility amount of USD 10,650 and at an interest rate of 6.00% per annum, guaranteed by Adlai Hangzhou.

 

16.FINANCIAL LIABILITIES AT FVTPL

 

Preferred shares and convertible loans

 

In late 2015, Adlai Hangzhou raised up to RMB70,000 from the Founders and certain onshore investors (“Series A Investors”).

 

In June 2018, the Company was established in the Cayman Island for seeking overseas listing opportunity, and the Company issued ordinary shares to the Founders and an option to the Series A Investors, which entitled Series A Investors to convert their equity interests in Adlai Hangzhou to up to 14,560,000 series A convertible preferred shares (“Series A Preferred Shares”) of the Company, at par value of $ 0.0001 per share, upon completion of the Reorganization. From January 2020 to April 2020, Series A Investors exercised the option and converted their equity interests in Adlai Hangzhou to Series A Preferred Shares of the Company.

 

In June 2018, to accommodate the Group’s Reorganization plan, certain onshore investors (“Series B Onshore Investors”) entered into convertible loan subscription agreement (the “Series B Loan Agreement”) with Adlai Hangzhou to issue a loan (the “Series B Convertible Loans”) to Series B Onshore Investors for a total consideration of RMB165,000. Meanwhile, the Company entered into a forward contract with these Series B Onshore investors to grant them an option (“Series B Preferred Shares Forward”) to convert Series B Convertible Loans issued by Adali Hangzhou to 6,600,000 series B convertible redeemable preferred shares (“Series B Preferred Shares”) of the Company, at par value of $ 0.0001 per share, upon completion of the Reorganization. Pursuant to the Series B Loan Agreement, these loans bore interest at 15% per annum and shall mature upon the exercise of the Series B Preferred Shares Forward. The Series B Onshore Investors agreed Adlai Hangzhou’s obligation of repayment the principal and accrued interests of these loans will be automatically relieved with the exercise of Series B Share Purchase Forward upon completion of the Reorganization. From April to May 2020, the Series B Onshore Investors have exercised their Series B Share Purchase Forward and converted their Series B Convertible Loans to an aggregate of 6,600,000 Series B Preferred Shares.

 

Concurrently, certain offshore investors (“Series B Offshore Investors”) subscribed 6,907,896 Series B Preferred Shares (“Series B Preferred Shares”) for a total consideration of $27,000. The Series B Onshore Investors and Series B Offshore Investors are collectively referred to as “Series B Investors”.

 

F-36

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

16.FINANCIAL LIABILITIES AT FVTPL (continued)

 

In December 2019, the Company issued 14,653,013 series C convertible redeemable preferred shares (“Series C Preferred Shares”) of the Company for a total consideration of $63,700 to certain investors (“Series C Investors”).

 

In April 2021, the Company entered into a Series D share purchase agreement with certain investors (“Series D Investors”) to issue an aggregate of 14,722,505 series D convertible redeemable preferred shares (“Series D Preferred Shares”) for a total consideration of $97,370 and paid in full as of December 31, 2021.

 

According to the original and amended Memorandum and Articles of Association (“MOA”) upon the issuance of each series of convertible redeemable preferred shares, the Group designated Series B, C and D Preferred Shares and Series B Convertible Loans as financial liabilities measured at FVTPL and recognized Series A Preferred Shares as equity in accordance with the relevant IFRS. There is no significant change in the major terms of MOA among of each series except mentioned otherwise in the notes to the Consolidated Financial Statements.

 

According to the MOA of the Company in May 2021, the key terms of the Series A, B, C and D Preferred Shares (collectively “Preferred Shares”) are as follows:

 

Conversion Rights (applicable to all Preferred Shares)

 

Each holder of Preferred Shares may, at the option of the holder thereof, be converted at any time into fully-paid and nonassessable ordinary shares of the Company based on the then-effective applicable conversion price (“Applicable Conversion Price”). Each holder of Preferred Shares shall automatically be converted, based on the Applicable Conversion Price, into ordinary shares of the Company upon the closing of a Qualified IPO (as defined below).

 

The Applicable Conversion Price is initially equal to the original issue price for each class of Preferred Shares and shall be subject to adjustment from time to time, including but not limited to share splits, share subdivision, share combination and the like, being no less than par value.

 

If the Company issues any additional ordinary shares at a subscription price less than the corresponding original subscription price of the Series B, C and D Preferred Shares, the Company shall issue new corresponding Series B, C and D Preferred Shares to the holders of Series B, C and D Preferred Shares at the nominal price or the minimum price allowed by applicable laws until the Applicable Conversion Price for each holders of Series B, C and D Preferred Shares is reduced to such issue price.

 

If the Group fails to meet any of the below two committed business objectives (“Business Objectives”) within the timelines, the holders of Series C Preferred Shares are entitled to request the Founders, affiliates of the Founders and the Group (collectively referred to as “Warrantors”) to jointly make up the share compensation necessary to make the pre-money valuation of the Company immediately before the investment by the holders of Preferred Shares be adjusted to 70% thereof. The share compensation arrangement shall be made on the basis of a nominal transfer price. The Business Objectives are:

 

a)promote at least three products (self-developed or by introduction) to the next clinical stage within eighteen months from the Series C Preferred Shares closing date, on the basis of existing clinical pipelines; and;

 

b)obtain the approval of one new drug application from the competent authority for drug administration in the US or PRC by the 3rd anniversary of Series C Preferred Shares closing date.

 

F-37

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

16.FINANCIAL LIABILITIES AT FVTPL (continued)

 

Qualified IPO means an underwritter initial public offering of the Company completed no later than the earlier of (i) September 7, 2023 and (ii) two years after the date of Closing of the Series D Preferred Shares and which occurs on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Market or such other reputable stock exchange approved by the a majority of all of the investor directors with (i) the pre-public offering market capitalization of no less than $650,000, unless otherwise agreed by the investor directors; and (ii) shares held by the investors can be listed for trading or otherwise disposed of without transfer restrictions after any applicable statutory lock-up period.

 

Voting Rights (applicable to all Preferred Shares)

 

Except as otherwise required by law or as set forth herein, the holder of each ordinary share issued and outstanding shall have one vote for each ordinary share held by such holder, and the holder of Preferred Shares shall be entitled to the number of votes equal to the number of ordinary shares into which such Preferred Shares could be converted.

 

Liquidation Preference (applicable to all Preferred Shares)

 

Upon any liquidation, closure, dissolution, merger or acquisition of any Group company; or the transfer of a controlling interest (i.e., more than 50% of the equity) by the shareholders of any Group company (excluding the holders of Series A, B, C and D Preferred Shares); or the sale of the majority of any Group’s assets to third parties; or the transfer of the majority of any Group’s intellectual property to third parties; or any event that can be defined as a transfer of control of any Group company; or any transfer of the Shares of any Group company (excluding the shares of the Company held by the holders of Series A, B, C and D Preferred Shares) or shares held by the Founders or their affiliates without the prior written consent of the Investor Director Majority, Series C Investors and Series D Investors; or any breach of the Warrantors under the Series D Share Purchase Agreements, the Series C Share Purchase Agreements, the Series B Share Purchase Agreement, the Shareholders’ Agreement and these Articles, as applicable (“Transaction Documents”) which would cause the Series C Investors and Series D Investors to claim for termination of any of the Transaction Documents (each a “Liquidation Event”), whether voluntary or involuntary, all assets and funds of the Company legally available for distribution to the shareholders is distributed to the shareholders of the Company in the sequence as follows:

 

a)Series D Preferred Shares

 

b)Series C Preferred Shares

 

c)Series B Preferred Shares

 

d)Series A Preferred Shares

 

If there are any assets or funds remaining after the aggregate Series A, B, C and D Preferred Shares have been distributed or paid fully, the remaining assets and funds of the Company available for distribution is distributed on a pro rata basis among all holders of outstanding ordinary shares and Preferred Shares.

 

Dividends (applicable to all Preferred Shares)

 

Each holder of the ordinary shares (on as-converted basis) shall be entitled to receive dividends on a pro rata basis on the number of ordinary shares, out of any funds legally available therefor, pro rata based on the number of ordinary shares held by each holder.

 

F-38

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

16.FINANCIAL LIABILITIES AT FVTPL (continued)

 

Redemption Rights (applicable to Series B, C and D Preferred Shares)

 

At any time after the earlier of the following, any investors of Preferred Shares shall be entitled to require the Company to redeem all or portion of the outstanding Preferred Shares held by them, and/or require each of the Warrantors to jointly and severally redeem or repurchase all or portion of the outstanding Preferred Shares held by them:

 

i.the Company fails to complete a Qualified IPO at the earlier of (a) September 7, 2023; and (b) two years after the date of Closing;

 

ii.(applicable to Series C Investors and Series D Investors only) with respect to any Series C Investor or Series D Investor, such Series C Investor or Series D Investor fails to achieve the investment return which is 100% of its investment amount and plus an amount that would accrue on its investment amount at a simple interest rate of ten percent (10%) per annum (if such period is less than a year, such interest amount shall be calculated proportionally) through transfer, dividends of the Preferred Shares, or disposal in any other way approved by such Series C Investors or Series D Investors plus the value of the Preferred Shares (if any) still held by such Series C Investors or Series D Investors by September 7, 2023 (with respect to Series C Investors) or by three years following its closing of Series D (with respect to Series D Investors);

 

iii.(applicable to Series C Investors only) the applicable Group company fails to meet any of the Committed Business Objectives within the timelines specified under these Articles;

 

iv.(applicable to Series C Investors only) the applicable Group company fails to obtain approval of a new medicine application from the competent authority for drug administration of its first medicine in the U.S. or the PRC by December 30, 2022;

 

v.(applicable to Series C Investors and Series D Investors only) the first disapproval or rejection by any competent governmental authority (including, without limitation, the National Medical Products Administration of the PRC or the U.S. Food and Drug Administration) of the application made by any Group company with respect to any of its new drugs;

 

vi.in case that the Group companies meet the requirements for a Qualified IPO, any of the Group companies or the management shareholders refuses the Qualified IPO or declines to make necessary cooperation for such Qualified IPO, or the Group companies fail to complete the Qualified IPO due to any reasons attributable to any management shareholder;

 

vii.without the written consent of the majority of investor directors, Series C Investors and Series D Investors, Mr. Yang Lu and Mr. Donghui Yang terminate their employment contracts with the applicable Group company or fail to comply their commitment to work full time as per the agreement with certain Series C Investors or Series D Investors prior to the latest to occur of the following events: (a) such Series C Investors or Series D Investors’ exit; (b) the occurrence of a Qualified IPO; (c) the expiry of the two years period after the closing of Series D; and (d) September 7, 2023;

 

viii.material change of principal business or, business scope of the Group companies without the written consent of the majority of investor directors, Series C Investors and Series D Investors;

 

ix.any significant intellectual property of any Group company becomes invalid, frozen, or is transferred, authorized, pledged, encumbered, hypothecated to any third party without prior written consent of the majority of investor directors;

 

x.the occurrence of a material breach by any Group company or any management shareholders of any of their respective representations, warranties, covenants or undertakings under the Transaction Documents and failure by applicable Group companies or management shareholders to make remedy within thirty days after so required;

 

F-39

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

16.FINANCIAL LIABILITIES AT FVTPL (continued)

 

xi.the occurrence of a material breach by any Group company or any management shareholder of any of mandatory laws or regulations in the applicable jurisdiction; and

 

xii.the occurrence of any material dishonesty problem by any Group company or any management shareholder.`

 

Next Equity Financing Warrant

 

In June 2018, in connection with the issuance of the Series B Preferred shares, the Company irrevocably issued to certain Series B Investors a warrant (“Next Equity Financing Warrant”), by which each of these Series B Investors shall be entitled but not obligated to purchase a certain number of the Company’s Preferred Shares with a par value of $0.0001 per share prior to the closing date of the Company’s next round equity or equity-linked financing (the “Next Equity Financing”), at an exercise price per share of ninety-five percent (95%) of the subscription price per share for the investors in such Next Equity Financing.

 

The Next Equity Financing Warrant expired upon the closing date of the Company’s Series C financing in August 2019 as none of these Series B Investors subscribed the Company’s Series C Preferred Shares.

 

CEHKL Warrant

 

On May 20, 2019, the Company entered into a warrant agreement with China Equities HK Limited (“CEHKL”), under which the Company agreed to issue certain Series B Preferred Shares to CEHKL with agreed price (“CEHKL Warrant”) and the CEHKL Warrant will expire on May 20, 2024. In July 2021, CEHKL elected to exercise the CEHKL Warrant and the Company issued 100,000 Series B Preferred Shares to CEHKL.

 

Presentation and classification

 

The Group and the Company have designated the Series B, C and D Preferred Shares and Series B Convertible Loans as financial liabilities measured at FVTPL upon initial recognition. The Next Equity Financing Warrant and CEHKL Warrant are initially recognized at fair value on the date on which the contract is entered into and are subsequently remeasured at fair value.

 

The change in fair value of financial liabilities at FVTPL is charged to profit or loss except for the portion attributable to credit risk change that shall be charged to other comprehensive income. The net gain or loss recognized in profit or loss includes any interest paid on the financial liabilities and is included in the loss on changes in fair value of financial liabilities at FVTPL line item. Management concluded that there is no credit risk of the financial liability that drives the change of the fair value of the financial liability.

 

The movements of the Group’s financial liabilities at FVTPL are set out as follows:

 

   Series B   Series C   Series D     
   Preferred   Preferred   Preferred     
   Shares   Shares   Shares   Total 
   $’000   $’000   $’000   $’000 
                 
At January 1, 2022   92,187    97,726    107,650    297,563 
Change in fair value   (1,803)   (594)   (4,798)   (7,195)
At December 31, 2022   90,384    97,132    102,852    290,368 
Change in fair value   13,943    15,207    10,021    39,171 
Conversion into ordinary shares upon IPO   (104,327)   (112,339)   (112,873)   (329,539)
At December 31, 2023   
    
    
    
 

 

F-40

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

16.FINANCIAL LIABILITIES AT FVTPL (continued)

 

The Company has used the discounted cash flow method and back-solve method to determine the underlying share value of the Company and adopted equity allocation model to determine the fair value of each financial liability as of the dates of issuance and at the end of each of the Relevant Periods.

 

Set out below is a summary of significant unobservable inputs to the valuation of financial instruments together with a quantitative sensitivity analysis as of December 31, 2022:

 

   As of
December 31,
 
   2022 
Fair value of ordinary shares of the Company  $6.15 
Risk-free interest rate (Note i)   4.68%
Expected term   0.44 years 
Volatility (Note ii)   52.86%

 

The Group estimated the risk-free interest rate based on the yield of the United States Government Bond with maturity close to the expected exit timing as of the valuation date. Under the option-pricing method, the cost of a put option, which can hedge the price change before the privately held shares can be sold, was considered as a basis to determine the lack of marketability discount. Volatility was estimated based on the annualized standard deviation of the daily stock price return of comparable companies for a period from the valuation date and with a similar time span to expiration.

 

In September 29, 2023, each holder of Preferred Shares automatically be converted, based on the Applicable Conversion Price, into ordinary shares of the Company upon the closing of IPO.

 

17.ORDINARY SHARES

 

Issued and fully paid:

 

   Number of   Ordinary 
   shares   Shares 
       $’000 
As of 1 January 2023   25,440,000    3 
Issuance of ordinary shares   12,717,391    1 
Conversion of Series A convertible preferred shares   14,560,000    1 
Conversion of Financial liabilities at FVTPL   42,983,414    5 
As at 31 December 2023   95,700,805    10 

 

The authorized share capital of the Company as of December 31, 2023 is $50 divided into 500,000,000 Shares of par value of $0.0001 each, including 442,456,586 ordinary shares.

 

In 2021, the Company issued 9,000,000 ordinary shares to Nortye Talent Limited and 6,000,000 ordinary shares to Nortye International Limited respectively to manage the Share Incentive Plan. All these ordinary shares in 2021 were unpaid shares as of December 31, 2022 and 2023. There was no movement in the Company’s ordinary shares in 2022.

 

F-41

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

18.DEFICITS

 

The amounts of the Group’s deficits and the movement therein for the Relevant Periods are presented in the consolidated statements of changes in equity.

 

(i)Additional paid-in capital

 

The additional paid-in capital represents the difference between the par value of the shares issued and the consideration received.

 

(ii)Share option reserve

 

The share option reverse of the Group represents the equity-settled share-based payments granted by the Group. Please refer to note 19 for details.

 

(iii)Exchange fluctuation reserve

 

The exchange fluctuation reserve represents exchange differences arising from the translation of the financial statements of Group companies whose functional currencies are different from the Group’s presentation currency.

 

19.SHARE INCENTIVE PLAN

 

Adlai Hangzhou Scheme

 

Adlai Hangzhou, a subsidiary of the Company, was once listed on the National Equities Exchange and Quotations (“NEEQ”) (stock code 870946) and adopted a share incentive scheme (the “Adlai Hangzhou Scheme”) for the primary purpose of providing incentives to eligible management and employees who render services to Adlai Hangzhou. On June 15, 2017, awards up to 1,220,000 shares were granted to management and employees at the exercise price of RMB7 per share. Awards granted under the Adlai Hangzhou Scheme shall have a contractual term of five years and generally vest over a four year period, with 25% of total awards vesting on the anniversary date one year after the vesting commencement date and the remaining 75% vesting subsequently in three equal annual instalments.

 

The fair value of the awards granted to management and employees were $ 0.083 per share and $ 0.0765 per share, respectively, using the binomial option-pricing model on the grant date. The variables and assumptions used in computing the fair value of the awards are based on the directors’ best estimate. Changes in variables and assumptions may result in changes in the fair value of the awards.

 

The Group recognized $81 of share-based payment expenses prior to 2021, and nil and nil share-based payment expenses for the years ended December 31, 2022 and 2023, respectively, in relation to the awards granted under the Adlai Hangzhou Scheme.

 

Adlai Share Incentive Plan

 

On June 8, 2020, the Company’s Board of Directors approved a share incentive scheme (the “Share Incentive Plan”) in order to provide additional incentives to employees and to promote the success of the Group’s business. Unless otherwise cancelled or amended, the Share Incentive Plan will remain in force for 10 years. Under the Share Incentive Plan, the maximum aggregate number of shares shall not exceed 4,000,000 ordinary shares, as appropriately adjusted for subsequent stock splits, stock dividends and the like. On May 28, 2021, the Company’s Board of Directors approved to further reserve 11,000,000 ordinary shares of the Company for the Share Incentive Plan for a total of 15,000,000 ordinary shares approved for the Share Incentive Plan. The exercise price of share options is determinable by the directors, but shall not be less than 100% of the fair market value on the grant date. Share options do not confer rights on the holders to dividends or to vote at shareholders’ meetings. The awards may be granted but not be exercised prior to the last day of the six-month period following the listing date of the Company.

 

F-42

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

19.SHARE INCENTIVE PLAN (continued)

 

On July 5, 2021, the Company issued 6,000,000 and 9,000,000 ordinary shares reserved under the Share Inventive Plan to Nortye International Limited and Nortye Talent Limited, respectively, which are holding vehicles of two trusts established by the Company in order to facilitate the administration of the Share Incentive Plan. The sole purpose of the two trusts is to facilitate the issuance of ordinary shares under the Share Incentive Plan, and as such the 15,000,000 ordinary shares are not included in the Company’s calculation of weighted average shares outstanding.

 

On September 8, 2020 and November 1, 2020, awards for 1,435,000 and 2,560,730 shares, respectively, were granted by the Company to its executives, employees and consultants.

 

On May 31, 2021, 3,348,483 awarded shares were granted by the Company to its executives, employees and consultants.

 

On October 1, 2021, 412,000 awarded shares were granted by the Company to its executives, employees and consultants.

 

On January 1, 2022, 83,500 options were granted to certain new employees; 376,172 options were granted to certain employees and managers for outstanding performance.

 

On April 1, 2022, 1,077,800 options were granted to certain new employees, promoted employees and senior managers; 33,336 options were granted to three consultants.

 

On July 1, 2022, 207,200 options were granted to five new employees.

 

On October 1, 2022, 179,200 options were granted to five new employees.

 

On April 2023, 352,500 options were granted to the employees with an exercise price of $2.20 under the 2020 Share Incentive Plan.

 

On April 2023, the Group adopted the 2023 Share Incentive Plan, which is effective upon the completion of this offering. The maximum aggregate number of ordinary shares that may be issued under this 2023 Share Incentive Plan is 15,000,000, including any reserved and issued share under the 2020 Share Incentive Plan.

 

On December 6, 2023, 121,200 options were granted to certain new employees; 25,414 options were granted to certain employees and managers for outstanding performance.

 

F-43

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

19.SHARE INCENTIVE PLAN (continued)

 

Accordingly, the Group measured the fair value of the awards as of the grant date and recognizes the amount as a compensation expense over the vesting period for each separately vesting portion of the awards.

 

               Weighted     
       Weighted   Weighted   Average     
       Average   Average   Remaining   Aggregate 
       Exercise   Grant Fair   Contractual   intrinsic 
   Number of   Price   Value   Life   value 
   awards   $ per share   $ per share   (in years)   $ 
Balances, January 1, 2022   7,635,444    1.72    1.36    9.11    26,950 
Options granted   1,957,208    2.20    3.56    9.26      
Options forfeited/cancelled   (82,550)   2.11    2.68    8.79      
Options exercised   
    
    
          
Balances, December 31, 2022   9,510,102    1.82    1.79    8.34    41,218 
Options granted   499,114    2.20    4.47    9.49      
Options forfeited/cancelled   (50,116)   2.30    5.36    9.51      
Options exercised   
    
    
          
Balances, December 31, 2023   9,959,100    1.83    1.91    7.44    11,596 
Vested but not exercisable as of December 31, 2022   4,980,069    1.59    1.15    8.00      
Vested but not exercisable as of December 31, 2023   5,400,955    1.75    1.69    7.28      

 

As of December 31, 2022 and 2023, there were 15,000,000 and 15,000,000 shares reserved for the option plan and there were 5,489,898 and 5,040,900 shares available for issuance, respectively.

 

The fair value of the award granted during the years ended December 31, 2022 and 2023 were $ 6,913 and $2,231. The Group recognized share-based payment expenses of $6,082 and $4,330, respectively, during the years ended December 31, 2022 and 2023.

 

The fair value of awards granted during the Relevant Periods was estimated as of the grant date using a binomial option-pricing model, taking into account the terms and conditions upon which the awards were granted. The following table lists the inputs to the model used:

 

   Jan 1,   Apr 1,   July 1,   Oct 1,   Apr 21,   Dec 6, 
   2022   2022   2022   2022   2023   2023 
Dividend yield (%)   0.00    0.00    0.00    0.00    0.00    0.00 
Expected volatility (%)   48.73    48.78    48.88    48.82    49.68    49.90 
Risk-free interest rate (%)   1.66    2.52    3.03    3.98    3.98    4.30 
Expected life of options (year)   10.00    10.00    10.00    10.00    10.00    10.00 

 

As of December 31, 2022 and 2023, the Company had 9,510,102 and 9,959,100 awards outstanding under the Share Incentive Plan, respectively. The exercise in full of the outstanding awards would, under the present capital structure of the Company, result in the issue of 9,510,102 and 9,959,100, respectively, additional ordinary shares of the Company and additional share capital of $1.0 and $1.0 (before issue expenses), respectively.

F-44

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

20.NOTES TO THE CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(a)Major non-cash transactions

 

During the year ended December 31, 2021, 2022 and 2023, the Group had non-cash additions to right-of-use assets and lease liabilities of nil and nil, respectively, in respect of lease arrangements for offices and equipment.

 

(b)Changes in liabilities arising from financing activities

 

   Financial   New bank             
   instrument   loans and       Payable     
   measured at   other   Lease   for issue     
   FVTPL   borrowings   liabilities   costs   Total 
   $’000   $’000   $’000   $’000   $’000 
At January 1, 2021   153,283    8,309    3,635    
    165,227 
Interest expense   
    422    160    
    582 
Transaction costs for the issuance of convertible redeemable preferred shares   
    
    
    758    758 
Additions   97,370    12,410    
    
    109,780 
Disposal   
    
    
    
    
 
Payment                         
 – financing cash flows   
    (10,430)   (966)   (758)   (12,154)
 – operating cash flows   
    
    
    
    
 
Interest paid   
    (427)   
    
    (427)
Change in fair value   46,910    
    
    
    46,910 
Exchange adjustment   
    184    59    
    243 
At December 31, 2021   297,563    10,468    2,888    
    310,919 
Interest expense   
    295    133    
    433 
Transaction costs for the issuance of convertible redeemable preferred shares   
    
    
    
    
 
Additions   
    7,897    463    
    8,360 
Disposal   
    
    
    
    
 
Payment                         
 – financing cash flows   
    (13,316)   (936)   
    (14,252)
 – operating cash flows   
    
    
    
    
 
Interest paid   
    (290)   (134)   
    (424)
Change in fair value   (7,195)   
    
    
    (7,195)
Exchange adjustment   
    (741)   (177)   
    (917)
At December 31, 2022   290,368    4,313    2,237    
    296,918 
Interest expense   
    708    83    
    791 
Transaction costs for the issuance of convertible redeemable preferred shares   
    
    
    
    
 
Additions   
    50,234    
    
    50,234 
Conversion into ordinary shares   (329,539)   
    
    
    (329,539)
Payment                         
 – financing cash flows   
    (24,069)   (1,020)   
    (25,089)
 – operating cash flows   
    
    
    
    
 
Interest paid   
    (602)   (83)   
    (685)
Change in fair value   39,171    
    
    
    39,171 
Exchange adjustment   
    (115)   (26)   
    (141)
At December 31, 2023   
    30,469    1,191    
    31,660 

 

F-45

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

20.NOTES TO THE CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)

 

(c)Investment activities

 

   Dual currency       Wealth     
   structured   investments at   management     
   deposit   amortized cost   product   Total 
   $’000   $’000   $’000   $’000 
Year ended December 31, 2021                
purchase   (17,000)   (17,965)   (46,269)   (81,234)
disposal   9,500    17,965    
    27,465 
interest received   28    4    
    32 
Year ended December 31, 2022                    
purchase   (14,900)   
    (44,080)   (58,980)
disposal   22,439    
    65,618    88,057 
interest received   19    
    531    550 
Year ended December 31, 2023                    
purchase   
    (31,849)   (7)   (31,856)
disposal   
    
    21,039    21,039 
interest received   
    
    62    62 

 

21.COMMITMENTS

 

The Group did not have capital commitments at the end of each of the Relevant Periods.

 

22.RELATED PARTY TRANSACTIONS

 

(a)Related parties

 

Parties are considered to be related if one party has the ability, directly or indirectly, to control or exercise significant influence over the other party.

 

Parties are also considered to be related if they are subject to common control. Members of key management of the Group and their close family members are also considered as related parties.

 

Name of related parties   Nature of relationship
Mr. Yang Lu   The chief executive officer and chairman of our board of directors and ultimate significant shareholder of the Company

 

As disclosed in note 15 (i) to 15 (v) to the consolidated financial statements, the RMB40,000 and RMB90,000 non-revolving facility agreements provided by five third party banks were guaranteed by the ultimate significant shareholder, Mr. Yang Lu for the years ended December 31, 2022 and 2023, respectively.

F-46

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

23. FINANCIAL INSTRUMENTS BY CATEGORY

 

The carrying amounts of each of the categories of financial instruments of the Group as of the end of each of the Relevant Periods are as follows:

 

   As of December 31, 
   2022   2023 
   $’000   $’000 
Financial assets:        
Financial assets at FVTPL:        
Dual currency structured deposit   
    
 
Wealth management product   21,287    7 
Total   21,287    7 
Other financial assets:          
Financial assets included in prepayments, other receivables and other assets   2,585    2,978 
Cash and cash equivalents   42,758    91,492 
Short-term investments at amortized cost.   
    7,000 
Long-term investments at amortized cost   
    24,849 
Total   45,343    126,319 
Financial liabilities:          
Trade payables   13,098    14,348 
Financial liabilities included in other payables and accruals   3,877    4,890 
Interest-bearing bank and other borrowings   4,307    30,357 
Total   21,282    49,595 
Financial liabilities at FVTPL:          
Financial instruments measured at FVTPL   290,368    
 
Total   290,368    
 

 

24.FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

 

The carrying amounts and fair values of the Group’s financial instruments, other than those with carrying amounts that reasonably approximate to fair values, are as follows:

 

   As of December 31, 2022   As of December 31, 2023 
   Carrying       Carrying     
   amount   Fair value   amount   Fair value 
   $’000   $’000   $’000   $’000 
Financial assets                
Dual currency structured deposit   
    
    
    
 
Wealth management product   21,287    21,287    7    7 
Total.   21,287    21,287    7    7 
Financial liabilities                    
Financial liabilities at FVTPL   290,368    290,368    
    
 
Total.   290,368    290,368    
    
 

 

F-47

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

24.FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

 

Management has assessed that the fair values of cash and cash equivalents, interest-bearing bank and other borrowings, trade payables, financial assets included in prepayments, other receivables and other assets, and financial liabilities included in other payables and accruals approximate to their carrying amounts largely due to the short term maturities of these instruments.

 

The Group’s finance department headed by the finance manager is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance manager reports directly to the chief financial officer and the audit committee. At the end of each of the Relevant Periods, the finance department analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation. The valuation is reviewed and approved by the chief financial officer. The valuation process and results are discussed with the audit committee twice a year for interim and annual financial reporting.

 

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The methods and assumptions used to estimate the fair value, including a summary of significant unobservable inputs together with a quantitative sensitivity analysis, are set out in note 15 to the Consolidated Financial Statements.

 

The fair values of the non-current portion of interest-bearing bank and other borrowings have been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities. The changes in fair value as a result of the Group’s own non-performance risk for interest-bearing bank and other borrowings as of the end of each of the Relevant Periods were assessed to be insignificant.

 

Fair value hierarchy

 

The following tables illustrate the fair value measurement hierarchy of the Group’s financial instruments:

 

As of December 31, 2022

 

   Fair value measurement using 
   Quoted prices   Significant   Significant     
   in active   observable   unobservable     
   markets   inputs   inputs     
   (Level 1)   (Level 2)   (Level 3)   Total 
   $’000   $’000   $’000   $’000 
Financial assets                
Dual currency structured deposit   
    
    
    
 
Wealth management product   21,287    
    
    21,287 
Total.   21,287    
    
    21,287 
Financial liabilities             290,368    290,368 
Financial liabilities at FVTPL   
    
    290,368    290,368 

 

As of December 31, 2023

 

   Fair value measurement using 
   Quoted prices   Significant   Significant     
   in active   observable   unobservable     
   markets   inputs   inputs     
   (Level 1)   (Level 2)   (Level 3)   Total 
Financial assets                
Dual currency structured deposit   
    
    
    
 
Wealth management product   7    
    
    7 
Total   7    
    
    7 

 

F-48

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

25.FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

 

The Group’s principal financial instruments comprise interest-bearing bank and other borrowings, convertible redeemable preferred shares and cash and cash equivalents. The main purpose of these financial instruments is to raise finance for the Group’s operations. The Group has various other financial assets and liabilities such as trade payables, other payables and accruals, which arise directly from its operations.

 

The main risks arising from the Group’s financial instruments are foreign currency risk and liquidity risk. The board of directors reviews and agrees policies for managing each of these risks and they are summarized below.

 

Foreign currency risk

 

The Group has transactional currency exposures. Such exposures arise from purchases by operating units in currencies other than the units’ functional currencies.

 

The following table demonstrates the sensitivity at the end of each of the Relevant Periods to a reasonably possible change in the $ and RMB exchange rate, with all other variables held constant, of the Group’s profit before tax (due to changes in the fair values of monetary assets and liabilities).

 

   Increase/   Increase/     
   (decrease) in   (decrease)   Increase/ 
   $/RMB   in net   (decrease) 
   rate%   loss   in equity 
       $’000   $’000 
At December 31, 2021            
If the $ strengthens against the RMB   5    
    2,398 
If the $ weakens against the RMB   (5)   
    (2,651)

 

   Increase/   Increase/     
   (decrease) in   (decrease)   Increase/ 
   $/RMB   in net   (decrease) 
   rate%   loss   in equity 
       $’000   $’000 
At December 31, 2022            
If the $ strengthens against the RMB   5    
    (1,939)
If the $ weakens against the RMB   (5)   
    4,081 

 

   Increase/   Increase/     
   (decrease) in   (decrease)   Increase/ 
   $/RMB   in net   (decrease) 
   rate%   loss   in equity 
       $’000   $’000 
As of December 31, 2023            
If the $ strengthens against the RMB   5    (1,010)   (943)
If the $ weakens against the RMB   (5)   1,116    1,042 

 

Liquidity risk

 

The Group monitors and maintains a level of cash and cash equivalents deemed adequate by the management of the Group to finance the operations and mitigate the effects of fluctuations in cash flows.

 

F-49

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

25.FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (continued)

 

The maturity profile of the Group’s financial liabilities as of the end of each Relevant Periods, based on the contractual undiscounted payments, is as follows:

 

   As of December 31, 2022 
       Less than             
   On demand   1 year   1 to 5 years   Over 5 years   Total 
   $’000   $’000   $’000   $’000   $’000 
Financial liabilities at FVTPL   
    290,368    
    
    290,368 
Trade and bills payables   13,098    
    
    
    13,098 
Financial liabilities included in other payables and accruals   3,877    
    
    
    3,877 
Interest-bearing bank borrowings   
    4,307    
    
    4,307 
Total   16,975    294,675    
    
    311,650 

 

   As of December 31, 2023 
       Less than             
   On demand   1 year   1 to 5 years   Over 5 years   Total 
   $’000   $’000   $’000   $’000   $’000 
Financial liabilities at FVTPL   
    
    
    
    
 
Trade and bills payables   14,348    
    
    
    14,348 
Financial liabilities included in other payables and accruals   4,890    
    
    
    4,890 
Interest-bearing bank borrowings   
    30,357    
    
    30,357 
Total   19,238    30,357    
    
    49,595 

 

Capital management

 

The primary objectives of the Group’s capital management are to safeguard the Group’s ability to continue as a going concern and to maintain healthy capital ratios in order to support its business and maximize shareholders’ value.

 

The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Group is not subject to any externally imposed capital requirements. No changes were made in the objectives, policies or processes for managing capital during the Relevant Periods.

 

The asset-liability ratios as of the end of each of the Relevant Periods are as follows:

 

   As of December 31, 
   2022   2023 
   $’000   $’000 
Total assets   72,594    130,189 
Total liabilities   313,887    50,786 
Asset-liability ratio (Note i)   0.23    2.56 

 

 

Note i:

 

The asset-liability ratio is calculated by dividing total assets by total liabilities.

 

F-50

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

26.SUBSEQUENT EVENTS

 

(a)Bank loan

 

In February 2024, Adlai Hangzhou entered into a non-revolving facility agreement with a third party financial institution for a facility amount of RMB20,000 at an interest rate of 4.0% per annum, guaranteed by Mr. Yang Lu and Adlai Shanghai. The maturity date is August 2, 2024.

 

In February 2024, Adlai US entered into a non-revolving facility agreement with a third party financial institution for a facility amount of USD3,000 at an interest rate of 6.57% per annum. The maturity date is February 26, 2025.

 

In February 2024, Adlai Hangzhou entered into a non-revolving facility agreement with a third party financial institution for a facility amount of RMB30,000 at an interest rate of 4.0% per annum, guaranteed by Mr. Yang Lu and Adlai Shanghai. The maturity date is March 4, 2024.And in March 2024, Adlai Hangzhou repaid a non-revolving facility amount of RMB30,000 at the maturity date.

 

In March 2024, Adlai Hangzhou entered into a non-revolving facility agreement with a third party financial institution for a facility amount of RMB60,000 at an interest rate of 3.5% per annum, guaranteed by Mr. Yang Lu and Adlai Shanghai. The maturity date is November 28, 2024.

 

In March 2024, Adlai Hangzhou repaid three non-revolving facility amount of RMB40,000 at the maturity date.

 

In April 2024, Adlai Hangzhou repaid a non-revolving facility amount of RMB30,000 at the maturity date.

 

(b)Subsidiaries

 

In March 2024, Shareholder of Hangzhou Tangchuang agreed to increase the company’s registered capital to RMB100 million, with an additional investment of RMB70 million from Hangzhou Hongxi Business Management Co., Ltd and an additional investment of RMB20 million from Adlai Hangzhou. After this capital increase, the company accounting for 30% of the registered capital in Hangzhou Tangchuang. And Hangzhou Tangchuang would no longer be a subsidiary within the company’s scope of consolidation.

 

27.CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY

 

The business transactions and assets of Adlai Hangzhou and Shanghai Adlai Nortye Biopharma Co., Ltd (“PRC Subsidiaries”) are primarily denominated in RMB, which is not freely convertible into foreign currencies. All foreign exchange transactions take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People’s Bank of China. Approval of foreign currency payments by the People’s Bank of China or other regulatory institutions requires submitting a payment application form together with suppliers’ invoices, shipping documents and signed contracts. These currency exchange control measures imposed by the PRC government may restrict the ability of PRC Subsidiaries to transfer their net assets to the Company through loans, advances or cash dividends.

 

The net assets of PRC Subsidiaries in aggregate exceeded 25% of the Company’s consolidated net assets. Accordingly, condensed parent company financial statements have been prepared in accordance with Rule 5.04 and Rule 12-04 of SEC Regulation S-X.

 

The subsidiaries did not pay any dividends to the Company for the periods presented. For the purpose of presenting parent-only financial information, the Company records its investment in its subsidiaries under the cost method of accounting. Such investment is presented on the separate condensed balance sheets of the Company as “Investment in subsidiaries”. Certain information and footnote disclosures generally included in financial statements prepared in accordance with IFRSs are not required.

 

F-51

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

27.CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY (continued)

 

As of December 31, 2022 and 2023, there were no material contingencies, significant provisions for long-term obligations, or guarantees of the Company, except for those which have been separately disclosed in the consolidated financial statements, if any.

 

PARENT COMPANY BALANCE SHEETS

 

   December 31, 
   2022   2023 
   $’000   $’000 
ASSETS        
Current assets        
Cash and cash equivalents   12,194    63,150 
Prepayments, other receivables and other assets   36    44 
short-term investments at amortized cost   
    7,000 
Total current assets   12,230    70,194 
Non-current assets          
Due from related parties   115,743    123,102 
Investment in subsidiaries   94,300    129,711 
Total non-current assets   210,043    252,813 
Total assets   222,273    323,007 
LIABILITIES          
Current liabilities          
Accounts payable   888    976 
Other payables and accruals.   
    53 
Due to related parties   
    40 
Interest payables   
    10,650 
Non-current liabilities due within one year        
 
Financial liabilities at FVTPL   290,368    
 
Total current liabilities   291,260    11,719 
Non-current liabilities          
Long-term loans   
    
 
Financial liabilities at FVTPL   
    
 
Total non-current liabilities   
    
 
Total liabilities   291,260    11,719 
Ordinary shares (par value of $0.0001 per share; 442,456,586 shares authorized; 40,440,000 shares issued and outstanding as of December 31, 2022; and nil outstanding as of December 31, 2023)   4    
 
Class A Ordinary shares (par value of $0.0001 per share; nil outstanding as of December 31,2022; and 93,710,805 shares outstanding as of December 31, 2023)   
    9 
Class B Ordinary shares (par value of $0.0001 per share; nil outstanding as of December 31,2022; and 16,990,000 shares outstanding as of December 31, 2023)   
    2 
Series A convertible preferred shares (par value of US$0.0001 per share; 14,560,000 and nil shares authorized, issued and outstanding as of   10,980    
 
Additional paid-in capital   6,415    438,707 
Share option reserve   11,730    16,059 
Accumulated deficit   (98,116)   (143,489)
Total shareholders’ deficit   (68,987)   311,288 
Total liabilities and shareholders’ equity   222,273    323,007 

 

F-52

 

 

ADLAI NORTYE LTD.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED
DECEMBER 31, 2021, 2022 AND 2023 (continued)

(All amounts in thousands, except share and per share data, or as otherwise noted)

 

27.CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY (continued)

 

PARENT COMPANY STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

 

   For the Years Ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
REVENUE   
    
    
 
Other operating income, net   
    156    242 
Administrative expenses   (2,376)   (1,390)   (6,196)
Research and development expenses   
    
    
 
Total operating loss   (2,376)   (1,234)   (5,954)
Other income and gains   173    
    
 
Other expenses   
    
    
 
Investment income   3    
    
 
Fair value loss on financial liabilities at FVTPL   (46,910)   7,194    (39,171)
Finance costs   (399)   
    (249)
LOSS BEFORE TAX   (49,509)   5,960    (45,374)
Income tax expense   
    
    
 
LOSS FOR THE YEAR   (49,509)   5,960    (45,374)
TOTAL COMPREHENSIVE (LOSS)/INCOME FOR THE YEAR   (49,509)   5,960    (45,374)

 

PARENT COMPANY STATEMENTS OF CASH FLOWS

 

   Year ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
Net cash flows used in operating activities   (1,610)   (1,134)   (13,143)
Net cash flows used in investing activities   (65,798)   (35,035)   (38,082)
Net cash flows from financing activities   96,428    
    102,181 
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS   29,020    (36,169)   50,956 
Cash and cash equivalents at beginning of year   19,343    48,363    12,194 
CASH AND CASH EQUIVALENTS AT END OF YEAR   48,363    12,194    63,150 

 

F-53

 

+86 0571-2891-8385 40440000 In October 2022, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 20,000 and at an interest rate of 4.80% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. The non-revolving facility agreement was repaid at the maturity date of April 24, 2023. In October 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 30,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. In September 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. And in March 2024, Adlai Hangzhou repaid it before the maturity date. In September 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. And in March 2024, Adlai Hangzhou repaid it before the maturity date. In November 2023, Adlai US entered into a non-revolving facility agreement for a facility amount of USD 3,000 and at an interest rate of 6.78% per annum, guaranteed by the company. In December 2023, Adlai US entered into a non-revolving facility agreement for a facility amount of USD 4,000 and at an interest rate of 6.30% per annum, guaranteed by the company. P18M P2Y P2Y P2Y P30D P4Y 3000000 0001944552 true FY 0001944552 2023-01-01 2023-12-31 0001944552 dei:BusinessContactMember 2023-01-01 2023-12-31 0001944552 anl:ClassaOrdinarySharesMember 2023-12-31 0001944552 anl:ClassbOrdinarySharesMember 2023-12-31 0001944552 2021-01-01 2021-12-31 0001944552 2022-01-01 2022-12-31 0001944552 2022-12-31 0001944552 2023-12-31 0001944552 anl:ClassaOrdinarySharesMember 2022-12-31 0001944552 anl:ClassbOrdinarySharesMember 2022-12-31 0001944552 anl:SeriesConvertiblePreferredSharesMember 2022-12-31 0001944552 anl:SeriesConvertiblePreferredSharesMember 2023-12-31 0001944552 ifrs-full:OrdinarySharesMember 2020-12-31 0001944552 ifrs-full:AdditionalPaidinCapitalMember 2020-12-31 0001944552 ifrs-full:PreferenceSharesMember 2020-12-31 0001944552 ifrs-full:ReserveOfSharebasedPaymentsMember 2020-12-31 0001944552 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-12-31 0001944552 ifrs-full:RetainedEarningsMember 2020-12-31 0001944552 2020-12-31 0001944552 ifrs-full:AdditionalPaidinCapitalMember 2021-01-01 2021-12-31 0001944552 ifrs-full:PreferenceSharesMember 2021-01-01 2021-12-31 0001944552 ifrs-full:ReserveOfSharebasedPaymentsMember 2021-01-01 2021-12-31 0001944552 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-01-01 2021-12-31 0001944552 ifrs-full:RetainedEarningsMember 2021-01-01 2021-12-31 0001944552 ifrs-full:OrdinarySharesMember 2021-01-01 2021-12-31 0001944552 ifrs-full:OrdinarySharesMember 2021-12-31 0001944552 ifrs-full:AdditionalPaidinCapitalMember 2021-12-31 0001944552 ifrs-full:PreferenceSharesMember 2021-12-31 0001944552 ifrs-full:ReserveOfSharebasedPaymentsMember 2021-12-31 0001944552 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-12-31 0001944552 ifrs-full:RetainedEarningsMember 2021-12-31 0001944552 2021-12-31 0001944552 ifrs-full:AdditionalPaidinCapitalMember 2022-01-01 2022-12-31 0001944552 ifrs-full:PreferenceSharesMember 2022-01-01 2022-12-31 0001944552 ifrs-full:ReserveOfSharebasedPaymentsMember 2022-01-01 2022-12-31 0001944552 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-01-01 2022-12-31 0001944552 ifrs-full:RetainedEarningsMember 2022-01-01 2022-12-31 0001944552 ifrs-full:OrdinarySharesMember 2022-01-01 2022-12-31 0001944552 ifrs-full:OrdinarySharesMember 2022-12-31 0001944552 ifrs-full:AdditionalPaidinCapitalMember 2022-12-31 0001944552 ifrs-full:PreferenceSharesMember 2022-12-31 0001944552 ifrs-full:ReserveOfSharebasedPaymentsMember 2022-12-31 0001944552 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-12-31 0001944552 ifrs-full:RetainedEarningsMember 2022-12-31 0001944552 ifrs-full:AdditionalPaidinCapitalMember 2023-01-01 2023-12-31 0001944552 ifrs-full:PreferenceSharesMember 2023-01-01 2023-12-31 0001944552 ifrs-full:ReserveOfSharebasedPaymentsMember 2023-01-01 2023-12-31 0001944552 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-01-01 2023-12-31 0001944552 ifrs-full:RetainedEarningsMember 2023-01-01 2023-12-31 0001944552 ifrs-full:OrdinarySharesMember 2023-01-01 2023-12-31 0001944552 ifrs-full:OrdinarySharesMember 2023-12-31 0001944552 ifrs-full:AdditionalPaidinCapitalMember 2023-12-31 0001944552 ifrs-full:PreferenceSharesMember 2023-12-31 0001944552 ifrs-full:ReserveOfSharebasedPaymentsMember 2023-12-31 0001944552 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-12-31 0001944552 ifrs-full:RetainedEarningsMember 2023-12-31 0001944552 anl:AlpineBioscienceLtdMember 2023-01-01 2023-12-31 0001944552 anl:AlpineBioscienceLtdMember 2023-12-31 0001944552 anl:AdlaiNortyeUsaIncMember 2023-01-01 2023-12-31 0001944552 anl:AdlaiNortyeUsaIncMember 2023-12-31 0001944552 anl:AdlaiNortyeSwitzerlandAgMember 2023-01-01 2023-12-31 0001944552 anl:AdlaiNortyeSwitzerlandAgMember 2023-12-31 0001944552 anl:AdlaiNortyePteltdMember 2023-01-01 2023-12-31 0001944552 anl:AdlaiNortyePteltdMember 2023-12-31 0001944552 anl:AdlaiNortyeHkLimitedMember 2023-01-01 2023-12-31 0001944552 anl:AdlaiNortyeHkLimitedMember 2023-12-31 0001944552 anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2023-01-01 2023-12-31 0001944552 anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2023-12-31 0001944552 anl:ShanghaiAdlaiNortyeBiopharmaCoLtdMember 2023-01-01 2023-12-31 0001944552 anl:ShanghaiAdlaiNortyeBiopharmaCoLtdMember 2023-12-31 0001944552 anl:HangzhouTangchuangWeilaiTechnolegyCoLtdMember 2023-01-01 2023-12-31 0001944552 anl:HangzhouTangchuangWeilaiTechnolegyCoLtdMember 2023-12-31 0001944552 anl:CashAndCashEquivalentMember 2023-12-31 0001944552 ifrs-full:ComputerSoftwareMember 2023-01-01 2023-12-31 0001944552 anl:AmendmentsToIAS1Member 2023-01-01 2023-12-31 0001944552 anl:AmendmentsToIFRS16Member 2023-01-01 2023-12-31 0001944552 anl:AmendmentsToIAS1OneMember 2023-01-01 2023-12-31 0001944552 anl:AmendmentsToIAS28AndIFRS10Member 2023-01-01 2023-12-31 0001944552 anl:PlantAndMachineryMember ifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001944552 anl:PlantAndMachineryMember ifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001944552 ifrs-full:OfficeEquipmentMember ifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001944552 ifrs-full:OfficeEquipmentMember ifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001944552 ifrs-full:MotorVehiclesMember 2023-01-01 2023-12-31 0001944552 anl:ElectronicEquipmentMember ifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001944552 anl:ElectronicEquipmentMember ifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001944552 anl:OfficesMember ifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001944552 anl:OfficesMember ifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001944552 ifrs-full:OfficeEquipmentMember ifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001944552 ifrs-full:OfficeEquipmentMember ifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001944552 ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember anl:SalesOfExclusiveOptionMember 2023-01-01 2023-12-31 0001944552 anl:SalesOfIntellectualPropertyMember 2021-01-01 2021-12-31 0001944552 anl:SalesOfExclusiveOptionMember 2021-01-01 2021-12-31 0001944552 anl:SalesOfExclusiveOptionMember 2022-01-01 2022-12-31 0001944552 anl:SalesOfExclusiveOptionMember 2023-01-01 2023-12-31 0001944552 country:US 2023-01-01 2023-12-31 0001944552 country:CN 2023-01-01 2023-12-31 0001944552 country:CN ifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001944552 country:CN ifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001944552 country:CN 2022-12-31 0001944552 country:CN 2023-12-31 0001944552 country:US 2022-12-31 0001944552 country:US 2023-12-31 0001944552 ifrs-full:PropertyPlantAndEquipmentMember 2022-12-31 0001944552 ifrs-full:PropertyPlantAndEquipmentMember 2023-12-31 0001944552 anl:CapitalizedResearchAndDevelopmentMember 2022-12-31 0001944552 anl:CapitalizedResearchAndDevelopmentMember 2023-12-31 0001944552 anl:AccruedAndPrepaidExpensesMember 2022-12-31 0001944552 anl:AccruedAndPrepaidExpensesMember 2023-12-31 0001944552 ifrs-full:RightofuseAssetsMember 2022-12-31 0001944552 ifrs-full:RightofuseAssetsMember 2023-12-31 0001944552 anl:AdvertisingExpensesInExcessOfDeductionLimitMember 2022-12-31 0001944552 anl:AdvertisingExpensesInExcessOfDeductionLimitMember 2023-12-31 0001944552 ifrs-full:AllowanceForCreditLossesMember 2022-12-31 0001944552 ifrs-full:AllowanceForCreditLossesMember 2023-12-31 0001944552 anl:StateTaxMember 2022-12-31 0001944552 anl:StateTaxMember 2023-12-31 0001944552 anl:StockOptionsMember 2022-12-31 0001944552 anl:StockOptionsMember 2023-12-31 0001944552 ifrs-full:UnusedTaxLossesMember 2022-12-31 0001944552 ifrs-full:UnusedTaxLossesMember 2023-12-31 0001944552 ifrs-full:ConvertibleInstrumentsMember 2021-01-01 2021-12-31 0001944552 ifrs-full:ShareOptionsMember 2021-01-01 2021-12-31 0001944552 ifrs-full:ConvertibleInstrumentsMember 2022-01-01 2022-12-31 0001944552 ifrs-full:ShareOptionsMember 2022-01-01 2022-12-31 0001944552 ifrs-full:ShareOptionsMember 2023-01-01 2023-12-31 0001944552 ifrs-full:LeaseholdImprovementsMember 2021-12-31 0001944552 anl:PlantAndMachineryMember 2021-12-31 0001944552 ifrs-full:OfficeEquipmentMember 2021-12-31 0001944552 ifrs-full:MotorVehiclesMember 2021-12-31 0001944552 anl:ElectronicEquipmentMember 2021-12-31 0001944552 ifrs-full:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0001944552 anl:PlantAndMachineryMember 2022-01-01 2022-12-31 0001944552 ifrs-full:OfficeEquipmentMember 2022-01-01 2022-12-31 0001944552 ifrs-full:MotorVehiclesMember 2022-01-01 2022-12-31 0001944552 anl:ElectronicEquipmentMember 2022-01-01 2022-12-31 0001944552 ifrs-full:LeaseholdImprovementsMember 2022-12-31 0001944552 anl:PlantAndMachineryMember 2022-12-31 0001944552 ifrs-full:OfficeEquipmentMember 2022-12-31 0001944552 ifrs-full:MotorVehiclesMember 2022-12-31 0001944552 anl:ElectronicEquipmentMember 2022-12-31 0001944552 ifrs-full:LeaseholdImprovementsMember 2023-01-01 2023-12-31 0001944552 anl:PlantAndMachineryMember 2023-01-01 2023-12-31 0001944552 ifrs-full:OfficeEquipmentMember 2023-01-01 2023-12-31 0001944552 anl:ElectronicEquipmentMember 2023-01-01 2023-12-31 0001944552 ifrs-full:LeaseholdImprovementsMember 2023-12-31 0001944552 anl:PlantAndMachineryMember 2023-12-31 0001944552 ifrs-full:OfficeEquipmentMember 2023-12-31 0001944552 ifrs-full:MotorVehiclesMember 2023-12-31 0001944552 anl:ElectronicEquipmentMember 2023-12-31 0001944552 ifrs-full:BottomOfRangeMember 2023-01-01 2023-12-31 0001944552 ifrs-full:TopOfRangeMember 2023-01-01 2023-12-31 0001944552 anl:OfficesMember 2021-12-31 0001944552 ifrs-full:OfficeEquipmentMember 2021-12-31 0001944552 anl:OfficesMember 2022-01-01 2022-12-31 0001944552 ifrs-full:OfficeEquipmentMember 2022-01-01 2022-12-31 0001944552 anl:OfficesMember 2022-12-31 0001944552 ifrs-full:OfficeEquipmentMember 2022-12-31 0001944552 anl:OfficesMember 2023-01-01 2023-12-31 0001944552 ifrs-full:OfficeEquipmentMember 2023-01-01 2023-12-31 0001944552 anl:OfficesMember 2023-12-31 0001944552 ifrs-full:OfficeEquipmentMember 2023-12-31 0001944552 ifrs-full:LeaseLiabilitiesMember 2023-01-01 2023-12-31 0001944552 anl:WealthManagementProductMember 2022-01-01 2022-12-31 0001944552 anl:WealthManagementProductMember 2022-12-31 0001944552 anl:WealthManagementProductMember 2023-12-31 0001944552 anl:NonRevolvingFacilityAgreement522InterestDueMarch222023GuaranteedMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2022-03-31 0001944552 anl:NonRevolvingFacilityAgreement48InterestMaturityDueApril242023GuaranteedMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2022-10-31 0001944552 anl:NonRevolvingFacilityAgreement48InterestMaturityDueApril242023GuaranteedMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2023-10-31 0001944552 anl:NonRevolvingFacilityAgreement42InterestMaturityDueMarch262024GuaranteedMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2023-03-31 0001944552 anl:NonRevolvingFacilityAgreement42InterestMaturityDueMarch262024GuaranteedMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2023-12-31 0001944552 anl:NonRevolvingFacilityAgreement40InterestMaturityDueSeptember172024GuaranteedMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2023-09-30 0001944552 anl:NonRevolvingFacilityAgreement40InterestMaturityDueSeptember182024GuaranteedMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2023-09-30 0001944552 anl:NonRevolvingFacilityAgreement678InterestMaturityDueNovember272024GuaranteedMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2023-11-30 0001944552 anl:NonRevolvingFacilityAgreement63InterestMaturityDueDecember262024GuaranteedMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2023-12-31 0001944552 anl:NonRevolvingFacilityAgreement60InterestMaturityDueNovember142024GuaranteedMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2023-12-31 0001944552 anl:NonRevolvingFacility522InterestDueMarch222023GuaranteedMember 2022-12-31 0001944552 anl:NonRevolvingFacility522InterestDueMarch222023GuaranteedMember 2023-12-31 0001944552 anl:NonRevolvingFacility48InterestDueApril242023GuaranteedMember 2022-12-31 0001944552 anl:NonRevolvingFacility48InterestDueApril242023GuaranteedMember 2023-12-31 0001944552 anl:NonRevolvingFacility42InterestDueMarch262024GuaranteedMember 2022-12-31 0001944552 anl:NonRevolvingFacility42InterestDueMarch262024GuaranteedMember 2023-12-31 0001944552 anl:NonRevolvingFacility40InterestDueSeptember172024GuaranteedMember 2022-12-31 0001944552 anl:NonRevolvingFacility40InterestDueSeptember172024GuaranteedMember 2023-12-31 0001944552 anl:NonRevolvingFacility40InterestDueSeptember182024GuaranteedMember 2022-12-31 0001944552 anl:NonRevolvingFacility40InterestDueSeptember182024GuaranteedMember 2023-12-31 0001944552 anl:NonRevolvingFacility40InterestDueApril152024GuaranteedMember 2022-12-31 0001944552 anl:NonRevolvingFacility40InterestDueApril152024GuaranteedMember 2023-12-31 0001944552 anl:NonRevolvingFacility678InterestDueNovember272024GuaranteedMember 2022-12-31 0001944552 anl:NonRevolvingFacility678InterestDueNovember272024GuaranteedMember 2023-12-31 0001944552 anl:NonRevolvingFacility60InterestDueNovember142024GuaranteedMember 2022-12-31 0001944552 anl:NonRevolvingFacility60InterestDueNovember142024GuaranteedMember 2023-12-31 0001944552 anl:NonRevolvingFacility63InterestDueDecember262024GuaranteedMember 2022-12-31 0001944552 anl:NonRevolvingFacility63InterestDueDecember262024GuaranteedMember 2023-12-31 0001944552 anl:NonRevolvingFacility40InterestDueDecember252024GuaranteedMember 2022-12-31 0001944552 anl:NonRevolvingFacility40InterestDueDecember252024GuaranteedMember 2023-12-31 0001944552 anl:InterestBearingBankBorrowingsMember 2023-01-01 2023-12-31 0001944552 ifrs-full:ShorttermBorrowingsMember 2021-12-31 0001944552 ifrs-full:ShorttermBorrowingsMember 2022-01-01 2022-12-31 0001944552 ifrs-full:ShorttermBorrowingsMember 2022-12-31 0001944552 ifrs-full:ShorttermBorrowingsMember 2023-01-01 2023-12-31 0001944552 ifrs-full:ShorttermBorrowingsMember 2023-12-31 0001944552 anl:SeriesaInvestorsMember anl:AdlaiHangzhouMember 2015-01-01 2015-12-31 0001944552 anl:SeriesConvertiblePreferredSharesMember anl:AdlaiHangzhouMember 2018-06-01 2018-06-30 0001944552 anl:SeriesConvertiblePreferredSharesMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2018-06-30 0001944552 anl:SeriesBConvertibleLoansMember anl:SeriesBOnshoreInvestorsMember anl:AdlaiHangzhouMember 2018-06-30 0001944552 anl:SeriesBConvertibleLoansMember anl:SeriesBConvertibleRedeemablePreferredSharesMember anl:SeriesBOnshoreInvestorsMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2018-06-01 2018-06-30 0001944552 anl:SeriesBConvertibleRedeemablePreferredSharesMember anl:SeriesBOnshoreInvestorsMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2018-06-30 0001944552 anl:SeriesBConvertibleLoansMember anl:SeriesBOnshoreInvestorsMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2018-06-30 0001944552 anl:SeriesBConvertibleLoansMember anl:SeriesBConvertibleRedeemablePreferredSharesMember anl:SeriesBOnshoreInvestorsMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2020-05-01 2020-05-31 0001944552 anl:SeriesBConvertibleRedeemablePreferredSharesMember anl:SeriesBOffshoreInvestorsMember 2023-01-01 2023-12-31 0001944552 anl:SeriesBConvertibleRedeemablePreferredSharesMember anl:SeriesBOffshoreInvestorsMember 2023-12-31 0001944552 anl:SeriesBConvertibleRedeemablePreferredSharesMember anl:SeriescInvestorsMember 2023-01-01 2023-12-31 0001944552 anl:SeriesBConvertibleRedeemablePreferredSharesMember anl:SeriesdInvestorsMember 2023-01-01 2023-12-31 0001944552 anl:IfGroupFailsToMeetCommittedBusinessObjectivesMember 2023-01-01 2023-12-31 0001944552 anl:SeriesCAndSeriesDConvertibleRedeemablePreferredSharesMember 2023-01-01 2023-12-31 0001944552 anl:NextEquityFinancingWarrantMember anl:SeriesBInvestorsMember 2018-06-30 0001944552 anl:NextEquityFinancingWarrantMember anl:SeriesBInvestorsMember 2018-06-01 2018-06-30 0001944552 anl:SeriesBConvertibleRedeemablePreferredSharesMember anl:ChinaEquitiesHkLimitedMember 2021-07-01 2021-07-31 0001944552 anl:SeriesBConvertibleRedeemablePreferredSharesMember 2021-12-31 0001944552 anl:SeriesCConvertibleRedeemablePreferredSharesMember 2021-12-31 0001944552 anl:SeriesDConvertibleRedeemablePreferredSharesMember 2021-12-31 0001944552 anl:SeriesBConvertibleRedeemablePreferredSharesMember 2022-01-01 2022-12-31 0001944552 anl:SeriesCConvertibleRedeemablePreferredSharesMember 2022-01-01 2022-12-31 0001944552 anl:SeriesDConvertibleRedeemablePreferredSharesMember 2022-01-01 2022-12-31 0001944552 anl:SeriesBConvertibleRedeemablePreferredSharesMember 2022-12-31 0001944552 anl:SeriesCConvertibleRedeemablePreferredSharesMember 2022-12-31 0001944552 anl:SeriesDConvertibleRedeemablePreferredSharesMember 2022-12-31 0001944552 anl:SeriesBConvertibleRedeemablePreferredSharesMember 2023-01-01 2023-12-31 0001944552 anl:SeriesCConvertibleRedeemablePreferredSharesMember 2023-01-01 2023-12-31 0001944552 anl:SeriesDConvertibleRedeemablePreferredSharesMember 2023-01-01 2023-12-31 0001944552 anl:SeriesBConvertibleRedeemablePreferredSharesMember 2023-12-31 0001944552 anl:SeriesCConvertibleRedeemablePreferredSharesMember 2023-12-31 0001944552 anl:SeriesDConvertibleRedeemablePreferredSharesMember 2023-12-31 0001944552 anl:FairValueOfSharesMeasurementInputMember 2022-12-31 0001944552 ifrs-full:InterestRateMeasurementInputMember 2022-12-31 0001944552 anl:ExpectedTermMeasurementInputMember 2022-12-31 0001944552 ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember 2022-12-31 0001944552 ifrs-full:CapitalReserveMember 2023-12-31 0001944552 ifrs-full:OrdinarySharesMember 2023-12-31 0001944552 anl:NortyeTalentLimitedMember 2021-01-01 2021-12-31 0001944552 anl:NortyeInternationalLimitedMember 2021-01-01 2021-12-31 0001944552 ifrs-full:IssuedCapitalMember 2022-12-31 0001944552 ifrs-full:OrdinarySharesMember 2022-12-31 0001944552 ifrs-full:IssuedCapitalMember 2023-01-01 2023-12-31 0001944552 ifrs-full:OrdinarySharesMember 2023-01-01 2023-12-31 0001944552 ifrs-full:IssuedCapitalMember 2023-12-31 0001944552 ifrs-full:TopOfRangeMember anl:ManagementAndEmployeesMember anl:ShareIncentiveSchemeMember 2017-06-15 2017-06-15 0001944552 anl:ManagementAndEmployeesMember anl:ShareIncentiveSchemeMember 2017-06-15 2017-06-15 0001944552 anl:ShareIncentiveSchemeMember 2017-06-15 2017-06-15 0001944552 anl:IfrsShareBasedPaymentArrangementTrancheOneMember anl:ShareIncentiveSchemeMember 2017-06-15 2017-06-15 0001944552 anl:IfrsShareBasedPaymentArrangementTrancheTwoMember anl:ShareIncentiveSchemeMember 2017-06-15 2017-06-15 0001944552 srt:ManagementMember anl:ShareIncentiveSchemeMember 2017-06-15 2017-06-15 0001944552 anl:EmployeesMember anl:ShareIncentiveSchemeMember 2017-06-15 2017-06-15 0001944552 anl:ShareIncentiveSchemeMember 2021-01-01 2021-12-31 0001944552 anl:ShareIncentiveSchemeMember 2022-01-01 2022-12-31 0001944552 anl:ShareIncentiveSchemeMember 2023-01-01 2023-12-31 0001944552 ifrs-full:TopOfRangeMember anl:ShareIncentivePlanMember 2021-05-28 0001944552 anl:ShareIncentivePlanMember 2021-05-28 0001944552 2021-05-28 0001944552 anl:NortyeInternationalLimitedMember anl:ShareIncentivePlanMember 2021-07-05 2021-07-05 0001944552 anl:NortyeTalentLimitedMember anl:ShareIncentivePlanMember 2021-07-05 2021-07-05 0001944552 anl:ShareIncentivePlanMember 2021-07-05 2021-07-05 0001944552 anl:ExecutivesEmployeesAndConsultantsMember anl:ShareIncentivePlanMember 2020-09-08 2020-09-08 0001944552 anl:ExecutivesEmployeesAndConsultantsMember anl:ShareIncentivePlanMember 2020-11-01 2020-11-01 0001944552 anl:ExecutivesEmployeesAndConsultantsMember anl:ShareIncentivePlanMember 2021-05-31 2021-05-31 0001944552 anl:ExecutivesEmployeesAndConsultantsMember anl:ShareIncentivePlanMember 2021-10-01 2021-10-01 0001944552 anl:CertainNewEmployeesMember anl:ShareIncentivePlanMember 2022-01-01 2022-01-01 0001944552 anl:CertainEmployeesAndManagersMember anl:ShareIncentivePlanMember 2022-01-01 2022-01-01 0001944552 anl:CertainNewEmployeesPromotedEmployeesAndSeniorManagersMember anl:ShareIncentivePlanMember 2022-04-01 2022-04-01 0001944552 anl:ThreeConsultantsMember anl:ShareIncentivePlanMember 2022-04-01 2022-04-01 0001944552 anl:FiveNewEmployeesMember anl:ShareIncentivePlanMember 2022-07-01 2022-07-01 0001944552 anl:FiveNewEmployeesMember anl:ShareIncentivePlanMember 2022-10-01 2022-10-01 0001944552 anl:EmployeesMember anl:ShareIncentivePlan2020Member 2023-04-01 2023-04-30 0001944552 anl:ShareIncentivePlan2023Member 2023-04-30 0001944552 anl:CertainNewEmployeesMember anl:ShareIncentivePlanMember 2023-12-06 2023-12-06 0001944552 anl:CertainEmployeesAndManagersMember anl:ShareIncentivePlanMember 2023-12-06 2023-12-06 0001944552 anl:ShareIncentivePlanMember 2022-12-31 0001944552 anl:ShareIncentivePlanMember 2023-12-31 0001944552 anl:ShareIncentivePlanMember 2022-01-01 2022-12-31 0001944552 anl:ShareIncentivePlanMember 2023-01-01 2023-12-31 0001944552 anl:ShareIncentivePlanMember 2021-12-30 0001944552 anl:ShareIncentivePlanMember 2021-12-31 2021-12-31 0001944552 anl:ShareIncentivePlanMember 2022-01-01 2022-01-01 0001944552 anl:ShareIncentivePlanMember 2022-04-01 2022-04-01 0001944552 anl:ShareIncentivePlanMember 2022-07-01 2022-07-01 0001944552 anl:ShareIncentivePlanMember 2022-10-01 2022-10-01 0001944552 anl:ShareIncentivePlanMember 2023-04-21 2023-04-21 0001944552 anl:ShareIncentivePlanMember 2023-12-06 2023-12-06 0001944552 anl:FinancialInstrumentMeasuredAtFairValueThroughProfitOrLossMember 2020-12-31 0001944552 anl:NewBankLoansAndOtherBorrowingsMember 2020-12-31 0001944552 ifrs-full:LeaseLiabilitiesMember 2020-12-31 0001944552 anl:PayableForIssueCostsMember 2020-12-31 0001944552 anl:FinancialInstrumentMeasuredAtFairValueThroughProfitOrLossMember 2021-01-01 2021-12-31 0001944552 anl:NewBankLoansAndOtherBorrowingsMember 2021-01-01 2021-12-31 0001944552 ifrs-full:LeaseLiabilitiesMember 2021-01-01 2021-12-31 0001944552 anl:PayableForIssueCostsMember 2021-01-01 2021-12-31 0001944552 anl:FinancialInstrumentMeasuredAtFairValueThroughProfitOrLossMember 2021-12-31 0001944552 anl:NewBankLoansAndOtherBorrowingsMember 2021-12-31 0001944552 ifrs-full:LeaseLiabilitiesMember 2021-12-31 0001944552 anl:PayableForIssueCostsMember 2021-12-31 0001944552 anl:FinancialInstrumentMeasuredAtFairValueThroughProfitOrLossMember 2022-01-01 2022-12-31 0001944552 anl:NewBankLoansAndOtherBorrowingsMember 2022-01-01 2022-12-31 0001944552 ifrs-full:LeaseLiabilitiesMember 2022-01-01 2022-12-31 0001944552 anl:PayableForIssueCostsMember 2022-01-01 2022-12-31 0001944552 anl:FinancialInstrumentMeasuredAtFairValueThroughProfitOrLossMember 2022-12-31 0001944552 anl:NewBankLoansAndOtherBorrowingsMember 2022-12-31 0001944552 ifrs-full:LeaseLiabilitiesMember 2022-12-31 0001944552 anl:PayableForIssueCostsMember 2022-12-31 0001944552 anl:FinancialInstrumentMeasuredAtFairValueThroughProfitOrLossMember 2023-01-01 2023-12-31 0001944552 anl:NewBankLoansAndOtherBorrowingsMember 2023-01-01 2023-12-31 0001944552 anl:PayableForIssueCostsMember 2023-01-01 2023-12-31 0001944552 anl:FinancialInstrumentMeasuredAtFairValueThroughProfitOrLossMember 2023-12-31 0001944552 anl:NewBankLoansAndOtherBorrowingsMember 2023-12-31 0001944552 ifrs-full:LeaseLiabilitiesMember 2023-12-31 0001944552 anl:PayableForIssueCostsMember 2023-12-31 0001944552 anl:DualCurrencyStructuredDepositMember 2021-01-01 2021-12-31 0001944552 anl:InvestmentsAtAmortizedCostMember 2021-01-01 2021-12-31 0001944552 anl:WealthManagementProductMember 2021-01-01 2021-12-31 0001944552 anl:DualCurrencyStructuredDepositMember 2022-01-01 2022-12-31 0001944552 anl:InvestmentsAtAmortizedCostMember 2022-01-01 2022-12-31 0001944552 anl:DualCurrencyStructuredDepositMember 2023-01-01 2023-12-31 0001944552 anl:InvestmentsAtAmortizedCostMember 2023-01-01 2023-12-31 0001944552 anl:WealthManagementProductMember 2023-01-01 2023-12-31 0001944552 anl:MrYangLuMember 2023-01-01 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:DualCurrencyStructuredDepositMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:DualCurrencyStructuredDepositMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:WealthManagementProductMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:WealthManagementProductMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:FinancialAssetsIncludedInPrepaymentsOtherReceivablesAndOtherAssetsMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:FinancialAssetsIncludedInPrepaymentsOtherReceivablesAndOtherAssetsMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:IfrsCashAndCashEquivalentsMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:IfrsCashAndCashEquivalentsMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:ShortTermInvestmentMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:ShortTermInvestmentMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:LongTermInvestmentsMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:LongTermInvestmentsMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember anl:TradePayablesMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember anl:TradePayablesMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember anl:FinancialLiabilitiesIncludedInOtherPayablesAndAccrualsMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember anl:FinancialLiabilitiesIncludedInOtherPayablesAndAccrualsMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember anl:InterestBearingBankAndOtherBorrowingsMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember anl:InterestBearingBankAndOtherBorrowingsMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember anl:FinancialLiabilitiesMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember anl:FinancialLiabilitiesMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2023-12-31 0001944552 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2022-12-31 0001944552 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:DualCurrencyStructuredDepositMember ifrs-full:Level1OfFairValueHierarchyMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:DualCurrencyStructuredDepositMember ifrs-full:Level2OfFairValueHierarchyMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:DualCurrencyStructuredDepositMember ifrs-full:Level3OfFairValueHierarchyMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:WealthManagementProductMember ifrs-full:Level1OfFairValueHierarchyMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:WealthManagementProductMember ifrs-full:Level2OfFairValueHierarchyMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:WealthManagementProductMember ifrs-full:Level3OfFairValueHierarchyMember 2022-12-31 0001944552 ifrs-full:Level1OfFairValueHierarchyMember 2022-12-31 0001944552 ifrs-full:Level2OfFairValueHierarchyMember 2022-12-31 0001944552 ifrs-full:Level3OfFairValueHierarchyMember 2022-12-31 0001944552 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember ifrs-full:Level1OfFairValueHierarchyMember 2022-12-31 0001944552 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember ifrs-full:Level2OfFairValueHierarchyMember 2022-12-31 0001944552 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember ifrs-full:Level3OfFairValueHierarchyMember 2022-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:DualCurrencyStructuredDepositMember ifrs-full:Level1OfFairValueHierarchyMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:DualCurrencyStructuredDepositMember ifrs-full:Level2OfFairValueHierarchyMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:DualCurrencyStructuredDepositMember ifrs-full:Level3OfFairValueHierarchyMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:WealthManagementProductMember ifrs-full:Level1OfFairValueHierarchyMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:WealthManagementProductMember ifrs-full:Level2OfFairValueHierarchyMember 2023-12-31 0001944552 ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember anl:WealthManagementProductMember ifrs-full:Level3OfFairValueHierarchyMember 2023-12-31 0001944552 ifrs-full:Level1OfFairValueHierarchyMember 2023-12-31 0001944552 ifrs-full:Level2OfFairValueHierarchyMember 2023-12-31 0001944552 ifrs-full:Level3OfFairValueHierarchyMember 2023-12-31 0001944552 ifrs-full:CurrencyRiskMember 2021-01-01 2021-12-31 0001944552 ifrs-full:CurrencyRiskMember 2022-01-01 2022-12-31 0001944552 ifrs-full:CurrencyRiskMember 2023-01-01 2023-12-31 0001944552 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember ifrs-full:OnDemandMember 2022-12-31 0001944552 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember ifrs-full:NotLaterThanOneYearMember 2022-12-31 0001944552 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2022-12-31 0001944552 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember ifrs-full:LaterThanFiveYearsMember 2022-12-31 0001944552 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2022-12-31 0001944552 anl:TradeAndBillsPayablesMember ifrs-full:OnDemandMember 2022-12-31 0001944552 anl:TradeAndBillsPayablesMember ifrs-full:NotLaterThanOneYearMember 2022-12-31 0001944552 anl:TradeAndBillsPayablesMember ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2022-12-31 0001944552 anl:TradeAndBillsPayablesMember ifrs-full:LaterThanFiveYearsMember 2022-12-31 0001944552 anl:TradeAndBillsPayablesMember 2022-12-31 0001944552 anl:FinancialLiabilitiesIncludedInOtherPayablesAndAccrualsMember ifrs-full:OnDemandMember 2022-12-31 0001944552 anl:FinancialLiabilitiesIncludedInOtherPayablesAndAccrualsMember ifrs-full:NotLaterThanOneYearMember 2022-12-31 0001944552 anl:FinancialLiabilitiesIncludedInOtherPayablesAndAccrualsMember ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2022-12-31 0001944552 anl:FinancialLiabilitiesIncludedInOtherPayablesAndAccrualsMember ifrs-full:LaterThanFiveYearsMember 2022-12-31 0001944552 anl:FinancialLiabilitiesIncludedInOtherPayablesAndAccrualsMember 2022-12-31 0001944552 ifrs-full:ShorttermBorrowingsMember ifrs-full:OnDemandMember 2022-12-31 0001944552 ifrs-full:ShorttermBorrowingsMember ifrs-full:NotLaterThanOneYearMember 2022-12-31 0001944552 ifrs-full:ShorttermBorrowingsMember ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2022-12-31 0001944552 ifrs-full:ShorttermBorrowingsMember ifrs-full:LaterThanFiveYearsMember 2022-12-31 0001944552 ifrs-full:ShorttermBorrowingsMember 2022-12-31 0001944552 ifrs-full:OnDemandMember 2022-12-31 0001944552 ifrs-full:NotLaterThanOneYearMember 2022-12-31 0001944552 ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2022-12-31 0001944552 ifrs-full:LaterThanFiveYearsMember 2022-12-31 0001944552 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember ifrs-full:OnDemandMember 2023-12-31 0001944552 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember ifrs-full:NotLaterThanOneYearMember 2023-12-31 0001944552 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2023-12-31 0001944552 ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember ifrs-full:LaterThanFiveYearsMember 2023-12-31 0001944552 anl:TradeAndBillsPayablesMember ifrs-full:OnDemandMember 2023-12-31 0001944552 anl:TradeAndBillsPayablesMember ifrs-full:NotLaterThanOneYearMember 2023-12-31 0001944552 anl:TradeAndBillsPayablesMember ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2023-12-31 0001944552 anl:TradeAndBillsPayablesMember ifrs-full:LaterThanFiveYearsMember 2023-12-31 0001944552 anl:TradeAndBillsPayablesMember 2023-12-31 0001944552 anl:FinancialLiabilitiesIncludedInOtherPayablesAndAccrualsMember ifrs-full:OnDemandMember 2023-12-31 0001944552 anl:FinancialLiabilitiesIncludedInOtherPayablesAndAccrualsMember ifrs-full:NotLaterThanOneYearMember 2023-12-31 0001944552 anl:FinancialLiabilitiesIncludedInOtherPayablesAndAccrualsMember ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2023-12-31 0001944552 anl:FinancialLiabilitiesIncludedInOtherPayablesAndAccrualsMember ifrs-full:LaterThanFiveYearsMember 2023-12-31 0001944552 anl:FinancialLiabilitiesIncludedInOtherPayablesAndAccrualsMember 2023-12-31 0001944552 ifrs-full:ShorttermBorrowingsMember ifrs-full:OnDemandMember 2023-12-31 0001944552 ifrs-full:ShorttermBorrowingsMember ifrs-full:NotLaterThanOneYearMember 2023-12-31 0001944552 ifrs-full:ShorttermBorrowingsMember ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2023-12-31 0001944552 ifrs-full:ShorttermBorrowingsMember ifrs-full:LaterThanFiveYearsMember 2023-12-31 0001944552 ifrs-full:ShorttermBorrowingsMember 2023-12-31 0001944552 ifrs-full:OnDemandMember 2023-12-31 0001944552 ifrs-full:NotLaterThanOneYearMember 2023-12-31 0001944552 ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2023-12-31 0001944552 ifrs-full:LaterThanFiveYearsMember 2023-12-31 0001944552 anl:NonRevolvingFacilityMember anl:SubsequentEventsMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2024-02-29 0001944552 anl:NonRevolvingFacilityMember anl:SubsequentEventsMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2024-02-29 2024-02-29 0001944552 anl:NonRevolvingFacilityMember anl:SubsequentEventsMember anl:AdlaiNortyeUsaIncMember 2024-02-29 0001944552 anl:NonRevolvingFacilityMember anl:SubsequentEventsMember anl:AdlaiNortyeUsaIncMember 2024-02-29 2024-02-29 0001944552 anl:NonRevolvingFacilityMember anl:MrYangLuAndAdlaiShanghaiMember anl:SubsequentEventsMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2024-02-29 0001944552 anl:NonRevolvingFacilityMember anl:MrYangLuAndAdlaiShanghaiMember anl:SubsequentEventsMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2024-02-29 2024-02-29 0001944552 anl:NonRevolvingFacilityMember anl:SubsequentEventsMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2024-03-01 2024-03-31 0001944552 anl:NonRevolvingFacilityMember anl:SubsequentEventsMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2024-03-31 0001944552 anl:SubsequentEventsMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2024-03-01 2024-03-31 0001944552 anl:SubsequentEventsMember anl:HangzhouAdlaiNortyeBiopharmaCoLtdMember 2024-04-01 2024-04-30 0001944552 anl:SubsequentEventsMember 2024-03-31 0001944552 anl:HangzhouHongxiBusinessManagementCoLtdMember anl:SubsequentEventsMember 2024-03-01 2024-03-31 0001944552 anl:SubsequentEventsMember anl:HangzhouTangchuangWeilaiTechnolegyCoLtdMember 2024-03-01 2024-03-31 0001944552 ifrs-full:SeparateMember 2022-12-31 0001944552 ifrs-full:SeparateMember 2023-12-31 0001944552 us-gaap:RelatedPartyMember ifrs-full:SeparateMember 2022-12-31 0001944552 us-gaap:RelatedPartyMember ifrs-full:SeparateMember 2023-12-31 0001944552 ifrs-full:OrdinarySharesMember ifrs-full:SeparateMember 2022-12-31 0001944552 ifrs-full:OrdinarySharesMember ifrs-full:SeparateMember 2023-12-31 0001944552 anl:ClassaOrdinarySharesMember ifrs-full:SeparateMember 2022-12-31 0001944552 anl:ClassaOrdinarySharesMember ifrs-full:SeparateMember 2023-12-31 0001944552 anl:ClassbOrdinarySharesMember ifrs-full:SeparateMember 2022-12-31 0001944552 anl:ClassbOrdinarySharesMember ifrs-full:SeparateMember 2023-12-31 0001944552 anl:SeriesConvertiblePreferredSharesMember ifrs-full:SeparateMember 2022-12-31 0001944552 anl:SeriesConvertiblePreferredSharesMember ifrs-full:SeparateMember 2023-12-31 0001944552 ifrs-full:SeparateMember 2021-01-01 2021-12-31 0001944552 ifrs-full:SeparateMember 2022-01-01 2022-12-31 0001944552 ifrs-full:SeparateMember 2023-01-01 2023-12-31 0001944552 ifrs-full:SeparateMember 2020-12-31 0001944552 ifrs-full:SeparateMember 2021-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:CNY anl:Integer iso4217:CNY xbrli:shares

Exhibit 12.1

 

Certification by the Chief Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Yang Lu, certify that:

 

1.I have reviewed this annual report on Form 20-F, as amended by Amendment No. 1 thereto, of Adlai Nortye Ltd.;

 

2.Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this annual report;

 

4.The company’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation; and

 

  (d) Disclosed in this annual report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

 

5.The company’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

 

  By: /s/ Yang Lu
    Name:  Yang Lu
    Title: Chief Executive Officer
Date: February 14, 2025    

Exhibit 12.2

 

Certification by the Chief Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Xiaofeng (Alex) Ye, certify that:

 

1.I have reviewed this annual report on Form 20-F, as amended by Amendment No. 1 thereto, of Adlai Nortye Ltd.;

 

2.Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this annual report;

 

4.The company’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

 

  (e) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

 

  (f) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (g) Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation; and

 

  (h) Disclosed in this annual report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

 

5.The company’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

 

  (c) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

 

  (d) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

 

     
  By: /s/ Xiaofeng (Alex) Ye
    Name:  Xiaofeng (Alex) Ye
    Title: Chief Financial Officer
Date: February 14, 2025    

 

Exhibit 13.1

 

Certification by the Chief Executive Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the Annual Report of Adlai Nortye Ltd. (the “Company”) on Form 20-F, as amended by Amendment No. 1 thereto, for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yang Lu, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  (a) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (b) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  By: /s/ Yang Lu
    Name:  Yang Lu
    Title: Chief Executive Officer
     
Date: February 14, 2025    

Exhibit 13.2

 

Certification by the Chief Financial Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the Annual Report of Adlai Nortye Ltd. (the “Company”) on Form 20-F, as amended by Amendment No. 1 thereto, for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Xiaofeng (Alex) Ye, chief financial officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  (a) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (b) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  By: /s/ Xiaofeng (Alex) Ye
    Name:  Xiaofeng (Alex) Ye
    Title: Chief Financial Officer
     
Date: February 14, 2025    

 

v3.25.0.1
Document And Entity Information
12 Months Ended
Dec. 31, 2023
shares
Document Information Line Items  
Entity Central Index Key 0001944552
Document Type 20-F/A
Document Registration Statement false
Document Annual Report true
Current Fiscal Year End Date --12-31
Document Period End Date Dec. 31, 2023
Document Fiscal Year Focus 2023
Document Transition Report false
Document Shell Company Report false
Entity File Number 001-41773
Entity Registrant Name Adlai Nortye Ltd.
Entity Incorporation, State or Country Code E9
Entity Address, Address Line One c/o PO Box 309
Entity Address, Address Line Two Ugland House
Entity Address, City or Town Grand Cayman
Entity Address, Postal Zip Code KY1-1104
Entity Address, Country KY
Title of 12(b) Security American Depositary Shares, each representing three Class A Ordinary Shares, par value $0.0001 per share
Trading Symbol ANL
Security Exchange Name NASDAQ
Entity Well-known Seasoned Issuer No
Entity Voluntary Filers No
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Non-accelerated Filer
Entity Emerging Growth Company true
Entity Ex Transition Period false
ICFR Auditor Attestation Flag false
Document Financial Statement Error Correction [Flag] false
Document Accounting Standard International Financial Reporting Standards
Entity Shell Company false
Auditor Name Mazars USA LLP
Auditor Location New York, USA
Auditor Firm ID 339
Amendment Description This Amendment No. 1 to Form 20-F (the “Form 20-F/A”) amends our annual report on Form 20-F for the year ended December 31, 2023 (the “Original Form 20-F”), which was originally filed with the U.S. Securities and Exchange Commission on April 19, 2024. The purpose of this Form 20-F/A is to include in the Original Form 20-F (1) the Report of Independent Registered Public Accounting Firm (the “Auditor's Report”) dated April 13, 2023 in connection with the Company’s consolidated statements of operations and comprehensive loss, changes in shareholders’ equity and cash flows for the year ended December 31, 2021, and (2) the Company’s accompanying consolidated statements of operations and comprehensive loss, changes in shareholders’ equity and cash flows for the year ended December 31, 2021 and the related notes. This Form 20-F/A does not reflect events occurring after the filing of the Original Form 20-F and does not modify or update the disclosure therein in any way except as described above. No other changes have been made to the Original Form 20-F. The filing of this Form 20-F/A should not be understood to mean that any statements contained in the Original Form 20-F, as amended by this Form 20-F/A, are true or complete as of any date subsequent to the original filing date of the Original Form 20-F. Accordingly, this Form 20-F/A should be read in conjunction with the Original Form 20-F.In addition, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is including new certifications by the Company’s principal executive officer and principal financial officer as exhibits to this Form 20-F/A pursuant to Rule 13a-14(a) of the Exchange Act.
Amendment Flag true
Document Fiscal Period Focus FY
Business Contact  
Document Information Line Items  
Entity Address, Address Line One Building 6 & 8, 1008 Xiangwang Street
Entity Address, Address Line Two Yuhang District
Entity Address, City or Town Hangzhou
Entity Address, Postal Zip Code 311121
Entity Address, Country CN
Contact Personnel Name Yang Lu
City Area Code +86
Local Phone Number 0571-2891-8385
Contact Personnel Email Address ir@adlainortye.com
ClassA Ordinary Shares  
Document Information Line Items  
Entity Common Stock, Shares Outstanding 93,710,805
ClassB Ordinary Shares  
Document Information Line Items  
Entity Common Stock, Shares Outstanding 16,990,000
v3.25.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Profit or loss [abstract]      
REVENUE $ 5,000 $ 45,726
Other operating income, net 890 259 183
Administrative expenses (15,289) (13,039) (12,450)
Research and development expenses (58,152) (54,490) (42,105)
Total operating loss (67,551) (67,270) (8,646)
Other income and gains 3,303 2,079 213
Other expenses (80) (1,395) (70)
Investment income 62 550 32
Fair value gain on financial assets at fair value through profit or loss (“FVTPL”) 484 40
Fair value (loss)/gain on financial liabilities at FVTPL (39,171) 7,195 (46,910)
Finance costs (791) (433) (1,337)
LOSS BEFORE TAX (104,228) (58,790) (56,678)
Income tax expense (643)
LOSS FOR THE YEAR (104,871) (58,790) (56,678)
Attributable to:      
Ordinary Equity Holders of the Parent (104,871) (58,790) (56,678)
OTHER COMPREHENSIVE LOSS      
Exchange differences on translation of the financial statements of subsidiaries (82) (3,157) (94)
Other comprehensive loss for the year, net of tax (82) (3,157) (94)
TOTAL COMPREHENSIVE LOSS FOR THE YEAR (104,953) (61,947) (56,772)
Attributable to:      
Ordinary Equity Holders of the Parent $ (104,953) $ (61,947) $ (56,772)
Basic and diluted      
Loss for the year ($ per share) (in Dollars per share) $ (2.42) $ (2.31) $ (2.23)
Diluted loss for the year ($ per share) (in Dollars per share) $ (2.42) $ (2.31) $ (2.23)
Weighted average common shares outstanding (in Shares) 43,342,068 25,440,000 25,440,000
Weighted average common shares outstanding, diluted (in Shares) 43,342,068 25,440,000 25,440,000
v3.25.0.1
Consolidated Statements of Financial Position - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 91,492 $ 42,758
Financial assets at FVTPL 7 21,287
Prepayments, other receivables and other assets 2,696 2,258
Short-term investments at amortized cost 7,000
Total current assets 101,195 66,303
Non-current assets    
Property, plant and equipment 2,646 3,713
Right-of-use assets 1,154 2,162
Other intangible assets 63 89
Prepayments, other receivables and other assets 282 327
Long-term investments at amortized cost 24,849
Total non-current assets 28,994 6,291
Total assets 130,189 72,594
Current liabilities    
Trade payables 14,348 13,098
Other payables and accruals 4,890 3,877
Interest-bearing bank borrowings 30,357 4,307
Lease liabilities 722 1,001
Financial liabilities at FVTPL 290,368
Total current liabilities 50,317 312,651
Non-current liabilities    
Lease liabilities 469 1,236
Total non-current liabilities 469 1,236
Total liabilities 50,786 313,887
SHAREHOLDERS’ (DEFICIT)/ EQUITY    
Ordinary shares 4
Additional paid-in capital 438,707 6,415
Share option reserve 18,018 13,688
Exchange fluctuation reserve (4,241) (4,159)
Accumulated deficit (373,092) (268,221)
Total shareholders’ (deficit)/equity 79,403 (241,293)
Total liabilities and shareholders’ (deficit)/equity 130,189 72,594
Class A Ordinary Shares    
SHAREHOLDERS’ (DEFICIT)/ EQUITY    
Ordinary shares 9  
Class B Ordinary Shares    
SHAREHOLDERS’ (DEFICIT)/ EQUITY    
Ordinary shares 2  
Series A Preferred Shares    
SHAREHOLDERS’ (DEFICIT)/ EQUITY    
Ordinary shares $ 10,980
v3.25.0.1
Consolidated Statements of Financial Position (Parentheticals) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Par value per share (in Dollars per share) $ 0.0001 $ 0.0001
Shares authorized 442,456,586 442,456,586
Shares issued   40,440,000
Shares outstanding 40,440,000
Class A Ordinary Shares    
Par value per share (in Dollars per share) $ 0.0001 $ 0.0001
Shares outstanding 93,710,805
Class B Ordinary Shares    
Par value per share (in Dollars per share) $ 0.0001 $ 0.0001
Shares outstanding 16,990,000
Series A Preferred Shares    
Par value per share (in Dollars per share) $ 0.0001 $ 0.0001
Shares authorized 14,560,000
Shares issued 14,560,000
Shares outstanding 14,560,000
v3.25.0.1
Consolidated Statements of Changes in Shareholders’ Equity - USD ($)
$ in Thousands
Ordinary Shares
Additional paid-in capital
Series A convertible preferred shares
Share option reserve
Exchange fluctuation reserve
Accumulated losses
Total
Balance at Dec. 31, 2020 $ 3 $ 6,416 $ 10,980 $ 4,220 $ (908) $ (152,753) $ (132,042)
Loss for the year   (56,678) (56,678)
Other comprehensive income for the year:              
Exchange differences on translation of the financial statements of subsidiaries (94)   (94)
Issuance of shares for the trust arrangement under the Share Incentive Plan 1 (1)    
Share-based compensation 3,386   3,386
Balance at Dec. 31, 2021 4 6,415 10,980 7,606 (1,002) (209,431) (185,428)
Loss for the year   (58,790) (58,790)
Other comprehensive income for the year:              
Exchange differences on translation of the financial statements of subsidiaries (3,157)   (3,157)
Share-based compensation 6,082   6,082
Balance at Dec. 31, 2022 4 6,415 10,980 13,688 (4,159) (268,221) (241,293)
Loss for the year   (104,871) (104,871)
Other comprehensive income for the year:              
Exchange differences on translation of the financial statements of subsidiaries (82)   (82)
Issuance of ordinary shares 1 91,779   91,780
Conversion of Financial liabilities at FVTPL 5 329,534     329,539
Conversion of Series A convertible preferred shares 1 10,979 (10,980)        
Share-based compensation 4,330   4,330
Balance at Dec. 31, 2023 $ 11 $ 438,707 $ 18,018 $ (4,241) $ (373,092) $ 79,403
v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES      
Net Loss $ (104,871) $ (58,790) $ (56,678)
Adjustments for:      
Finance costs 791 433 1,337
Investment income (62) (550) (32)
Fair value (gain)/loss on financial liabilities at FVTPL 39,171 (7,195) 46,910
Fair value gain on financial assets at FVTPL (484) (40)
Loss/(gain) on disposal of items of property, plant and equipment (7) 5
Depreciation of property, plant and equipment 1,213 931 861
Amortization of intangible assets 25 20 16
Depreciation of right-of-use assets 984 1,090 951
Equity-settled share-based payment expenses 4,330 6,082 3,386
(Increase)/Decrease in prepayments, other receivables and other assets (436) 4,346 (419)
(Increase)/Decrease in non-current assets 45 128 (157)
Increase in current assets (390)
Increase in trade payables 1,252 10,117 600
Increase in other payables and accruals 906 656 619
Decrease in advances from customers (3)
Net cash flows used in operating activities (56,652) (43,223) (3,034)
CASH FLOWS FROM INVESTING ACTIVITIES      
Purchases of property, plant and equipment (200) (1,249) (1,018)
Purchases of intangible assets (19) (102)
Proceeds from disposal of items of property, plant and equipment 1 17
Purchases of financial assets at FVTPL (7) (58,980) (81,234)
Disposal of financial assets at FVTPL 21,039 88,057 27,465
Purchases of investments at amortized cost (31,849)
Received investment income of financial assets at FVTPL 62 550 32
Net cash flows provided/(used in) from investing activities (10,954) 28,376 (54,857)
CASH FLOWS FROM FINANCING ACTIVITIES      
Proceeds from issuance of ordinary shares 91,780 97,370
Addition of bank borrowings 50,234 7,897 12,411
Bank borrowings interest paid (602) (292) (427)
Repayment of bank borrowings (24,069) (13,315) (10,430)
Transaction costs for issuance of convertible redeemable preferred shares (758)
Payment for lease liabilities (1,103) (1,070) (966)
Net cash flows (used in)/from financing activities 116,240 (6,780) 97,200
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS 48,634 (21,627) 39,309
Cash and cash equivalents at beginning of year 42,758 64,131 24,261
Effect of foreign exchange rate changes, net 100 254 561
CASH AND CASH EQUIVALENTS AT END OF YEAR $ 91,492 $ 42,758 $ 64,131
v3.25.0.1
Corporate and Group Information
12 Months Ended
Dec. 31, 2023
Corporate and Group Information [Abstract]  
CORPORATE AND GROUP INFORMATION
1.CORPORATE AND GROUP INFORMATION

 

Adlai Nortye Ltd. (the “Company”) is a limited liability company incorporated in the Cayman Islands on 9 May 2018. The registered office of the Company is located at Harneys Fiduciary (Cayman) Limited, 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman, KY1-1002, Cayman Islands.

 

The Company is an investing holding company. The Company’s subsidiaries were involved in the research and development of pharmaceutical products.

 

As of the date of this report, the Company had direct and indirect interests in its subsidiaries, all of which are private limited liability companies, the particulars of which are set out below:

 

            Percentage   
            of equity   
      Date and place of  Issued ordinary  attributable to   
      incorporation / registration  share/  the Company   
Name  Notes  and place of operations  registered capital  Direct  Indirect  Principal activities
Alpine Bioscience Ltd. (“Alpine BVI”)     British Virgin Islands 8 January 2018  One share of par value $1  100%    Investment holding
Adlai Nortye USA Inc (“Adlai US”)     The United States 30 January 2018  10,000 shares of par value $0.0001 each    100%  Clinical studies and testing, and technology development and transfer
Adlai Nortye (Switzerland) AG (“Adlai Swiss”)     Switzerland 21 June 2022  100 shares of par value CHF1’000 each    100%  Investment holding
Adlai Nortye PTE.LTD (“Adlai SGP”)     Singapore 22 April 2022  Two shars of par value $1    100%  Investment holding
Adlai Nortye (HK) Limited (“Adlai HK”)     Hong Kong 24 April 2018  HKD 0.001    100%  Investment holding

Hangzhou Adlai Nortye Biopharma Co., Ltd* (“Adlai Hangzhou”)

     the People’s Republic of China (“PRC”)/Mainland China 14 September 2004  RMB 200,000    100%  Product research and development, technology transfer and consulting services business

Shanghai Adlai Nortye Biopharma Co., Ltd* (“Adlai Shanghai”)

     the People’s Republic of China (“PRC”)/Mainland China 22 December 2021  RMB 10,000    100%  Product research and development, technology transfer and consulting services business

Hangzhou Tangchuang Weilai Technolegy Co., Ltd (“Hangzhou Tangchuang”)

     the People’s Republic of China (“PRC”)/Mainland China 2 November 2022  RMB 10,000    100%  Product research and development, technology transfer and consulting services business
*The English name of the subsidiary registered in the PRC represents the best efforts made by management of the Company to translate its Chinese name as the subsidiary does not have an official English name.
v3.25.0.1
Basis of Presentation
12 Months Ended
Dec. 31, 2023
Basis Of Presentation Abstract  
BASIS OF PRESENTATION
2.1BASIS OF PRESENTATION

 

The consolidated financial statements of the Group include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.

 

2.2BASIS OF PREPARATION

 

As of December 31, 2023, the Group’s balance of cash and cash equivalents was $91,492 and short-term investments of $7,000 and the Group had net current assets of $50,878. Management has evaluated the sufficiency of its working capital and concluded that the Group’s available cash and cash equivalents and short-term investments will be sufficient to support its continuous operations and to meet its payment obligations when liabilities fall due within the next twelve months from the date of issuance of these consolidated financial statements. Accordingly, management continues to prepare the Group’s consolidated financial statements on going concern basis.

 

The Consolidated Financial Statements have been prepared in accordance with International Financial Reporting Standards (“IFRSs”), which comprise all standards and interpretations approved by the International Accounting Standards Board (the “IASB”). All IFRSs effective for the accounting period commencing from January 1, 2020, together with the relevant transitional provisions, have been early adopted by the Group in the preparation of the Consolidated Financial Statements throughout the Relevant Periods and in the period covered by the Interim Comparative Financial Information.

 

Recently issued accounting pronouncements:

 

In 2016, the IASB issued IFRS 16, which increases lease transparency and comparability among organizations. Under the new standard, lessees will be required to recognize all assets and liabilities arising from leases on the balance sheet, with the exception of leases with a term of 12 months or less, which permits a lessee to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. IFRS 16 is effective for fiscal years beginning after January 1, 2019. The Company adopted the new lease accounting standard as of January 1, 2019. Adoption of this update increased the amounts of total assets and total liabilities on the Company’s consolidated financial position, and did not have a material impact on the Company’s consolidated results of operations and cash flows.

 

The Consolidated Financial Statements have been prepared under the historical cost convention except for certain financial liabilities which have been measured at fair value at the end of each of the Relevant Periods.

 

2.3ISSUED BUT NOT YET EFFECTIVE IFRSs

 

The Group has not applied the following new and revised IFRSs that have been issued but are not yet effective in the Consolidated Financial Statements.

 

      Effective for
accounting year
beginning on or after
Amendments to IAS 1  Classification of Liabilities as current and non-current  January 1, 2024
Amendments to IFRS 16  Lease Liability in a Sale and Leaseback  January 1, 2024
Amendments to IAS 1  Non-current Liabilities with Covenants  January 1, 2024
Amendments to IAS 28 and IFRS 10  Sale or contribution of assets between an investor and its associate or joint venture  To be determined

 

The Group is in the process of making an assessment of the impact of these new and revised IFRSs upon initial application. So far, the Group expects that these standards will not have a significant effect on the Group’s financial performance and financial position.

2.4SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Subsidiaries

 

A subsidiary is an entity (including a structured entity), directly or indirectly, controlled by the Company. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee (i.e., existing rights that give the Group the current ability to direct the relevant activities of the investee). When the Company has, directly or indirectly, less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

 

(a)contractual arrangements with other vote holders of the investee;

 

(b)rights arising from other contractual arrangements; and

 

(c)the Group’s voting rights and potential voting rights.

 

The financial statements of subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. The results of subsidiaries are consolidated from the date on which the Group obtains control, and continue to be consolidated until the date that such control ceases.

 

Profit or loss and each component of other comprehensive income are attributed to the owners of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

 

Fair value measurement

 

The Group measures certain financial instruments at fair value at the end of each of the Relevant Periods. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability, or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or most advantageous market must be accessible by the Group. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

 

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the Consolidated Financial Statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

 

Level 1 based on quoted prices (unadjusted) in active markets for identical assets or liabilities

 

Level 2 based on valuation techniques for which the lowest level input that is significant to the fair value measurement is observable, either directly or indirectly

 

Level 3 based on valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

 

For assets and liabilities that are recognized in the Consolidated Financial Statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each of the Relevant Periods.

 

Impairment of non-financial assets

 

Where an indication of impairment exists, or when annual impairment testing for an asset is required (other than financial assets), the asset’s recoverable amount is estimated. An asset’s recoverable amount is the higher of the asset or cash-generating unit’s value in use and its fair value less cost of disposal, and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case the recoverable amount is determined for the cash-generating unit to which the asset belongs.

 

An impairment loss is recognized only if the carrying amount of an asset exceeds its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An impairment loss is charged to profit or loss in the period in which it arises in those expense categories consistent with the function of the impaired asset.

 

An assessment is made at the end of each of the Relevant Periods as to whether there is an indication that previously recognized impairment losses may no longer exist or may have decreased. If such an indication exists, the recoverable amount is estimated. A previously recognized impairment loss of an asset other than goodwill is reversed only if there has been a change in the estimates used to determine the recoverable amount of that asset, but not to an amount higher than the carrying amount that would have been determined (net of any depreciation/amortization) had no impairment loss been recognized for the asset in prior years. A reversal of such an impairment loss is credited to profit or loss in the period in which it arises.

 

Related parties

 

A party is considered to be related to the Group if:

 

(a)the party is a person or a close member of that person’s family and that person

 

(i)has control or joint control over the Group;

 

(ii)has significant influence over the Group; or

 

(iii)is a member of the key management personnel of the Group or of a parent of the Group;

 

or

(b)the party is an entity where any of the following conditions applies:

 

(i)the entity and the Group are members of the same group;

 

(ii)one entity is an associate or joint venture of the other entity (or of a parent, subsidiary or fellow subsidiary of the other entity);

 

(iii)the entity and the Group are joint ventures of the same third party;

 

(iv)one entity is a joint venture of a third entity and the other entity is an associate of the third entity;

 

(v)the entity is a post-employment benefit plan for the benefit of employees of either the Group or an entity related to the Group; and the sponsoring employers of the post-employment benefit plan;

 

(vi)the entity is controlled or jointly controlled by a person identified in(a);

 

(vii)a person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity); and

 

(viii)the entity, or any member of a group of which it is a part, provides key management personnel services to the Group or to the parent of the Group.

 

Property, plant and equipment and depreciation

 

Property, plant and equipment, other than construction in progress, are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property, plant and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.

 

Expenditure incurred after items of property, plant and equipment have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalized in the carrying amount of the asset as a replacement. Where significant parts of property, plant and equipment are required to be replaced at intervals, the Group recognizes such parts as individual assets with specific useful lives and depreciates them accordingly.

 

Depreciation is calculated on the straight-line basis to write off the cost of each item of property, plant and equipment to its residual value over its estimated useful life. The principal annual rates used for this purpose are as follows:

 

Plant and machinery   10% to 19%
Office equipment   19% to 20%
Motor vehicles   19%
Electronic equipment   19% to 20%
Leasehold improvements   The shorter of remaining lease terms or estimated useful lives

 

Where parts of an item of property, plant and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately. Residual values, useful lives and the depreciation method are reviewed, and adjusted if appropriate, at least at the end of each of the Relevant Periods.

An item of property, plant and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on disposal or retirement recognized in the statement of profit or loss and other comprehensive income in the year the asset is derecognized is the difference between the net sales proceeds and the carrying amount of the relevant asset.

 

Construction in progress is reclassified to the appropriate category of property, plant and equipment when completed and ready for use.

 

Other intangible assets (other than goodwill)

 

Other intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is the fair value at the date of acquisition. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are subsequently amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least at the end of each of the Relevant Periods.

 

Computer software

 

Computer software is stated at cost less any impairment losses and amortized on a straight-line basis over its estimated useful life of 5 years.

 

The estimated useful life of software is determined by considering the period of the economic benefits to the Group, as well as by referring to industry practice.

 

Research and development costs

 

All research costs are charged to expense as incurred.

 

Expenditure incurred on projects to develop new products is capitalized and deferred only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the project and the Group’s ability to measure reliably the expenditure during the development. Product development expenditure which does not meet these criteria is expensed when incurred.

 

Leases

 

The Group assesses at contract inception whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

 

Group as a lessee

 

The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

(a)Right-of-use assets

 

Right-of-use assets are recognized at the commencement date of the lease (the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and any impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease terms and the estimated useful lives of the assets as follows:

 

Offices  2 to 5 years
Office equipment  2 to 5 years

 

If ownership of the leased asset transfers to the Group by the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset.

 

(b)Lease liabilities

 

Lease liabilities are recognized at the commencement date of the lease at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for termination of a lease, if the lease term reflects the Group exercising the option to terminate the lease. Variable lease payments that do not depend on an index or a rate are recognized as an expense in the period in which the event or condition that triggers the payment occurs.

 

In calculating the present value of lease payments, the Group uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in lease payments (e.g., a change to future lease payments resulting from a change in an index or rate) or a change in assessment of an option to purchase the underlying asset.

 

(c)Short-term leases and leases of low-value assets

 

The Group applies the short-term lease recognition exemption to its short-term leases of office equipment (that is those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the recognition exemption for leases of low-value assets to leases of office equipment that are considered to be of low value.

 

Lease payments on short-term leases and leases of low-value assets are recognized as an expense on a straight-line basis over the lease term.

 

Financial assets

 

Initial recognition and measurement

 

Financial assets are classified, at initial recognition, as subsequently measured at amortized cost, fair value through other comprehensive income, and fair value through profit or loss.

The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and the Group’s business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient of not adjusting the effect of a significant financing component, the Group initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs.

 

In order for a financial asset to be classified and measured at amortized cost or fair value through other comprehensive income, it needs to give rise to cash flows that are solely payments of principal and interest (“SPPI”) on the principal amount outstanding. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss, irrespective of the business model.

 

The Group’s business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Financial assets classified and measured at amortized cost are held within a business model with the objective to hold financial assets in order to collect contractual cash flows, while financial assets classified and measured at fair value through other comprehensive income are held within a business model with the objective of both holding to collect contractual cash flows and selling. Financial assets which are not held within the aforementioned business models are classified and measured at fair value through profit or loss.

 

All regular way purchases and sales of financial assets are recognized on the trade date, that is, the date that the Group commits to purchase or sell the asset. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the period generally established by regulation or convention in the marketplace.

 

Subsequent measurement

 

The subsequent measurement of financial assets depends on their classification as follows:

 

Financial assets at amortized cost (debt instruments)

 

Financial assets at amortized cost are subsequently measured using the effective interest method and are subject to impairment. Gains and losses are recognized in the statement of profit or loss and other comprehensive income when the asset is derecognized, modified or impaired.

 

Financial assets at fair value through profit or loss

 

Financial assets at fair value through profit or loss are carried in the statement of financial position at fair value with net changes in fair value recognized in the statement of profit or loss and other comprehensive income.

 

This category includes derivative instruments and equity investments which the Group has not irrevocably elected to classify at fair value through other comprehensive income. Dividends on equity investments classified as financial assets at fair value through profit or loss are also recognized as other income in the statement of profit or loss and other comprehensive income when the right of payment has been established, it is probable that the economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably.

A derivative embedded in a hybrid contract, with a financial liability or non-financial host, is separated from the host and accounted for as a separate derivative if the economic characteristics and risks are not closely related to the host; a separate instrument with the same terms as the embedded derivative would meet the definition of a derivative; and the hybrid contract is not measured at fair value through profit or loss. Embedded derivatives are measured at fair value with changes in fair value recognized in the statement of profit or loss and other comprehensive income. Reassessment only occurs if there is either a change in the terms of the contract that significantly modifies the cash flows that would otherwise be required or a reclassification of a financial asset out of the fair value through profit or loss category.

 

A derivative embedded within a hybrid contract containing a financial asset host is not accounted for separately. The financial asset host together with the embedded derivative is required to be classified in its entirety as a financial asset at fair value through profit or loss.

 

Derecognition of financial assets

 

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Group’s consolidated statement of financial position) when:

 

the rights to receive cash flows from the asset have expired; or

 

the Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a “pass-through” arrangement; and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

 

When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if, and to what extent, it has retained the risk and rewards of ownership of the asset. When it has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the Group continues to recognize the transferred asset to the extent of the Group’s continuing involvement. In that case, the Group also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

 

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Group could be required to repay.

 

Impairment of financial assets

 

The Group recognizes an allowance for expected credit losses (“ECLs”) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

 

General approach

 

ECLs are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12 months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

At the end of each of the Relevant Periods, the Group assesses whether the credit risk on a financial instrument has increased significantly since initial recognition. When making the assessment, the Group compares the risk of a default occurring on the financial instrument as of the reporting date with the risk of a default occurring on the financial instrument as of the date of initial recognition and considers reasonable and supportable information that is available without undue cost or effort, including historical and forward-looking information.

 

The Group considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Group may also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

 

Financial assets at amortized cost are subject to impairment under the general approach and they are classified within the following stages for measurement of ECLs except for trade receivables and contract assets which apply the simplified approach as detailed below.

 

Stage 1 Financial instruments for which credit risk has not increased significantly since initial recognition and for which the loss allowance is measured at an amount equal to 12-month ECLs
     
Stage 2  — Financial instruments for which credit risk has increased significantly since initial recognition but that are not credit-impaired financial assets and for which the loss allowance is measured at an amount equal to lifetime ECLs
     
Stage 3  — Financial assets that are credit-impaired at the reporting date (but that are not purchased or originated credit-impaired) and for which the loss allowance is measured at an amount equal to lifetime ECLs

 

Simplified approach

 

For trade receivables that do not contain a significant financing component or when the Group applies the practical expedient of not adjusting the effect of a significant financing component, the Group applies the simplified approach in calculating ECLs. Under the simplified approach, the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at the end of each of the Relevant Periods.

 

Financial liabilities

 

Initial recognition and measurement

 

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, as appropriate.

 

All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

 

The Group’s financial liabilities include trade and other payables, derivative financial instruments, interest-bearing bank and other borrowings and certain financial instruments designated at FVTPL.

Subsequent measurement

 

The subsequent measurement of financial liabilities depends on their classification as follows:

 

Financial liabilities at fair value through profit or loss

 

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss.

 

Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Group that are not designated as hedging instruments in hedge relationships as defined by IFRS 9. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments. Gains or losses on liabilities held for trading are recognized in the statement of profit or loss. The net fair value gain or loss recognized in the statement of profit or loss does not include any interest charged on these financial liabilities.

 

Financial liabilities designated upon initial recognition as at fair value through profit or loss are designated at the initial date of recognition, and only if the criteria in IFRS 9 are satisfied. Gains or losses on liabilities designated at fair value through profit or loss are recognized in the statement of profit or loss, except for the gains or losses arising from the Group’s own credit risk which are presented in other comprehensive income with no subsequent reclassification to the statement of profit or loss. The net fair value gain or loss recognized in the statement of profit or loss does not include any interest charged on these financial liabilities.

 

The company assessed the contract characteristics of each series of convertible redeemable preferred shares to determine whether they should be classified as equity instruments or financial liabilities. The Series B, C, and D Preferred Shares and Series B Convertible Loans were classified as financial liabilities measured at fair value through profit or loss. The decision was based on the presence of a redemption feature and a conversion option with a price adjustment feature, which are considered financial liabilities under IAS 32.

 

The company also determined that the Series B Convertible Loans are a hybrid instrument that includes a non-derivative host contract and embedded derivatives, which should be accounted for at fair value through profit or loss.

 

Financial liabilities at amortized cost (loans and borrowings)

 

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost, using the effective interest rate method unless the effect of discounting would be immaterial, in which case they are stated at cost. Gains and losses are recognized in the statement of profit or loss and other comprehensive income when the liabilities are derecognized as well as through the effective interest rate amortization process.

 

Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortization is included in finance costs in the statement of profit or loss and other comprehensive income.

 

Derecognition of financial liabilities

 

A financial liability is derecognized when the obligation under the liability is discharged or cancelled, or expires.

When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and a recognition of a new liability, and the difference between the respective carrying amounts is recognized in the statement of profit or loss and other comprehensive income.

 

Derivative financial instruments

 

Initial recognition and subsequent measurement

 

The Group uses derivative financial instruments, such as warrants. Such derivative financial instruments are initially recognized at fair value on the date on which a derivative contract is entered into and are subsequently remeasured at fair value. Derivatives are carried as assets when the fair value is positive and as liabilities when the fair value is negative.

 

Any gains or losses arising from changes in fair value of derivatives are taken directly to profit or loss.

 

Current versus non-current classification

 

Derivative instruments that are not designated as effective hedging instruments are classified as current or non-current or separated into current and non-current portions based on an assessment of the facts and circumstances (i.e., the underlying contracted cash flows):

 

Where the Group expects to hold a derivative as an economic hedge (and does not apply hedge accounting) for a period beyond 12 months after the end of the reporting period, the derivative is classified as non-current (or separated into current and non-current portions) consistently with the classification of the underlying item.

 

Embedded derivatives that are not closely related to the host contract are classified consistently with the cash flows of the host contract.

 

Derivative instruments that are designated as, and are effective hedging instruments, are classified consistently with the classification of the underlying hedged item. The derivative instruments are separated into current portions and non-current portions only if a reliable allocation can be made.

 

Cash and cash equivalents

 

For the purpose of the consolidated statement of cash flows, cash and cash equivalents comprise cash on hand and demand deposits, and short term highly liquid investments that are readily convertible into known amounts of cash, are subject to an insignificant risk of changes in value, and have a short maturity of generally within three months when acquired.

 

For the purpose of the consolidated statement of financial position, cash and cash equivalents comprise cash on hand and at banks, including term deposits, and assets similar in nature to cash, which are not restricted as to use.

 

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents at high-quality and accredited financial institutions in amounts that could exceed the $250,000 maximum amount insured by the Federal Deposit Insurance Corporation (FDIC). The Company does not believe that its cash and cash equivalents are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

Provisions

 

A provision is recognized when a present obligation (legal or constructive) has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation.

 

When the effect of discounting is material, the amount recognized for a provision is the present value at the end of the reporting period of the future expenditures expected to be required to settle the obligation. The increase in the discounted present value amount arising from the passage of time is included in finance costs in the statement of profit or loss and other comprehensive income.

 

Income tax

 

Income tax comprises current and deferred tax. Income tax relating to items recognized outside profit or loss is recognized outside profit or loss, either in other comprehensive income or directly in equity.

 

Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period, taking into consideration interpretations and practices prevailing in the countries in which the Group operates.

 

Deferred tax is provided, using the liability method, on all temporary differences at the end of the reporting period between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

 

Deferred tax liabilities are recognized for all taxable temporary differences, except:

 

when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and

 

in respect of taxable temporary differences associated with investments in subsidiaries, associates and joint ventures, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

 

Deferred tax assets are recognized for all deductible temporary differences, the carryforward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carryforward of unused tax credits and unused tax losses can be utilized, except:

 

when the deferred tax asset relating to the deductible temporary differences arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and

 

in respect of deductible temporary differences associated with investments in subsidiaries, associates and joint ventures, deferred tax assets are only recognized to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.

The carrying amount of deferred tax assets is reviewed at the end of each of the Relevant Periods and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at the end of each of the Relevant Periods and are recognized to the extent that it has become probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be recovered.

 

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

 

Deferred tax assets and deferred tax liabilities are offset if and only if the Group has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities which intend either to settle current tax liabilities and assets on a net basis, or to realise the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

 

In compliance with IFRIC 23, accruals for risk on income tax are part of the income tax within the statements of operations and comprehensive loss and income tax payable within the statements of financial position.

 

Government grants

 

Government grants are recognized at their fair value where there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed.

 

Revenue recognition

 

Sales of intellectual property

 

Revenue from sales of intellectual property is recognized when control of the intellectual property is transferred to the customers at an amount that reflects the consideration to which the Group expects to be entitled in exchange for the intellectual property.

 

When the consideration of sales of intellectual property includes a variable amount, the amount of consideration is estimated to which the Group will be entitled in exchange for transferring the intellectual property to the customer. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved.

 

Milestone payments and sales-based royalties represent a form of variable consideration which is included in the transaction price to the extent that it is highly probable that a significant reversal of accumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. When the Group cannot conclude that it is highly probable that a significant revenue reversal of cumulative revenue under the contract will not occur, the Group constrains the related variable consideration resulting in its exclusion from the transaction price.

 

As part of the accounting for this arrangement, the Group must use significant judgement to determine: (a) the performance obligations; and (b) the method to estimate variable consideration.

 

At contract inception, the Group assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.

The Group uses judgement to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. If a milestone or other variable consideration relates specifically to the Group’s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Group generally allocates that milestone amount entirely to that performance obligation once it is highly probable that a significant revenue reversal would not occur.

 

The Group recognizes revenue only when it satisfies a performance obligation by transferring control of the promised goods or services. The transfer of control can occur over time or at a point in time. A performance obligation is satisfied over time if it meets one of the following criteria:

 

The counterparty simultaneously receives and consumes the benefits provided by the Group’s performance as the Group performs; or

 

The Group’s performance creates or enhances an asset that the counterparty controls as the asset is created or enhanced

 

The Group’s performance does not create an asset with an alternative use to the Group and the Group has an enforceable right to payment for performance completed to date.

 

The portion of the transaction price that is allocated to performance obligations satisfied at a point in time is recognized as revenue when control of the goods or services is transferred to the counterparty. If the performance obligation is satisfied over time, the portion of the transaction price allocated to that performance obligation is recognized as revenue as the performance obligation is satisfied. The Group adopts an appropriate method of measuring progress for purposes of recognizing revenue. The Group evaluates the measure of progress at the end of each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

 

Upfront fees

 

Upfront payment is allocated to the performance obligations based on the Group’s best estimate of their relative stand-alone selling prices. The Group recognizes revenues from non-refundable upfront fees at a point in time when the transfer of control of the intellectual property to the counterparty occurs and the counterpary is able to use and benefit from the intellectual property.

 

Milestone payments

 

At the inception of each arrangement that includes milestone payments, the Group evaluates whether the milestones are considered highly probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is highly probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Group, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are received. The Group evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgement involved in determining whether it is highly probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Group re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Milestone payments are allocated to performance obligations based on the Group’s best estimate of their relative stand-alone selling prices unless the criteria under IFRS 15.85 are met, in which case the milestone payments are allocated entirely to the performance obligation which the milestone payments are specifically related to.

The Group assessed that achievement of all the remaining contractual milestones is highly uncertain and the related milestone payments are not included in the transaction price. Milestones are achieved when the triggering event described in the related agreement occurs.

 

Sales royalties

 

The Group recognizes revenue for a sales-based royalty promised in exchange for the sales of intellectual property only when (or as) the later of the following events occurs:

 

(a)the subsequent sale occurs; and

 

(b)the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied.

 

Revenue from other sources

 

Rental income is recognized on a time proportion basis over the lease terms. Variable lease payments that do not depend on an index or a rate are recognized as income in the accounting period in which they are incurred.

 

Interest income

 

Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.

 

Share-based payments

 

The Company operates a share option scheme for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group’s operations. Employees (including directors) of the Group receive remuneration in the form of share-based payments, whereby employees render services as consideration for equity instruments (“equity-settled transactions”).

 

The cost of equity-settled transactions with employees for grants is measured by reference to the fair value at the date at which they are granted. The fair value is determined by an external valuer using a binomial model, further details of which are given in note 19 to the Consolidated Financial Statements.

 

The cost of equity-settled transactions is recognized in employee benefit expense, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled. The cumulative expense recognized for equity-settled transactions at the end of each of the Relevant Periods until the vesting date reflects the extent to which the vesting period has expired and the Group’s best estimate of the number of equity instruments that will ultimately vest. The charge or credit to the statement of profit or loss and other comprehensive income for a period represents the movement in the cumulative expense recognized as of the beginning and end of that period.

 

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group’s best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.

Other employee benefits

 

Pension schemes

 

The employees of the Group’s subsidiaries who operate in Mainland China are required to participate in a central pension scheme operated by the local municipal government. These subsidiaries are required to contribute a certain percentage of their payroll costs to the central pension scheme. The contributions are charged to profit or loss as they become payable in accordance with the rules of the central pension scheme.

 

The subsidiary in the U.S. maintains multiple qualified contributory savings plans as allowed under Section 401(k) of the Internal Revenue Code in the U.S. These plans are defined contribution plans covering substantially all its qualifying employees and provide for voluntary contributions by employees, subject to certain limits. The contributions are made by both the employees and the employer. The employees’ contributions are primarily based on specified dollar amounts or percentages of employee compensation. The only obligation of the subsidiary in the U.S. with respect to the retirement benefits plans is to make the specified contributions under the plans.

 

Housing fund — Mainland China

 

The Group contributes on a monthly basis to a defined contribution housing fund plan operated by the local municipal government. Contributions to this plan by the Group are expensed as incurred.

 

Borrowing costs

 

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets (i.e., assets that necessarily take a substantial period of time to get ready for their intended use or sale) are capitalized as part of the cost of those assets. The capitalization of such borrowing costs ceases when the assets are substantially ready for their intended use or sale. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs capitalized. All other borrowing costs are expensed in the period in which they are incurred. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

 

Foreign currencies

 

These consolidated financial statements are presented in United States dollars (“$”), which is the Company’s functional currency. Each entity in the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency. Foreign currency transactions recorded by the entities in the Group are initially recorded using their respective functional currency rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency rates of exchange at the end of the reporting period. Differences arising on settlement or translation of monetary items are recognized in the statement of operations and comprehensive loss.

 

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured. The gain or loss arising on translation of a non-monetary item measured at fair value is treated in line with the recognition of the gain or loss on change in fair value of the item (i.e., translation difference on the item whose fair value gain or loss is recognized in other comprehensive income or profit or loss is also recognized in other comprehensive income or profit or loss, respectively).

In determining the exchange rate on initial recognition of the related asset, expense or income on the derecognition of a non-monetary asset or non-monetary liability relating to an advance consideration, the date of the initial transaction is the date on which the Group initially recognizes the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of the advance consideration.

 

The functional currencies of certain subsidiaries established in the PRC are currencies other than $. As of the end of the reporting period, the assets and liabilities of these entities are translated into $ at the exchange rates prevailing at the end of the reporting period and their statements of profit or loss and other comprehensive income are translated into $ at the weighted average exchange rates for the year.

 

The resulting exchange differences are recognized in other comprehensive income and accumulated in the exchange fluctuation reserve. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is recognized in the statement of profit or loss and other comprehensive income.

 

For the purpose of the consolidated statement of cash flows, the cash flows of the subsidiaries established in the PRC are translated into $ at the exchange rates at the dates of the cash flows. Frequently recurring cash flows of the subsidiaries established in the PRC which arise throughout the year are translated into $ at the weighted average exchange rates for the year.

v3.25.0.1
Significant Accounting Judgements and Estimates
12 Months Ended
Dec. 31, 2023
Significant Accounting Judgements and Estimates [Abstract]  
SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES
3.SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES

 

Use of Estimates

 

The preparation of the Group’s Consolidated Financial Statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and their accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amounts of the assets or liabilities affected in the future.

 

Estimation uncertainty

 

The key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are described below.

 

Fair value of financial liabilities measured at FVTPL

 

The fair value of the financial liabilities, including convertible redeemable preferred shares, convertible loans, forwards and warrants, are measured at FVTPL and determined using the valuation techniques, including the discounted cash flow method and the back-solve method. Such valuation requires the Group to make estimates of the key assumptions including the risk-free interest rate, discount for lack of marketability (“DLOM”) and volatility, which are subject to uncertainty and might materially differ from the actual results. Further details are included in note 16 to the Consolidated Financial Statements.

 

Fair value of share-based payment

 

The fair value of the awarded shares is determined at the grant dates by the binomial option-pricing model. Significant estimates on assumptions, including the underlying equity value, discount rate, expected volatility, and dividend yield, are made by management. Further details are included in note 19 to the Consolidated Financial Statements.

The preparation of the consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reporting amounts of assets and liabilities, and disclosure of contingent assets and liabilities, as of the date of the consolidated financial statements, and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the valuation and accounting for financial liabilities at FVTPL and equity awards.

 

Impairment of non-financial assets (other than goodwill)

 

The Group assesses whether there are any indicators of impairment for all non-financial assets (including the right-of-use assets) at the end of each of the Relevant Periods. Other non-financial assets are tested for impairment when there are indicators that the carrying amounts may not be recoverable. An impairment exists when the carrying value of an asset or a cash-generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The calculation of the fair value less costs of disposal is based on available data from binding sales transactions in an arm’s length transaction of similar assets or observable market prices less incremental costs for disposing of the asset. When value-in-use calculations are undertaken, management must estimate the expected future cash flows from the asset or cash-generating unit and choose a suitable discount rate in order to calculate the present value of those cash flows.

 

Deferred tax assets

 

Deferred tax assets are recognized for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and level of future taxable profits together with future tax planning strategies. Further details are contained in note 6 to the Consolidated Financial Statements.

 

Uncertain tax positions

 

In assessing any uncertainty over income tax treatments, the Group considers whether it is probable that the relevant tax authority will accept the uncertain tax treatment used, or proposed to be used, by individual group entities in their income tax filings. If it is probable, the current and deferred taxes are determined consistently with the tax treatment in the income tax filings. If it is not probable that the relevant taxation authority will accept an uncertain tax treatment, the effect of each uncertainty is reflected by using either the most likely amount or the expected value.

 

The Group has evaluated the uncertain tax position of each of the companies within the Group as of December 31, 2022 and 2023, the Group did not have any significant unrecognized uncertain tax positions.

 

Leases — Estimating the incremental borrowing rate

 

The Group cannot readily determine the interest rate implicit in a lease, and therefore, it uses an incremental borrowing rate (“IBR”) to measure lease liabilities. The IBR is the rate of interest that the Group would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. The IBR therefore reflects what the Group “would have to pay”, which requires estimation when no observable rates are available (such as for subsidiaries that do not enter into financing transactions) or when it needs to be adjusted to reflect the terms and conditions of the lease (for example, when leases are not in the subsidiary’s functional currency). The Group estimates the IBR using observable inputs (such as market interest rates) when available and is required to make certain entity-specific estimates (such as the subsidiary’s stand-alone credit rating).

v3.25.0.1
Revenue
12 Months Ended
Dec. 31, 2023
Revenue [Abstract]  
REVENUE
4.REVENUE

 

An analysis of revenue is as follows:

 

   2021   2022   2023 
   $’000   $’000   $’000 
Sales of intellectual property   45,726           
Sales of an exclusive option.   
    
    5,000 
Total   45,726    
    5,000 

 

Revenue of $5,000 for the year ended December 31, 2023 was derived from the option grant fee for the sale of an exclusive option to enter into a license agreement to further develop and commercialize products to a single customer, recognized at a point in time, and there was no further performance obligation to be performed.

 

The Group entered into a collaboration agreement with one customer in the year ended December 31,2021 for a list of patents and related research material, know-how, and research results generated through studies of the five products. The terms of the arrangement include: non-refundable upfront fees of RMB295,000 (approximately equivalent to $45,726), milestone payments for the achievement of specified certain development and sales targets and sales-based royalties.

 

Revenue of $45,726 for the year ended December 31, 2021 was derived from the upfront fee for the sale of intellectual property to a single customer, recognized at a point in time, and there was no further performance obligation to be performed.

v3.25.0.1
Finance Costs
12 Months Ended
Dec. 31, 2023
Finance Costs [Abstract]  
FINANCE COSTS
5.FINANCE COSTS

 

An analysis of finance costs is as follows:

 

   Year ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
Transaction cost for issuance of the Group’s convertible redeemable preferred shares   758    
    
 
Interest expenses on bank and other borrowings   421    295    708 
Interest expenses on lease liabilities   158    138    83 
Total   1,337    433    791 
v3.25.0.1
Income Tax
12 Months Ended
Dec. 31, 2023
Income Tax [Abstract]  
INCOME TAX
6.INCOME TAX

 

The company is subject to income tax on an entity basis on profit arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

 

Cayman Islands

 

Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gains.

 

The United States

 

The subsidiary incorporated in the United States (“U.S.”) is subject to U.S. federal income tax and New Jersey state income tax at the rates of 21% and 9%, respectively, during the Relevant Periods on the estimated assessable profits arising in the United States.

Mainland China

 

The provision for corporate income tax in Mainland China is based on the statutory rate of 25% of the assessable profits as determined in accordance with the PRC Corporate Income Tax Law, which was approved and became effective on January 1, 2008.

 

Pursuant to the relevant regulations on extension for expiries of unused tax losses of High and New Technology Enterprises and Small and Medium-sized Technological Enterprises issued in August 2018, the accumulated tax losses that did not expire from 2018 will have expiries extending from 5 years to 10 years from then on. Adlai Hangzhou qualified as a High and New Technology Enterprise during the years 2022-2024.

 

The income tax expense of the company for the Relevant Periods is analyzed as follows:

 

   Year ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
Current   
    
    643 
Deferred   
    
    
 
Total   
    
    643 

 

A reconciliation of the tax expense applicable to loss before tax at the statutory rate to the tax expense at the effective tax rate is as follows:

 

   Year ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
Loss before tax   (56,678)   (58,790)   (104,228)
Tax at the statutory tax rate (25%)   (14,169)   (14,698)   (26,057)
Foreign rate differential   13,240    2,933    14,711 
Expenses not deductible for tax   603    2,171    126 
Income not subject to tax   (2,890)   (4)   
 
Additional deductible allowance for qualified research and development costs   (1,109)   (1,681)   (2,338)
Unrecognized deferred tax assets   4,325    11,279    14,201 
Current income tax expense   
    
    643 
Tax charge at the Group’s effective rate   
    
    0.62%

Deferred tax

 

The Group considers positive and negative evidence to determine whether some portion or all of the deferred tax assets will be probable realized. Deferred tax assets have not been recognized in respect of these tax losses as they have been incurred in subsidiaries that were loss-making in the past and it is not probable that they will generate sufficient taxable income in the foreseeable future to utilize such tax losses.

 

   Year ended December 31 
   2022   2023 
   $’000   $’000 
Fixed assets   (13)   2 
Capitalized R&D   5,494    11,050 
Accrued and prepaid expenses   669    (101)
ROU Assets   (72)   5 
Advertising expenses in excess of deduction limit   14    11 
Allowance against receivables   
    3 
State tax   (1)   (1)
Stock options   1,075    883 
NOL   21,758    31,408 
Subtotal   28,923    43,260 
Unrecognized deferred tax assets   (28,923)   (43,260)
Total Deferred tax   
    
 

 

The Group has accumulated tax losses arising in Adlai Hangzhou in Mainland China of $83,103 and $102,647 as of December 31, 2022 and 2023, respectively, that will expire in five to ten years after the loss incurring year for offsetting against future taxable profits.

 

The Group also has accumulated tax losses in the U.S. of $46,201 and $54,168 as of December 31, 2022 and 2023, respectively, that can be carried forward indefinitely to offset against future taxable profits of the companies in which losses were incurred, subject to 80% taxable income limitation annually.

 

Uncertain Tax Position

 

The Company did not identify any significant unrecognized tax benefits for each of the periods presented. The Group did not incur any interest related to unrecognized tax benefits, did not recognize any penalties as income tax expense and also does not anticipate any significant change in unrecognized tax benefits within 12 months from December 31, 2023.

v3.25.0.1
Dividends
12 Months Ended
Dec. 31, 2023
Dividends [Abstract]  
DIVIDENDS
7.DIVIDENDS

 

No dividends have been declared and paid by the Company or the Group during the Relevant Periods.

v3.25.0.1
Loss Per Share Attributable To Ordinary Equity Holders of The Parent
12 Months Ended
Dec. 31, 2023
Loss Per Share Attributable To Ordinary Equity Holders of The Parent [Abstract]  
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT
8.LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

 

The calculation of the basic loss per share amount is based on the loss for the year attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 25,440,000, 25,440,000 and 43,342,068 in issue during the years ended December 31, 2021, 2022 and 2023, respectively.

 

The calculation of the basic loss per share amount is based on the loss for the years attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares in issue or deemed to be in issue during the year ended December 31, 2021, 2022 and 2023.

 

Basic loss per share is computed on the basis of the weighted average number of ordinary shares outstanding during the period of the financial statements.

 

Diluted loss per share of ordinary stock is computed on the basis of the weighted average number of shares of ordinary stock and dilutive securities (such as stock options and convertible securities) outstanding. As of December 31, 2021 the Company had 62,967,406 dilutive shares consisting of 57,543,414 relating to convertible preferred stock and 5,423,992 relating to options. As of December 31, 2022 the Company had 64,300,522 dilutive shares consisting of 57,543,414 relating to convertible preferred stock and 6,757,108 relating to options. As of December 31, 2023 the Company had 3,869,554 dilutive shares relating to options. Dilutive securities that have an anti-dilutive effect on diluted loss per share are excluded from the calculation.

 

No adjustment has been made to the basic loss per share amounts presented for the years ended December 31, 2021, 2022 and 2023 in respect of a dilution as the impact of the outstanding share options, restricted stock units and warrant liability had an anti-dilutive effect on the basic loss per share amounts presented.

v3.25.0.1
Property, Plant and Equipment
12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT AND EQUIPMENT
9.PROPERTY, PLANT AND EQUIPMENT

 

   Leasehold   Plant and   Office   Motor   Electronic     
   improvements   machinery   equipment   vehicles   equipment   Total 
   $’000   $’000   $’000   $’000   $’000   $’000 
At January 1, 2022, net of accumulated depreciation   1,601    1,842    68    12    132    3,655 
Additions   710    360    
    168    11    1,249 
Depreciation provided during the year   (416)   (412)   (31)   (19)   (53)   (931)
Disposals   
    
    
    (10)   
    (10)
Exchange realignment   (121)   (117)   (4)   
    (8)   (250)
At December 31, 2022, net of accumulated depreciation   1,774    1,673    33    151    82    3,713 
As of December 31, 2022:                              
Cost   2,532    3,386    150    199    276    6,543 
Accumulated depreciation   (758)   (1,713)   (117)   (48)   (194)   (2,830)
Net carrying amount   1,774    1,673    33    151    82    3,713 
   Leasehold   Plant and   Office   Motor   Electronic     
   improvements   machinery   equipment   vehicles   equipment   Total 
   $’000   $’000   $’000   $’000   $’000   $’000 
At January 1, 2023, net of accumulated depreciation   1,774    1,673    33    151    82    3,713 
Additions   28    27    
    127    18    200 
Depreciation provided during the year   (700)   (416)   (20)   (43)   (34)   (1,213)
Disposals   
    
    
    
    (1)   (1)
Exchange realignment   (25)   (23)   
    (3)   (2)   (53)
At Dec 31, 2023, net of accumulated depreciation   1,077    1,261    13    232    63    2,646 
As of December 31, 2023                              
Cost   2,519    3,373    148    322    228    6,590 
Accumulated depreciation   (1,442)   (2,112)   (135)   (90)   (165)   (3,944)
Net carrying amount   1,077    1,261    13    232    63    2,646 

 

During the Relevant Periods, none of the Group’s property, plant and equipment were pledged.

 

There was no impairment for the Group’s property, plant and equipment during the Relevant Periods.

v3.25.0.1
Leases
12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
LEASES
10.LEASES

 

The Group has lease contracts of properties and used in its operation with lease terms between 2 and 5 years.

 

(a)Right-of-use assets

 

The carrying amounts of the Group’s right-of-use assets and the movements during the Relevant Periods are as follows:

 

   Offices   Office
equipment
   Total 
   $’000   $’000   $’000 
As of January 1, 2022   2,725    209    2,934 
Additions   463    
    463 
Depreciation provided during the year   (961)   (129)   (1,090)
Exchange realignment   (141)   (4)   (145)
As of December 31, 2022   2,086    76    2,162 

 

   Offices   Office
equipment
   Total 
   $’000   $’000   $’000 
As of January 1, 2023   2,086    76    2,162 
Additions   
    
    
 
Depreciation provided during the year   (931)   (53)   (984)
Exchange realignment   (23)   (1)   (24)
As of December 31, 2023   1,132    22    1,154 
(b)Lease liabilities

 

The carrying amount of lease liabilities and the movements during the Relevant Periods are as follows:

 

   Lease
liabilities
 
   $’000 
As of January 1, 2022   (2,888)
Additions   (463)
Accretion of interest recognized during the year   (133)
Payments   1,070 
Exchange realignment   177 
As of December 31, 2022   (2,237)
As of January 1, 2023   (2,237)
Additions   
 
Accretion of interest recognized during the year   (83)
Payments   1,103 
Exchange realignment   26 
As of December 31, 2023   (1,191)

 

   2022   2023 
   $’000   $’000 
Analyzed into:        
Current portion   1,001    722 
Non-current portion   1,236    469 
Total   2,237    1,191 

 

(c)The amounts recognized in profit or loss in relation to leases are as follows:

 

   Year ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
Interest on lease liabilities   158    133    83 
Depreciation charge of right-of-use assets   951    1,090    984 
Total amount recognized in profit or loss   1,109    1,223    1,067 
v3.25.0.1
Prepayments, Other Receivables and Other Assets
12 Months Ended
Dec. 31, 2023
Prepayments, Other Receivables and Other Assets [Abstract]  
PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS
11.PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS

 

   As of December 31, 
   2022   2023 
   $’000   $’000 
Current:        
Prepayments (Note i)   1,912    2,337 
VAT deductible tax   100    135 
Deposits and other receivables   246    224 
    2,258    2,696 
Non-current:          
Deposits and other receivables   
    
 
Prepaid expenses   327    282 
    327    282 
Total   2,585    2,978 

Note i:

 

The amount represents prepayments for Contract Research Organizations (“CROs”) and deposit of property, plant and equipment not yet placed in use.

 

Other receivables had no historical default. The financial assets included in the above balances relate to receivables which were categorized in stage 1 at the end of each of the Relevant Periods. In calculating the expected credit loss rate, the Group considers the historical loss rate and adjusts for forward-looking factors and information. During the Relevant Periods, the Group estimated that the expected credit loss rate for other receivables and deposits was minimal.

 

The Group seeks to maintain strict control over its outstanding receivables to minimize credit risk. Long ageing balances are reviewed regularly by senior management. In view of the fact that the Group’s deposits and other receivables relate to a large number of diversified counterparties, there is no significant concentration of credit risk. The Group does not hold any collateral or other credit enhancements over its deposits and other receivable balances.

v3.25.0.1
Financial Assets at FVTPL
12 Months Ended
Dec. 31, 2023
Financial Assets At FVTPL [Abstract]  
FINANCIAL ASSETS AT FVTPL
12.FINANCIAL ASSETS AT FVTPL

 

   As of December 31, 
   2022   2023 
   $’000   $’000 
Current:        
Wealth management product   21,287    7 
Total   21,287    7 

 

During the Relevant Periods, the Group used surplus capital to purchase dual currency structured deposit and wealth management product from domestic commercial banks, which preserved capital and liquidity.

 

The wealth management product held as of December 31, 2022 was an investment into a mutual fund whose portfolio included a mixture of fixed income assets, preferred shares and repos, which were redeemable every 3 months. The wealth management product held as of December 31, 2023 was an investment into a money market fund that invests in short-term debt instruments such as treasury bills, certain certificates of deposit, bonds, government gilts and commercial paper. The returns on all of the financial product was not guaranteed, hence their contractual cash flows did not qualify solely as payments of principal and interest. Therefore, those products were accounted at fair value through profit or loss. Further details are included in note 20(c) to the Unaudited Condensed Consolidated Financial Statements.

v3.25.0.1
Investment at Amortized Cost
12 Months Ended
Dec. 31, 2023
Investment at Amortized Cost [Abstract]  
INVESTMENT AT AMORTIZED COST
13.INVESTMENT AT AMORTIZED COST

 

   As of December 31, 
   2022   2023 
   $’000   $’000 
Short-term investments at amortized cost   
    7,000 
Long-term investments at amortized cost   
    24,849 
Total   
    31,849 

 

Short-term investment at amortized cost represent time deposits placed with banks with original maturities between three months and one year.

 

Long-term investment at amortized cost represent time deposits placed with banks with original maturities more than one year.

v3.25.0.1
Other Payables and Accruals
12 Months Ended
Dec. 31, 2023
Other Payables and Accruals [Abstract]  
OTHER PAYABLES AND ACCRUALS
14.OTHER PAYABLES AND ACCRUALS

 

   As of December 31, 
   2022   2023 
   $’000   $’000 
Other payables and accruals (Note i)   255    303 
Tax payable   
 
    773 
Payroll and bonus payables   3,622    3,814 
Total   3,877    4,890 

Note i:

 

Other payables and accruals are unsecured, non-interest-bearing and repayable on demand. The fair values of other payables and accruals at the end of each of the Relevant Periods approximated to their corresponding carrying amounts.

v3.25.0.1
Interest-Bearing Bank Borrowings
12 Months Ended
Dec. 31, 2023
Interest-Bearing Bank Borrowings [Abstract]  
INTEREST-BEARING BANK BORROWINGS
15.INTEREST-BEARING BANK BORROWINGS

 

   As of December 31, 
   2022   2023 
   $’000   $’000 
Non-Revolving Facility, 5.22% interest, due March 22,2023, guaranteed (Note i)   1,436    
 
Non-Revolving Facility, 4.8% interest, due April 24,2023, guaranteed (Note ii)   2,871    
 
Non Revolving Facility, 4.2% interest, due March 26, 2024, guaranteed (Note iii)   
    2,824 
Non Revolving Facility, 4.0% interest, due September 17, 2024, guaranteed  (Note v)   
    1,412 
Non Revolving Facility, 4.0% interest, due September 18, 2024, guaranteed (Note v).   
    1,412 
Non Revolving Facility, 4.0% interest, due April 15, 2024, guaranteed (Note ii)   
    4,235 
Non Revolving Facility, 6.78% interest, due November 27, 2024, guaranteed  (Note vi)   
    3,000 
Non Revolving Facility, 6.0% interest, due November 14, 2024, guaranteed (Note vii).   
    10,650 
Non Revolving Facility, 6.3% interest, due December 26, 2024, guaranteed (Note vi).   
    4,000 
Non Revolving Facility, 4.0% interest, due December 25, 2024, guaranteed (Note iv)   
    2,824 
Total   4,307    30,357 

 

   Bank 
borrowings
   Total 
   $’000   $’000 
As of January 1, 2022   10,457    10,457 
Additions   7,897    7,897 
Repayments   (13,316)   (13,316)
Effect of foreign exchange rate changes   (731)   (731)
As of December 31, 2022   4,307    4,307 
Additions   50,234    50,234 
Repayments   (24,069)   (24,069)
Effect of foreign exchange rate changes   (115)   (115)
As of December 31, 2023   30,357    30,357 

 

All of the Group’s bank borrowings were obtained from third party financial institutions. As of December 31, 2022 and 2023, the Group’s credit facilities were $4,307 and $30,357, respectively, of which nil and nil was unused by the Group.

Notes:

 

(i)In March 2022, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 5.22% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. The non-revolving facility agreement was repaid at the maturity date of March 22, 2023.

 

(ii)In October 2022, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 20,000 and at an interest rate of 4.80% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. The non-revolving facility agreement was repaid at the maturity date of April 24, 2023.

 

In October 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 30,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors.

 

(iii)In March 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 20,000 and at an interest rate of 4.20% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. The non-revolving facility agreement was repaid at the maturity date of March 26, 2024. And in March 2024, Adlai Hangzhou repaid it at the maturity date.

 

(iv)In December 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 20,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors.
(v)In September 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. And in March 2024, Adlai Hangzhou repaid it before the maturity date.

 

In September 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. And in March 2024, Adlai Hangzhou repaid it before the maturity date.

 

(vi)In November 2023, Adlai US entered into a non-revolving facility agreement for a facility amount of USD 3,000 and at an interest rate of 6.78% per annum, guaranteed by the company.

 

In December 2023, Adlai US entered into a non-revolving facility agreement for a facility amount of USD 4,000 and at an interest rate of 6.30% per annum, guaranteed by the company.

 

(vii)In December 2023, the company entered into a non-revolving facility agreement for a facility amount of USD 10,650 and at an interest rate of 6.00% per annum, guaranteed by Adlai Hangzhou.
v3.25.0.1
Financial Liabilities At Fvtpl
12 Months Ended
Dec. 31, 2023
Financial Liabilities At Fvtpl [Abstract]  
FINANCIAL LIABILITIES AT FVTPL
16.FINANCIAL LIABILITIES AT FVTPL

 

Preferred shares and convertible loans

 

In late 2015, Adlai Hangzhou raised up to RMB70,000 from the Founders and certain onshore investors (“Series A Investors”).

 

In June 2018, the Company was established in the Cayman Island for seeking overseas listing opportunity, and the Company issued ordinary shares to the Founders and an option to the Series A Investors, which entitled Series A Investors to convert their equity interests in Adlai Hangzhou to up to 14,560,000 series A convertible preferred shares (“Series A Preferred Shares”) of the Company, at par value of $ 0.0001 per share, upon completion of the Reorganization. From January 2020 to April 2020, Series A Investors exercised the option and converted their equity interests in Adlai Hangzhou to Series A Preferred Shares of the Company.

 

In June 2018, to accommodate the Group’s Reorganization plan, certain onshore investors (“Series B Onshore Investors”) entered into convertible loan subscription agreement (the “Series B Loan Agreement”) with Adlai Hangzhou to issue a loan (the “Series B Convertible Loans”) to Series B Onshore Investors for a total consideration of RMB165,000. Meanwhile, the Company entered into a forward contract with these Series B Onshore investors to grant them an option (“Series B Preferred Shares Forward”) to convert Series B Convertible Loans issued by Adali Hangzhou to 6,600,000 series B convertible redeemable preferred shares (“Series B Preferred Shares”) of the Company, at par value of $ 0.0001 per share, upon completion of the Reorganization. Pursuant to the Series B Loan Agreement, these loans bore interest at 15% per annum and shall mature upon the exercise of the Series B Preferred Shares Forward. The Series B Onshore Investors agreed Adlai Hangzhou’s obligation of repayment the principal and accrued interests of these loans will be automatically relieved with the exercise of Series B Share Purchase Forward upon completion of the Reorganization. From April to May 2020, the Series B Onshore Investors have exercised their Series B Share Purchase Forward and converted their Series B Convertible Loans to an aggregate of 6,600,000 Series B Preferred Shares.

 

Concurrently, certain offshore investors (“Series B Offshore Investors”) subscribed 6,907,896 Series B Preferred Shares (“Series B Preferred Shares”) for a total consideration of $27,000. The Series B Onshore Investors and Series B Offshore Investors are collectively referred to as “Series B Investors”.

In December 2019, the Company issued 14,653,013 series C convertible redeemable preferred shares (“Series C Preferred Shares”) of the Company for a total consideration of $63,700 to certain investors (“Series C Investors”).

 

In April 2021, the Company entered into a Series D share purchase agreement with certain investors (“Series D Investors”) to issue an aggregate of 14,722,505 series D convertible redeemable preferred shares (“Series D Preferred Shares”) for a total consideration of $97,370 and paid in full as of December 31, 2021.

 

According to the original and amended Memorandum and Articles of Association (“MOA”) upon the issuance of each series of convertible redeemable preferred shares, the Group designated Series B, C and D Preferred Shares and Series B Convertible Loans as financial liabilities measured at FVTPL and recognized Series A Preferred Shares as equity in accordance with the relevant IFRS. There is no significant change in the major terms of MOA among of each series except mentioned otherwise in the notes to the Consolidated Financial Statements.

 

According to the MOA of the Company in May 2021, the key terms of the Series A, B, C and D Preferred Shares (collectively “Preferred Shares”) are as follows:

 

Conversion Rights (applicable to all Preferred Shares)

 

Each holder of Preferred Shares may, at the option of the holder thereof, be converted at any time into fully-paid and nonassessable ordinary shares of the Company based on the then-effective applicable conversion price (“Applicable Conversion Price”). Each holder of Preferred Shares shall automatically be converted, based on the Applicable Conversion Price, into ordinary shares of the Company upon the closing of a Qualified IPO (as defined below).

 

The Applicable Conversion Price is initially equal to the original issue price for each class of Preferred Shares and shall be subject to adjustment from time to time, including but not limited to share splits, share subdivision, share combination and the like, being no less than par value.

 

If the Company issues any additional ordinary shares at a subscription price less than the corresponding original subscription price of the Series B, C and D Preferred Shares, the Company shall issue new corresponding Series B, C and D Preferred Shares to the holders of Series B, C and D Preferred Shares at the nominal price or the minimum price allowed by applicable laws until the Applicable Conversion Price for each holders of Series B, C and D Preferred Shares is reduced to such issue price.

 

If the Group fails to meet any of the below two committed business objectives (“Business Objectives”) within the timelines, the holders of Series C Preferred Shares are entitled to request the Founders, affiliates of the Founders and the Group (collectively referred to as “Warrantors”) to jointly make up the share compensation necessary to make the pre-money valuation of the Company immediately before the investment by the holders of Preferred Shares be adjusted to 70% thereof. The share compensation arrangement shall be made on the basis of a nominal transfer price. The Business Objectives are:

 

a)promote at least three products (self-developed or by introduction) to the next clinical stage within eighteen months from the Series C Preferred Shares closing date, on the basis of existing clinical pipelines; and;

 

b)obtain the approval of one new drug application from the competent authority for drug administration in the US or PRC by the 3rd anniversary of Series C Preferred Shares closing date.

Qualified IPO means an underwritter initial public offering of the Company completed no later than the earlier of (i) September 7, 2023 and (ii) two years after the date of Closing of the Series D Preferred Shares and which occurs on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Market or such other reputable stock exchange approved by the a majority of all of the investor directors with (i) the pre-public offering market capitalization of no less than $650,000, unless otherwise agreed by the investor directors; and (ii) shares held by the investors can be listed for trading or otherwise disposed of without transfer restrictions after any applicable statutory lock-up period.

 

Voting Rights (applicable to all Preferred Shares)

 

Except as otherwise required by law or as set forth herein, the holder of each ordinary share issued and outstanding shall have one vote for each ordinary share held by such holder, and the holder of Preferred Shares shall be entitled to the number of votes equal to the number of ordinary shares into which such Preferred Shares could be converted.

 

Liquidation Preference (applicable to all Preferred Shares)

 

Upon any liquidation, closure, dissolution, merger or acquisition of any Group company; or the transfer of a controlling interest (i.e., more than 50% of the equity) by the shareholders of any Group company (excluding the holders of Series A, B, C and D Preferred Shares); or the sale of the majority of any Group’s assets to third parties; or the transfer of the majority of any Group’s intellectual property to third parties; or any event that can be defined as a transfer of control of any Group company; or any transfer of the Shares of any Group company (excluding the shares of the Company held by the holders of Series A, B, C and D Preferred Shares) or shares held by the Founders or their affiliates without the prior written consent of the Investor Director Majority, Series C Investors and Series D Investors; or any breach of the Warrantors under the Series D Share Purchase Agreements, the Series C Share Purchase Agreements, the Series B Share Purchase Agreement, the Shareholders’ Agreement and these Articles, as applicable (“Transaction Documents”) which would cause the Series C Investors and Series D Investors to claim for termination of any of the Transaction Documents (each a “Liquidation Event”), whether voluntary or involuntary, all assets and funds of the Company legally available for distribution to the shareholders is distributed to the shareholders of the Company in the sequence as follows:

 

a)Series D Preferred Shares

 

b)Series C Preferred Shares

 

c)Series B Preferred Shares

 

d)Series A Preferred Shares

 

If there are any assets or funds remaining after the aggregate Series A, B, C and D Preferred Shares have been distributed or paid fully, the remaining assets and funds of the Company available for distribution is distributed on a pro rata basis among all holders of outstanding ordinary shares and Preferred Shares.

 

Dividends (applicable to all Preferred Shares)

 

Each holder of the ordinary shares (on as-converted basis) shall be entitled to receive dividends on a pro rata basis on the number of ordinary shares, out of any funds legally available therefor, pro rata based on the number of ordinary shares held by each holder.

Redemption Rights (applicable to Series B, C and D Preferred Shares)

 

At any time after the earlier of the following, any investors of Preferred Shares shall be entitled to require the Company to redeem all or portion of the outstanding Preferred Shares held by them, and/or require each of the Warrantors to jointly and severally redeem or repurchase all or portion of the outstanding Preferred Shares held by them:

 

i.the Company fails to complete a Qualified IPO at the earlier of (a) September 7, 2023; and (b) two years after the date of Closing;

 

ii.(applicable to Series C Investors and Series D Investors only) with respect to any Series C Investor or Series D Investor, such Series C Investor or Series D Investor fails to achieve the investment return which is 100% of its investment amount and plus an amount that would accrue on its investment amount at a simple interest rate of ten percent (10%) per annum (if such period is less than a year, such interest amount shall be calculated proportionally) through transfer, dividends of the Preferred Shares, or disposal in any other way approved by such Series C Investors or Series D Investors plus the value of the Preferred Shares (if any) still held by such Series C Investors or Series D Investors by September 7, 2023 (with respect to Series C Investors) or by three years following its closing of Series D (with respect to Series D Investors);

 

iii.(applicable to Series C Investors only) the applicable Group company fails to meet any of the Committed Business Objectives within the timelines specified under these Articles;

 

iv.(applicable to Series C Investors only) the applicable Group company fails to obtain approval of a new medicine application from the competent authority for drug administration of its first medicine in the U.S. or the PRC by December 30, 2022;

 

v.(applicable to Series C Investors and Series D Investors only) the first disapproval or rejection by any competent governmental authority (including, without limitation, the National Medical Products Administration of the PRC or the U.S. Food and Drug Administration) of the application made by any Group company with respect to any of its new drugs;

 

vi.in case that the Group companies meet the requirements for a Qualified IPO, any of the Group companies or the management shareholders refuses the Qualified IPO or declines to make necessary cooperation for such Qualified IPO, or the Group companies fail to complete the Qualified IPO due to any reasons attributable to any management shareholder;

 

vii.without the written consent of the majority of investor directors, Series C Investors and Series D Investors, Mr. Yang Lu and Mr. Donghui Yang terminate their employment contracts with the applicable Group company or fail to comply their commitment to work full time as per the agreement with certain Series C Investors or Series D Investors prior to the latest to occur of the following events: (a) such Series C Investors or Series D Investors’ exit; (b) the occurrence of a Qualified IPO; (c) the expiry of the two years period after the closing of Series D; and (d) September 7, 2023;

 

viii.material change of principal business or, business scope of the Group companies without the written consent of the majority of investor directors, Series C Investors and Series D Investors;

 

ix.any significant intellectual property of any Group company becomes invalid, frozen, or is transferred, authorized, pledged, encumbered, hypothecated to any third party without prior written consent of the majority of investor directors;

 

x.the occurrence of a material breach by any Group company or any management shareholders of any of their respective representations, warranties, covenants or undertakings under the Transaction Documents and failure by applicable Group companies or management shareholders to make remedy within thirty days after so required;
xi.the occurrence of a material breach by any Group company or any management shareholder of any of mandatory laws or regulations in the applicable jurisdiction; and

 

xii.the occurrence of any material dishonesty problem by any Group company or any management shareholder.`

 

Next Equity Financing Warrant

 

In June 2018, in connection with the issuance of the Series B Preferred shares, the Company irrevocably issued to certain Series B Investors a warrant (“Next Equity Financing Warrant”), by which each of these Series B Investors shall be entitled but not obligated to purchase a certain number of the Company’s Preferred Shares with a par value of $0.0001 per share prior to the closing date of the Company’s next round equity or equity-linked financing (the “Next Equity Financing”), at an exercise price per share of ninety-five percent (95%) of the subscription price per share for the investors in such Next Equity Financing.

 

The Next Equity Financing Warrant expired upon the closing date of the Company’s Series C financing in August 2019 as none of these Series B Investors subscribed the Company’s Series C Preferred Shares.

 

CEHKL Warrant

 

On May 20, 2019, the Company entered into a warrant agreement with China Equities HK Limited (“CEHKL”), under which the Company agreed to issue certain Series B Preferred Shares to CEHKL with agreed price (“CEHKL Warrant”) and the CEHKL Warrant will expire on May 20, 2024. In July 2021, CEHKL elected to exercise the CEHKL Warrant and the Company issued 100,000 Series B Preferred Shares to CEHKL.

 

Presentation and classification

 

The Group and the Company have designated the Series B, C and D Preferred Shares and Series B Convertible Loans as financial liabilities measured at FVTPL upon initial recognition. The Next Equity Financing Warrant and CEHKL Warrant are initially recognized at fair value on the date on which the contract is entered into and are subsequently remeasured at fair value.

 

The change in fair value of financial liabilities at FVTPL is charged to profit or loss except for the portion attributable to credit risk change that shall be charged to other comprehensive income. The net gain or loss recognized in profit or loss includes any interest paid on the financial liabilities and is included in the loss on changes in fair value of financial liabilities at FVTPL line item. Management concluded that there is no credit risk of the financial liability that drives the change of the fair value of the financial liability.

 

The movements of the Group’s financial liabilities at FVTPL are set out as follows:

 

   Series B   Series C   Series D     
   Preferred   Preferred   Preferred     
   Shares   Shares   Shares   Total 
   $’000   $’000   $’000   $’000 
                 
At January 1, 2022   92,187    97,726    107,650    297,563 
Change in fair value   (1,803)   (594)   (4,798)   (7,195)
At December 31, 2022   90,384    97,132    102,852    290,368 
Change in fair value   13,943    15,207    10,021    39,171 
Conversion into ordinary shares upon IPO   (104,327)   (112,339)   (112,873)   (329,539)
At December 31, 2023   
    
    
    
 

The Company has used the discounted cash flow method and back-solve method to determine the underlying share value of the Company and adopted equity allocation model to determine the fair value of each financial liability as of the dates of issuance and at the end of each of the Relevant Periods.

 

Set out below is a summary of significant unobservable inputs to the valuation of financial instruments together with a quantitative sensitivity analysis as of December 31, 2022:

 

   As of
December 31,
 
   2022 
Fair value of ordinary shares of the Company  $6.15 
Risk-free interest rate (Note i)   4.68%
Expected term   0.44 years 
Volatility (Note ii)   52.86%

 

The Group estimated the risk-free interest rate based on the yield of the United States Government Bond with maturity close to the expected exit timing as of the valuation date. Under the option-pricing method, the cost of a put option, which can hedge the price change before the privately held shares can be sold, was considered as a basis to determine the lack of marketability discount. Volatility was estimated based on the annualized standard deviation of the daily stock price return of comparable companies for a period from the valuation date and with a similar time span to expiration.

 

In September 29, 2023, each holder of Preferred Shares automatically be converted, based on the Applicable Conversion Price, into ordinary shares of the Company upon the closing of IPO.

v3.25.0.1
Ordinary Shares
12 Months Ended
Dec. 31, 2023
Ordinary Shares [Abstract]  
ORDINARY SHARES
17.ORDINARY SHARES

 

Issued and fully paid:

 

   Number of   Ordinary 
   shares   Shares 
       $’000 
As of 1 January 2023   25,440,000    3 
Issuance of ordinary shares   12,717,391    1 
Conversion of Series A convertible preferred shares   14,560,000    1 
Conversion of Financial liabilities at FVTPL   42,983,414    5 
As at 31 December 2023   95,700,805    10 

 

The authorized share capital of the Company as of December 31, 2023 is $50 divided into 500,000,000 Shares of par value of $0.0001 each, including 442,456,586 ordinary shares.

 

In 2021, the Company issued 9,000,000 ordinary shares to Nortye Talent Limited and 6,000,000 ordinary shares to Nortye International Limited respectively to manage the Share Incentive Plan. All these ordinary shares in 2021 were unpaid shares as of December 31, 2022 and 2023. There was no movement in the Company’s ordinary shares in 2022.

v3.25.0.1
Deficits
12 Months Ended
Dec. 31, 2023
Deficits [Abstract]  
DEFICITS
18.DEFICITS

 

The amounts of the Group’s deficits and the movement therein for the Relevant Periods are presented in the consolidated statements of changes in equity.

 

(i)Additional paid-in capital

 

The additional paid-in capital represents the difference between the par value of the shares issued and the consideration received.

 

(ii)Share option reserve

 

The share option reverse of the Group represents the equity-settled share-based payments granted by the Group. Please refer to note 19 for details.

 

(iii)Exchange fluctuation reserve

 

The exchange fluctuation reserve represents exchange differences arising from the translation of the financial statements of Group companies whose functional currencies are different from the Group’s presentation currency.

v3.25.0.1
Share Incentive Plan
12 Months Ended
Dec. 31, 2023
Share Incentive Plan [Abstract]  
SHARE INCENTIVE PLAN
19.SHARE INCENTIVE PLAN

 

Adlai Hangzhou Scheme

 

Adlai Hangzhou, a subsidiary of the Company, was once listed on the National Equities Exchange and Quotations (“NEEQ”) (stock code 870946) and adopted a share incentive scheme (the “Adlai Hangzhou Scheme”) for the primary purpose of providing incentives to eligible management and employees who render services to Adlai Hangzhou. On June 15, 2017, awards up to 1,220,000 shares were granted to management and employees at the exercise price of RMB7 per share. Awards granted under the Adlai Hangzhou Scheme shall have a contractual term of five years and generally vest over a four year period, with 25% of total awards vesting on the anniversary date one year after the vesting commencement date and the remaining 75% vesting subsequently in three equal annual instalments.

 

The fair value of the awards granted to management and employees were $ 0.083 per share and $ 0.0765 per share, respectively, using the binomial option-pricing model on the grant date. The variables and assumptions used in computing the fair value of the awards are based on the directors’ best estimate. Changes in variables and assumptions may result in changes in the fair value of the awards.

 

The Group recognized $81 of share-based payment expenses prior to 2021, and nil and nil share-based payment expenses for the years ended December 31, 2022 and 2023, respectively, in relation to the awards granted under the Adlai Hangzhou Scheme.

 

Adlai Share Incentive Plan

 

On June 8, 2020, the Company’s Board of Directors approved a share incentive scheme (the “Share Incentive Plan”) in order to provide additional incentives to employees and to promote the success of the Group’s business. Unless otherwise cancelled or amended, the Share Incentive Plan will remain in force for 10 years. Under the Share Incentive Plan, the maximum aggregate number of shares shall not exceed 4,000,000 ordinary shares, as appropriately adjusted for subsequent stock splits, stock dividends and the like. On May 28, 2021, the Company’s Board of Directors approved to further reserve 11,000,000 ordinary shares of the Company for the Share Incentive Plan for a total of 15,000,000 ordinary shares approved for the Share Incentive Plan. The exercise price of share options is determinable by the directors, but shall not be less than 100% of the fair market value on the grant date. Share options do not confer rights on the holders to dividends or to vote at shareholders’ meetings. The awards may be granted but not be exercised prior to the last day of the six-month period following the listing date of the Company.

On July 5, 2021, the Company issued 6,000,000 and 9,000,000 ordinary shares reserved under the Share Inventive Plan to Nortye International Limited and Nortye Talent Limited, respectively, which are holding vehicles of two trusts established by the Company in order to facilitate the administration of the Share Incentive Plan. The sole purpose of the two trusts is to facilitate the issuance of ordinary shares under the Share Incentive Plan, and as such the 15,000,000 ordinary shares are not included in the Company’s calculation of weighted average shares outstanding.

 

On September 8, 2020 and November 1, 2020, awards for 1,435,000 and 2,560,730 shares, respectively, were granted by the Company to its executives, employees and consultants.

 

On May 31, 2021, 3,348,483 awarded shares were granted by the Company to its executives, employees and consultants.

 

On October 1, 2021, 412,000 awarded shares were granted by the Company to its executives, employees and consultants.

 

On January 1, 2022, 83,500 options were granted to certain new employees; 376,172 options were granted to certain employees and managers for outstanding performance.

 

On April 1, 2022, 1,077,800 options were granted to certain new employees, promoted employees and senior managers; 33,336 options were granted to three consultants.

 

On July 1, 2022, 207,200 options were granted to five new employees.

 

On October 1, 2022, 179,200 options were granted to five new employees.

 

On April 2023, 352,500 options were granted to the employees with an exercise price of $2.20 under the 2020 Share Incentive Plan.

 

On April 2023, the Group adopted the 2023 Share Incentive Plan, which is effective upon the completion of this offering. The maximum aggregate number of ordinary shares that may be issued under this 2023 Share Incentive Plan is 15,000,000, including any reserved and issued share under the 2020 Share Incentive Plan.

 

On December 6, 2023, 121,200 options were granted to certain new employees; 25,414 options were granted to certain employees and managers for outstanding performance.

Accordingly, the Group measured the fair value of the awards as of the grant date and recognizes the amount as a compensation expense over the vesting period for each separately vesting portion of the awards.

 

               Weighted     
       Weighted   Weighted   Average     
       Average   Average   Remaining   Aggregate 
       Exercise   Grant Fair   Contractual   intrinsic 
   Number of   Price   Value   Life   value 
   awards   $ per share   $ per share   (in years)   $ 
Balances, January 1, 2022   7,635,444    1.72    1.36    9.11    26,950 
Options granted   1,957,208    2.20    3.56    9.26      
Options forfeited/cancelled   (82,550)   2.11    2.68    8.79      
Options exercised   
    
    
          
Balances, December 31, 2022   9,510,102    1.82    1.79    8.34    41,218 
Options granted   499,114    2.20    4.47    9.49      
Options forfeited/cancelled   (50,116)   2.30    5.36    9.51      
Options exercised   
    
    
          
Balances, December 31, 2023   9,959,100    1.83    1.91    7.44    11,596 
Vested but not exercisable as of December 31, 2022   4,980,069    1.59    1.15    8.00      
Vested but not exercisable as of December 31, 2023   5,400,955    1.75    1.69    7.28      

 

As of December 31, 2022 and 2023, there were 15,000,000 and 15,000,000 shares reserved for the option plan and there were 5,489,898 and 5,040,900 shares available for issuance, respectively.

 

The fair value of the award granted during the years ended December 31, 2022 and 2023 were $ 6,913 and $2,231. The Group recognized share-based payment expenses of $6,082 and $4,330, respectively, during the years ended December 31, 2022 and 2023.

 

The fair value of awards granted during the Relevant Periods was estimated as of the grant date using a binomial option-pricing model, taking into account the terms and conditions upon which the awards were granted. The following table lists the inputs to the model used:

 

   Jan 1,   Apr 1,   July 1,   Oct 1,   Apr 21,   Dec 6, 
   2022   2022   2022   2022   2023   2023 
Dividend yield (%)   0.00    0.00    0.00    0.00    0.00    0.00 
Expected volatility (%)   48.73    48.78    48.88    48.82    49.68    49.90 
Risk-free interest rate (%)   1.66    2.52    3.03    3.98    3.98    4.30 
Expected life of options (year)   10.00    10.00    10.00    10.00    10.00    10.00 

 

As of December 31, 2022 and 2023, the Company had 9,510,102 and 9,959,100 awards outstanding under the Share Incentive Plan, respectively. The exercise in full of the outstanding awards would, under the present capital structure of the Company, result in the issue of 9,510,102 and 9,959,100, respectively, additional ordinary shares of the Company and additional share capital of $1.0 and $1.0 (before issue expenses), respectively.

v3.25.0.1
Notes to the Consolidated Statements of Cash Flows
12 Months Ended
Dec. 31, 2023
Notes to the Consolidated Statements of Cash Flows [Abstract]  
NOTES TO THE CONSOLIDATED STATEMENTS OF CASH FLOWS
20.NOTES TO THE CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(a)Major non-cash transactions

 

During the year ended December 31, 2021, 2022 and 2023, the Group had non-cash additions to right-of-use assets and lease liabilities of nil and nil, respectively, in respect of lease arrangements for offices and equipment.

 

(b)Changes in liabilities arising from financing activities

 

   Financial   New bank             
   instrument   loans and       Payable     
   measured at   other   Lease   for issue     
   FVTPL   borrowings   liabilities   costs   Total 
   $’000   $’000   $’000   $’000   $’000 
At January 1, 2021   153,283    8,309    3,635    
    165,227 
Interest expense   
    422    160    
    582 
Transaction costs for the issuance of convertible redeemable preferred shares   
    
    
    758    758 
Additions   97,370    12,410    
    
    109,780 
Disposal   
    
    
    
    
 
Payment                         
 – financing cash flows   
    (10,430)   (966)   (758)   (12,154)
 – operating cash flows   
    
    
    
    
 
Interest paid   
    (427)   
    
    (427)
Change in fair value   46,910    
    
    
    46,910 
Exchange adjustment   
    184    59    
    243 
At December 31, 2021   297,563    10,468    2,888    
    310,919 
Interest expense   
    295    133    
    433 
Transaction costs for the issuance of convertible redeemable preferred shares   
    
    
    
    
 
Additions   
    7,897    463    
    8,360 
Disposal   
    
    
    
    
 
Payment                         
 – financing cash flows   
    (13,316)   (936)   
    (14,252)
 – operating cash flows   
    
    
    
    
 
Interest paid   
    (290)   (134)   
    (424)
Change in fair value   (7,195)   
    
    
    (7,195)
Exchange adjustment   
    (741)   (177)   
    (917)
At December 31, 2022   290,368    4,313    2,237    
    296,918 
Interest expense   
    708    83    
    791 
Transaction costs for the issuance of convertible redeemable preferred shares   
    
    
    
    
 
Additions   
    50,234    
    
    50,234 
Conversion into ordinary shares   (329,539)   
    
    
    (329,539)
Payment                         
 – financing cash flows   
    (24,069)   (1,020)   
    (25,089)
 – operating cash flows   
    
    
    
    
 
Interest paid   
    (602)   (83)   
    (685)
Change in fair value   39,171    
    
    
    39,171 
Exchange adjustment   
    (115)   (26)   
    (141)
At December 31, 2023   
    30,469    1,191    
    31,660 
(c)Investment activities

 

   Dual currency       Wealth     
   structured   investments at   management     
   deposit   amortized cost   product   Total 
   $’000   $’000   $’000   $’000 
Year ended December 31, 2021                
purchase   (17,000)   (17,965)   (46,269)   (81,234)
disposal   9,500    17,965    
    27,465 
interest received   28    4    
    32 
Year ended December 31, 2022                    
purchase   (14,900)   
    (44,080)   (58,980)
disposal   22,439    
    65,618    88,057 
interest received   19    
    531    550 
Year ended December 31, 2023                    
purchase   
    (31,849)   (7)   (31,856)
disposal   
    
    21,039    21,039 
interest received   
    
    62    62 
v3.25.0.1
Commitments
12 Months Ended
Dec. 31, 2023
Notes and other explanatory information [abstract]  
COMMITMENTS
21.COMMITMENTS

 

The Group did not have capital commitments at the end of each of the Relevant Periods.

v3.25.0.1
Related Party Transactions
12 Months Ended
Dec. 31, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS
22.RELATED PARTY TRANSACTIONS

 

(a)Related parties

 

Parties are considered to be related if one party has the ability, directly or indirectly, to control or exercise significant influence over the other party.

 

Parties are also considered to be related if they are subject to common control. Members of key management of the Group and their close family members are also considered as related parties.

 

Name of related parties   Nature of relationship
Mr. Yang Lu   The chief executive officer and chairman of our board of directors and ultimate significant shareholder of the Company

 

As disclosed in note 15 (i) to 15 (v) to the consolidated financial statements, the RMB40,000 and RMB90,000 non-revolving facility agreements provided by five third party banks were guaranteed by the ultimate significant shareholder, Mr. Yang Lu for the years ended December 31, 2022 and 2023, respectively.

v3.25.0.1
Financial Instruments by Category
12 Months Ended
Dec. 31, 2023
Financial Instruments by Category [Abstract]  
FINANCIAL INSTRUMENTS BY CATEGORY

23. FINANCIAL INSTRUMENTS BY CATEGORY

 

The carrying amounts of each of the categories of financial instruments of the Group as of the end of each of the Relevant Periods are as follows:

 

   As of December 31, 
   2022   2023 
   $’000   $’000 
Financial assets:        
Financial assets at FVTPL:        
Dual currency structured deposit   
    
 
Wealth management product   21,287    7 
Total   21,287    7 
Other financial assets:          
Financial assets included in prepayments, other receivables and other assets   2,585    2,978 
Cash and cash equivalents   42,758    91,492 
Short-term investments at amortized cost.   
    7,000 
Long-term investments at amortized cost   
    24,849 
Total   45,343    126,319 
Financial liabilities:          
Trade payables   13,098    14,348 
Financial liabilities included in other payables and accruals   3,877    4,890 
Interest-bearing bank and other borrowings   4,307    30,357 
Total   21,282    49,595 
Financial liabilities at FVTPL:          
Financial instruments measured at FVTPL   290,368    
 
Total   290,368    
 
v3.25.0.1
Fair Value and Fair Value Hierarchy of Financial Instruments
12 Months Ended
Dec. 31, 2023
Fair Value and Fair Value Hierarchy of Financial Instruments [Abstract]  
FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS
24.FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

 

The carrying amounts and fair values of the Group’s financial instruments, other than those with carrying amounts that reasonably approximate to fair values, are as follows:

 

   As of December 31, 2022   As of December 31, 2023 
   Carrying       Carrying     
   amount   Fair value   amount   Fair value 
   $’000   $’000   $’000   $’000 
Financial assets                
Dual currency structured deposit   
    
    
    
 
Wealth management product   21,287    21,287    7    7 
Total.   21,287    21,287    7    7 
Financial liabilities                    
Financial liabilities at FVTPL   290,368    290,368    
    
 
Total.   290,368    290,368    
    
 

Management has assessed that the fair values of cash and cash equivalents, interest-bearing bank and other borrowings, trade payables, financial assets included in prepayments, other receivables and other assets, and financial liabilities included in other payables and accruals approximate to their carrying amounts largely due to the short term maturities of these instruments.

 

The Group’s finance department headed by the finance manager is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance manager reports directly to the chief financial officer and the audit committee. At the end of each of the Relevant Periods, the finance department analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation. The valuation is reviewed and approved by the chief financial officer. The valuation process and results are discussed with the audit committee twice a year for interim and annual financial reporting.

 

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The methods and assumptions used to estimate the fair value, including a summary of significant unobservable inputs together with a quantitative sensitivity analysis, are set out in note 15 to the Consolidated Financial Statements.

 

The fair values of the non-current portion of interest-bearing bank and other borrowings have been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities. The changes in fair value as a result of the Group’s own non-performance risk for interest-bearing bank and other borrowings as of the end of each of the Relevant Periods were assessed to be insignificant.

 

Fair value hierarchy

 

The following tables illustrate the fair value measurement hierarchy of the Group’s financial instruments:

 

As of December 31, 2022

 

   Fair value measurement using 
   Quoted prices   Significant   Significant     
   in active   observable   unobservable     
   markets   inputs   inputs     
   (Level 1)   (Level 2)   (Level 3)   Total 
   $’000   $’000   $’000   $’000 
Financial assets                
Dual currency structured deposit   
    
    
    
 
Wealth management product   21,287    
    
    21,287 
Total.   21,287    
    
    21,287 
Financial liabilities             290,368    290,368 
Financial liabilities at FVTPL   
    
    290,368    290,368 

 

As of December 31, 2023

 

   Fair value measurement using 
   Quoted prices   Significant   Significant     
   in active   observable   unobservable     
   markets   inputs   inputs     
   (Level 1)   (Level 2)   (Level 3)   Total 
Financial assets                
Dual currency structured deposit   
    
    
    
 
Wealth management product   7    
    
    7 
Total   7    
    
    7 
v3.25.0.1
Financial Risk Management Objectives and Policies
12 Months Ended
Dec. 31, 2023
Financial Risk Management Objectives and Policies [Abstract]  
Financial Risk Management Objectives and Policies
25.FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

 

The Group’s principal financial instruments comprise interest-bearing bank and other borrowings, convertible redeemable preferred shares and cash and cash equivalents. The main purpose of these financial instruments is to raise finance for the Group’s operations. The Group has various other financial assets and liabilities such as trade payables, other payables and accruals, which arise directly from its operations.

 

The main risks arising from the Group’s financial instruments are foreign currency risk and liquidity risk. The board of directors reviews and agrees policies for managing each of these risks and they are summarized below.

 

Foreign currency risk

 

The Group has transactional currency exposures. Such exposures arise from purchases by operating units in currencies other than the units’ functional currencies.

 

The following table demonstrates the sensitivity at the end of each of the Relevant Periods to a reasonably possible change in the $ and RMB exchange rate, with all other variables held constant, of the Group’s profit before tax (due to changes in the fair values of monetary assets and liabilities).

 

   Increase/   Increase/     
   (decrease) in   (decrease)   Increase/ 
   $/RMB   in net   (decrease) 
   rate%   loss   in equity 
       $’000   $’000 
At December 31, 2021            
If the $ strengthens against the RMB   5    
    2,398 
If the $ weakens against the RMB   (5)   
    (2,651)

 

   Increase/   Increase/     
   (decrease) in   (decrease)   Increase/ 
   $/RMB   in net   (decrease) 
   rate%   loss   in equity 
       $’000   $’000 
At December 31, 2022            
If the $ strengthens against the RMB   5    
    (1,939)
If the $ weakens against the RMB   (5)   
    4,081 

 

   Increase/   Increase/     
   (decrease) in   (decrease)   Increase/ 
   $/RMB   in net   (decrease) 
   rate%   loss   in equity 
       $’000   $’000 
As of December 31, 2023            
If the $ strengthens against the RMB   5    (1,010)   (943)
If the $ weakens against the RMB   (5)   1,116    1,042 

 

Liquidity risk

 

The Group monitors and maintains a level of cash and cash equivalents deemed adequate by the management of the Group to finance the operations and mitigate the effects of fluctuations in cash flows.

The maturity profile of the Group’s financial liabilities as of the end of each Relevant Periods, based on the contractual undiscounted payments, is as follows:

 

   As of December 31, 2022 
       Less than             
   On demand   1 year   1 to 5 years   Over 5 years   Total 
   $’000   $’000   $’000   $’000   $’000 
Financial liabilities at FVTPL   
    290,368    
    
    290,368 
Trade and bills payables   13,098    
    
    
    13,098 
Financial liabilities included in other payables and accruals   3,877    
    
    
    3,877 
Interest-bearing bank borrowings   
    4,307    
    
    4,307 
Total   16,975    294,675    
    
    311,650 

 

   As of December 31, 2023 
       Less than             
   On demand   1 year   1 to 5 years   Over 5 years   Total 
   $’000   $’000   $’000   $’000   $’000 
Financial liabilities at FVTPL   
    
    
    
    
 
Trade and bills payables   14,348    
    
    
    14,348 
Financial liabilities included in other payables and accruals   4,890    
    
    
    4,890 
Interest-bearing bank borrowings   
    30,357    
    
    30,357 
Total   19,238    30,357    
    
    49,595 

 

Capital management

 

The primary objectives of the Group’s capital management are to safeguard the Group’s ability to continue as a going concern and to maintain healthy capital ratios in order to support its business and maximize shareholders’ value.

 

The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Group is not subject to any externally imposed capital requirements. No changes were made in the objectives, policies or processes for managing capital during the Relevant Periods.

 

The asset-liability ratios as of the end of each of the Relevant Periods are as follows:

 

   As of December 31, 
   2022   2023 
   $’000   $’000 
Total assets   72,594    130,189 
Total liabilities   313,887    50,786 
Asset-liability ratio (Note i)   0.23    2.56 

Note i:

 

The asset-liability ratio is calculated by dividing total assets by total liabilities.

v3.25.0.1
Subsequent Events
12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS
26.SUBSEQUENT EVENTS

 

(a)Bank loan

 

In February 2024, Adlai Hangzhou entered into a non-revolving facility agreement with a third party financial institution for a facility amount of RMB20,000 at an interest rate of 4.0% per annum, guaranteed by Mr. Yang Lu and Adlai Shanghai. The maturity date is August 2, 2024.

 

In February 2024, Adlai US entered into a non-revolving facility agreement with a third party financial institution for a facility amount of USD3,000 at an interest rate of 6.57% per annum. The maturity date is February 26, 2025.

 

In February 2024, Adlai Hangzhou entered into a non-revolving facility agreement with a third party financial institution for a facility amount of RMB30,000 at an interest rate of 4.0% per annum, guaranteed by Mr. Yang Lu and Adlai Shanghai. The maturity date is March 4, 2024.And in March 2024, Adlai Hangzhou repaid a non-revolving facility amount of RMB30,000 at the maturity date.

 

In March 2024, Adlai Hangzhou entered into a non-revolving facility agreement with a third party financial institution for a facility amount of RMB60,000 at an interest rate of 3.5% per annum, guaranteed by Mr. Yang Lu and Adlai Shanghai. The maturity date is November 28, 2024.

 

In March 2024, Adlai Hangzhou repaid three non-revolving facility amount of RMB40,000 at the maturity date.

 

In April 2024, Adlai Hangzhou repaid a non-revolving facility amount of RMB30,000 at the maturity date.

 

(b)Subsidiaries

 

In March 2024, Shareholder of Hangzhou Tangchuang agreed to increase the company’s registered capital to RMB100 million, with an additional investment of RMB70 million from Hangzhou Hongxi Business Management Co., Ltd and an additional investment of RMB20 million from Adlai Hangzhou. After this capital increase, the company accounting for 30% of the registered capital in Hangzhou Tangchuang. And Hangzhou Tangchuang would no longer be a subsidiary within the company’s scope of consolidation.

v3.25.0.1
Condensed Financial Information of the Parent Company
12 Months Ended
Dec. 31, 2023
Condensed Financial Information of the Parent Company [Abstract]  
CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY
27.CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY

 

The business transactions and assets of Adlai Hangzhou and Shanghai Adlai Nortye Biopharma Co., Ltd (“PRC Subsidiaries”) are primarily denominated in RMB, which is not freely convertible into foreign currencies. All foreign exchange transactions take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People’s Bank of China. Approval of foreign currency payments by the People’s Bank of China or other regulatory institutions requires submitting a payment application form together with suppliers’ invoices, shipping documents and signed contracts. These currency exchange control measures imposed by the PRC government may restrict the ability of PRC Subsidiaries to transfer their net assets to the Company through loans, advances or cash dividends.

 

The net assets of PRC Subsidiaries in aggregate exceeded 25% of the Company’s consolidated net assets. Accordingly, condensed parent company financial statements have been prepared in accordance with Rule 5.04 and Rule 12-04 of SEC Regulation S-X.

 

The subsidiaries did not pay any dividends to the Company for the periods presented. For the purpose of presenting parent-only financial information, the Company records its investment in its subsidiaries under the cost method of accounting. Such investment is presented on the separate condensed balance sheets of the Company as “Investment in subsidiaries”. Certain information and footnote disclosures generally included in financial statements prepared in accordance with IFRSs are not required.

As of December 31, 2022 and 2023, there were no material contingencies, significant provisions for long-term obligations, or guarantees of the Company, except for those which have been separately disclosed in the consolidated financial statements, if any.

 

PARENT COMPANY BALANCE SHEETS

 

   December 31, 
   2022   2023 
   $’000   $’000 
ASSETS        
Current assets        
Cash and cash equivalents   12,194    63,150 
Prepayments, other receivables and other assets   36    44 
short-term investments at amortized cost   
    7,000 
Total current assets   12,230    70,194 
Non-current assets          
Due from related parties   115,743    123,102 
Investment in subsidiaries   94,300    129,711 
Total non-current assets   210,043    252,813 
Total assets   222,273    323,007 
LIABILITIES          
Current liabilities          
Accounts payable   888    976 
Other payables and accruals.   
    53 
Due to related parties   
    40 
Interest payables   
    10,650 
Non-current liabilities due within one year        
 
Financial liabilities at FVTPL   290,368    
 
Total current liabilities   291,260    11,719 
Non-current liabilities          
Long-term loans   
    
 
Financial liabilities at FVTPL   
    
 
Total non-current liabilities   
    
 
Total liabilities   291,260    11,719 
Ordinary shares (par value of $0.0001 per share; 442,456,586 shares authorized; 40,440,000 shares issued and outstanding as of December 31, 2022; and nil outstanding as of December 31, 2023)   4    
 
Class A Ordinary shares (par value of $0.0001 per share; nil outstanding as of December 31,2022; and 93,710,805 shares outstanding as of December 31, 2023)   
    9 
Class B Ordinary shares (par value of $0.0001 per share; nil outstanding as of December 31,2022; and 16,990,000 shares outstanding as of December 31, 2023)   
    2 
Series A convertible preferred shares (par value of US$0.0001 per share; 14,560,000 and nil shares authorized, issued and outstanding as of   10,980    
 
Additional paid-in capital   6,415    438,707 
Share option reserve   11,730    16,059 
Accumulated deficit   (98,116)   (143,489)
Total shareholders’ deficit   (68,987)   311,288 
Total liabilities and shareholders’ equity   222,273    323,007 

PARENT COMPANY STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

 

   For the Years Ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
REVENUE   
    
    
 
Other operating income, net   
    156    242 
Administrative expenses   (2,376)   (1,390)   (6,196)
Research and development expenses   
    
    
 
Total operating loss   (2,376)   (1,234)   (5,954)
Other income and gains   173    
    
 
Other expenses   
    
    
 
Investment income   3    
    
 
Fair value loss on financial liabilities at FVTPL   (46,910)   7,194    (39,171)
Finance costs   (399)   
    (249)
LOSS BEFORE TAX   (49,509)   5,960    (45,374)
Income tax expense   
    
    
 
LOSS FOR THE YEAR   (49,509)   5,960    (45,374)
TOTAL COMPREHENSIVE (LOSS)/INCOME FOR THE YEAR   (49,509)   5,960    (45,374)

 

PARENT COMPANY STATEMENTS OF CASH FLOWS

 

   Year ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
Net cash flows used in operating activities   (1,610)   (1,134)   (13,143)
Net cash flows used in investing activities   (65,798)   (35,035)   (38,082)
Net cash flows from financing activities   96,428    
    102,181 
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS   29,020    (36,169)   50,956 
Cash and cash equivalents at beginning of year   19,343    48,363    12,194 
CASH AND CASH EQUIVALENTS AT END OF YEAR   48,363    12,194    63,150 
v3.25.0.1
Accounting Policies, by Policy (Policies)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Subsidiaries

Subsidiaries

A subsidiary is an entity (including a structured entity), directly or indirectly, controlled by the Company. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee (i.e., existing rights that give the Group the current ability to direct the relevant activities of the investee). When the Company has, directly or indirectly, less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

(a)contractual arrangements with other vote holders of the investee;
(b)rights arising from other contractual arrangements; and
(c)the Group’s voting rights and potential voting rights.

The financial statements of subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. The results of subsidiaries are consolidated from the date on which the Group obtains control, and continue to be consolidated until the date that such control ceases.

Profit or loss and each component of other comprehensive income are attributed to the owners of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

Fair value measurement

Fair value measurement

The Group measures certain financial instruments at fair value at the end of each of the Relevant Periods. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability, or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or most advantageous market must be accessible by the Group. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the Consolidated Financial Statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 based on quoted prices (unadjusted) in active markets for identical assets or liabilities
Level 2 based on valuation techniques for which the lowest level input that is significant to the fair value measurement is observable, either directly or indirectly
Level 3 based on valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognized in the Consolidated Financial Statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by reassessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each of the Relevant Periods.

Impairment of non-financial assets

Impairment of non-financial assets

Where an indication of impairment exists, or when annual impairment testing for an asset is required (other than financial assets), the asset’s recoverable amount is estimated. An asset’s recoverable amount is the higher of the asset or cash-generating unit’s value in use and its fair value less cost of disposal, and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case the recoverable amount is determined for the cash-generating unit to which the asset belongs.

An impairment loss is recognized only if the carrying amount of an asset exceeds its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An impairment loss is charged to profit or loss in the period in which it arises in those expense categories consistent with the function of the impaired asset.

An assessment is made at the end of each of the Relevant Periods as to whether there is an indication that previously recognized impairment losses may no longer exist or may have decreased. If such an indication exists, the recoverable amount is estimated. A previously recognized impairment loss of an asset other than goodwill is reversed only if there has been a change in the estimates used to determine the recoverable amount of that asset, but not to an amount higher than the carrying amount that would have been determined (net of any depreciation/amortization) had no impairment loss been recognized for the asset in prior years. A reversal of such an impairment loss is credited to profit or loss in the period in which it arises.

Related parties

Related parties

A party is considered to be related to the Group if:

(a)the party is a person or a close member of that person’s family and that person
(i)has control or joint control over the Group;
(ii)has significant influence over the Group; or
(iii)is a member of the key management personnel of the Group or of a parent of the Group;

or

(b)the party is an entity where any of the following conditions applies:
(i)the entity and the Group are members of the same group;
(ii)one entity is an associate or joint venture of the other entity (or of a parent, subsidiary or fellow subsidiary of the other entity);
(iii)the entity and the Group are joint ventures of the same third party;
(iv)one entity is a joint venture of a third entity and the other entity is an associate of the third entity;
(v)the entity is a post-employment benefit plan for the benefit of employees of either the Group or an entity related to the Group; and the sponsoring employers of the post-employment benefit plan;
(vi)the entity is controlled or jointly controlled by a person identified in(a);
(vii)a person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity); and
(viii)the entity, or any member of a group of which it is a part, provides key management personnel services to the Group or to the parent of the Group.
Property, plant and equipment and depreciation

Property, plant and equipment and depreciation

Property, plant and equipment, other than construction in progress, are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property, plant and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.

Expenditure incurred after items of property, plant and equipment have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalized in the carrying amount of the asset as a replacement. Where significant parts of property, plant and equipment are required to be replaced at intervals, the Group recognizes such parts as individual assets with specific useful lives and depreciates them accordingly.

Depreciation is calculated on the straight-line basis to write off the cost of each item of property, plant and equipment to its residual value over its estimated useful life. The principal annual rates used for this purpose are as follows:

Plant and machinery   10% to 19%
Office equipment   19% to 20%
Motor vehicles   19%
Electronic equipment   19% to 20%
Leasehold improvements   The shorter of remaining lease terms or estimated useful lives

Where parts of an item of property, plant and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately. Residual values, useful lives and the depreciation method are reviewed, and adjusted if appropriate, at least at the end of each of the Relevant Periods.

An item of property, plant and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on disposal or retirement recognized in the statement of profit or loss and other comprehensive income in the year the asset is derecognized is the difference between the net sales proceeds and the carrying amount of the relevant asset.

Construction in progress is reclassified to the appropriate category of property, plant and equipment when completed and ready for use.

Other intangible assets (other than goodwill)

Other intangible assets (other than goodwill)

Other intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is the fair value at the date of acquisition. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are subsequently amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least at the end of each of the Relevant Periods.

Computer software

Computer software is stated at cost less any impairment losses and amortized on a straight-line basis over its estimated useful life of 5 years.

The estimated useful life of software is determined by considering the period of the economic benefits to the Group, as well as by referring to industry practice.

Research and development costs

Research and development costs

All research costs are charged to expense as incurred.

Expenditure incurred on projects to develop new products is capitalized and deferred only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the project and the Group’s ability to measure reliably the expenditure during the development. Product development expenditure which does not meet these criteria is expensed when incurred.

Leases

Leases

The Group assesses at contract inception whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

Group as a lessee

The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

(a)Right-of-use assets

Right-of-use assets are recognized at the commencement date of the lease (the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and any impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease terms and the estimated useful lives of the assets as follows:

Offices  2 to 5 years
Office equipment  2 to 5 years

If ownership of the leased asset transfers to the Group by the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset.

(b)Lease liabilities

Lease liabilities are recognized at the commencement date of the lease at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for termination of a lease, if the lease term reflects the Group exercising the option to terminate the lease. Variable lease payments that do not depend on an index or a rate are recognized as an expense in the period in which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Group uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in lease payments (e.g., a change to future lease payments resulting from a change in an index or rate) or a change in assessment of an option to purchase the underlying asset.

(c)Short-term leases and leases of low-value assets

The Group applies the short-term lease recognition exemption to its short-term leases of office equipment (that is those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the recognition exemption for leases of low-value assets to leases of office equipment that are considered to be of low value.

Lease payments on short-term leases and leases of low-value assets are recognized as an expense on a straight-line basis over the lease term.

Financial assets

Financial assets

Initial recognition and measurement

Financial assets are classified, at initial recognition, as subsequently measured at amortized cost, fair value through other comprehensive income, and fair value through profit or loss.

The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and the Group’s business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient of not adjusting the effect of a significant financing component, the Group initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs.

In order for a financial asset to be classified and measured at amortized cost or fair value through other comprehensive income, it needs to give rise to cash flows that are solely payments of principal and interest (“SPPI”) on the principal amount outstanding. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss, irrespective of the business model.

The Group’s business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Financial assets classified and measured at amortized cost are held within a business model with the objective to hold financial assets in order to collect contractual cash flows, while financial assets classified and measured at fair value through other comprehensive income are held within a business model with the objective of both holding to collect contractual cash flows and selling. Financial assets which are not held within the aforementioned business models are classified and measured at fair value through profit or loss.

All regular way purchases and sales of financial assets are recognized on the trade date, that is, the date that the Group commits to purchase or sell the asset. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the period generally established by regulation or convention in the marketplace.

Subsequent measurement

The subsequent measurement of financial assets depends on their classification as follows:

Financial assets at amortized cost (debt instruments)

Financial assets at amortized cost are subsequently measured using the effective interest method and are subject to impairment. Gains and losses are recognized in the statement of profit or loss and other comprehensive income when the asset is derecognized, modified or impaired.

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are carried in the statement of financial position at fair value with net changes in fair value recognized in the statement of profit or loss and other comprehensive income.

This category includes derivative instruments and equity investments which the Group has not irrevocably elected to classify at fair value through other comprehensive income. Dividends on equity investments classified as financial assets at fair value through profit or loss are also recognized as other income in the statement of profit or loss and other comprehensive income when the right of payment has been established, it is probable that the economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably.

A derivative embedded in a hybrid contract, with a financial liability or non-financial host, is separated from the host and accounted for as a separate derivative if the economic characteristics and risks are not closely related to the host; a separate instrument with the same terms as the embedded derivative would meet the definition of a derivative; and the hybrid contract is not measured at fair value through profit or loss. Embedded derivatives are measured at fair value with changes in fair value recognized in the statement of profit or loss and other comprehensive income. Reassessment only occurs if there is either a change in the terms of the contract that significantly modifies the cash flows that would otherwise be required or a reclassification of a financial asset out of the fair value through profit or loss category.

A derivative embedded within a hybrid contract containing a financial asset host is not accounted for separately. The financial asset host together with the embedded derivative is required to be classified in its entirety as a financial asset at fair value through profit or loss.

Derecognition of financial assets

Derecognition of financial assets

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Group’s consolidated statement of financial position) when:

the rights to receive cash flows from the asset have expired; or
the Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a “pass-through” arrangement; and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if, and to what extent, it has retained the risk and rewards of ownership of the asset. When it has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the Group continues to recognize the transferred asset to the extent of the Group’s continuing involvement. In that case, the Group also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Group could be required to repay.

Impairment of financial assets

Impairment of financial assets

The Group recognizes an allowance for expected credit losses (“ECLs”) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

General approach

ECLs are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12 months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

At the end of each of the Relevant Periods, the Group assesses whether the credit risk on a financial instrument has increased significantly since initial recognition. When making the assessment, the Group compares the risk of a default occurring on the financial instrument as of the reporting date with the risk of a default occurring on the financial instrument as of the date of initial recognition and considers reasonable and supportable information that is available without undue cost or effort, including historical and forward-looking information.

The Group considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Group may also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

Financial assets at amortized cost are subject to impairment under the general approach and they are classified within the following stages for measurement of ECLs except for trade receivables and contract assets which apply the simplified approach as detailed below.

Stage 1 Financial instruments for which credit risk has not increased significantly since initial recognition and for which the loss allowance is measured at an amount equal to 12-month ECLs
     
Stage 2  — Financial instruments for which credit risk has increased significantly since initial recognition but that are not credit-impaired financial assets and for which the loss allowance is measured at an amount equal to lifetime ECLs
     
Stage 3  — Financial assets that are credit-impaired at the reporting date (but that are not purchased or originated credit-impaired) and for which the loss allowance is measured at an amount equal to lifetime ECLs

Simplified approach

For trade receivables that do not contain a significant financing component or when the Group applies the practical expedient of not adjusting the effect of a significant financing component, the Group applies the simplified approach in calculating ECLs. Under the simplified approach, the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at the end of each of the Relevant Periods.

Financial liabilities

Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, as appropriate.

All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Group’s financial liabilities include trade and other payables, derivative financial instruments, interest-bearing bank and other borrowings and certain financial instruments designated at FVTPL.

Subsequent measurement

The subsequent measurement of financial liabilities depends on their classification as follows:

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss.

Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Group that are not designated as hedging instruments in hedge relationships as defined by IFRS 9. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments. Gains or losses on liabilities held for trading are recognized in the statement of profit or loss. The net fair value gain or loss recognized in the statement of profit or loss does not include any interest charged on these financial liabilities.

Financial liabilities designated upon initial recognition as at fair value through profit or loss are designated at the initial date of recognition, and only if the criteria in IFRS 9 are satisfied. Gains or losses on liabilities designated at fair value through profit or loss are recognized in the statement of profit or loss, except for the gains or losses arising from the Group’s own credit risk which are presented in other comprehensive income with no subsequent reclassification to the statement of profit or loss. The net fair value gain or loss recognized in the statement of profit or loss does not include any interest charged on these financial liabilities.

The company assessed the contract characteristics of each series of convertible redeemable preferred shares to determine whether they should be classified as equity instruments or financial liabilities. The Series B, C, and D Preferred Shares and Series B Convertible Loans were classified as financial liabilities measured at fair value through profit or loss. The decision was based on the presence of a redemption feature and a conversion option with a price adjustment feature, which are considered financial liabilities under IAS 32.

The company also determined that the Series B Convertible Loans are a hybrid instrument that includes a non-derivative host contract and embedded derivatives, which should be accounted for at fair value through profit or loss.

Financial liabilities at amortized cost (loans and borrowings)

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost, using the effective interest rate method unless the effect of discounting would be immaterial, in which case they are stated at cost. Gains and losses are recognized in the statement of profit or loss and other comprehensive income when the liabilities are derecognized as well as through the effective interest rate amortization process.

Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortization is included in finance costs in the statement of profit or loss and other comprehensive income.

Derecognition of financial liabilities

Derecognition of financial liabilities

A financial liability is derecognized when the obligation under the liability is discharged or cancelled, or expires.

When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and a recognition of a new liability, and the difference between the respective carrying amounts is recognized in the statement of profit or loss and other comprehensive income.

Derivative financial instruments

Derivative financial instruments

Initial recognition and subsequent measurement

The Group uses derivative financial instruments, such as warrants. Such derivative financial instruments are initially recognized at fair value on the date on which a derivative contract is entered into and are subsequently remeasured at fair value. Derivatives are carried as assets when the fair value is positive and as liabilities when the fair value is negative.

Any gains or losses arising from changes in fair value of derivatives are taken directly to profit or loss.

Current versus non-current classification

Derivative instruments that are not designated as effective hedging instruments are classified as current or non-current or separated into current and non-current portions based on an assessment of the facts and circumstances (i.e., the underlying contracted cash flows):

Where the Group expects to hold a derivative as an economic hedge (and does not apply hedge accounting) for a period beyond 12 months after the end of the reporting period, the derivative is classified as non-current (or separated into current and non-current portions) consistently with the classification of the underlying item.
Embedded derivatives that are not closely related to the host contract are classified consistently with the cash flows of the host contract.
Derivative instruments that are designated as, and are effective hedging instruments, are classified consistently with the classification of the underlying hedged item. The derivative instruments are separated into current portions and non-current portions only if a reliable allocation can be made.
Cash and cash equivalents

Cash and cash equivalents

For the purpose of the consolidated statement of cash flows, cash and cash equivalents comprise cash on hand and demand deposits, and short term highly liquid investments that are readily convertible into known amounts of cash, are subject to an insignificant risk of changes in value, and have a short maturity of generally within three months when acquired.

For the purpose of the consolidated statement of financial position, cash and cash equivalents comprise cash on hand and at banks, including term deposits, and assets similar in nature to cash, which are not restricted as to use.

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents at high-quality and accredited financial institutions in amounts that could exceed the $250,000 maximum amount insured by the Federal Deposit Insurance Corporation (FDIC). The Company does not believe that its cash and cash equivalents are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

Provisions

Provisions

A provision is recognized when a present obligation (legal or constructive) has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation.

When the effect of discounting is material, the amount recognized for a provision is the present value at the end of the reporting period of the future expenditures expected to be required to settle the obligation. The increase in the discounted present value amount arising from the passage of time is included in finance costs in the statement of profit or loss and other comprehensive income.

Income tax

Income tax

Income tax comprises current and deferred tax. Income tax relating to items recognized outside profit or loss is recognized outside profit or loss, either in other comprehensive income or directly in equity.

Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period, taking into consideration interpretations and practices prevailing in the countries in which the Group operates.

Deferred tax is provided, using the liability method, on all temporary differences at the end of the reporting period between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

Deferred tax liabilities are recognized for all taxable temporary differences, except:

when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
in respect of taxable temporary differences associated with investments in subsidiaries, associates and joint ventures, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred tax assets are recognized for all deductible temporary differences, the carryforward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carryforward of unused tax credits and unused tax losses can be utilized, except:

when the deferred tax asset relating to the deductible temporary differences arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
in respect of deductible temporary differences associated with investments in subsidiaries, associates and joint ventures, deferred tax assets are only recognized to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.

The carrying amount of deferred tax assets is reviewed at the end of each of the Relevant Periods and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at the end of each of the Relevant Periods and are recognized to the extent that it has become probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax assets and deferred tax liabilities are offset if and only if the Group has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities which intend either to settle current tax liabilities and assets on a net basis, or to realise the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

In compliance with IFRIC 23, accruals for risk on income tax are part of the income tax within the statements of operations and comprehensive loss and income tax payable within the statements of financial position.

Government grants

Government grants

Government grants are recognized at their fair value where there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed.

Revenue recognition

Revenue recognition

Sales of intellectual property

Revenue from sales of intellectual property is recognized when control of the intellectual property is transferred to the customers at an amount that reflects the consideration to which the Group expects to be entitled in exchange for the intellectual property.

When the consideration of sales of intellectual property includes a variable amount, the amount of consideration is estimated to which the Group will be entitled in exchange for transferring the intellectual property to the customer. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved.

Milestone payments and sales-based royalties represent a form of variable consideration which is included in the transaction price to the extent that it is highly probable that a significant reversal of accumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. When the Group cannot conclude that it is highly probable that a significant revenue reversal of cumulative revenue under the contract will not occur, the Group constrains the related variable consideration resulting in its exclusion from the transaction price.

As part of the accounting for this arrangement, the Group must use significant judgement to determine: (a) the performance obligations; and (b) the method to estimate variable consideration.

At contract inception, the Group assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.

The Group uses judgement to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. If a milestone or other variable consideration relates specifically to the Group’s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Group generally allocates that milestone amount entirely to that performance obligation once it is highly probable that a significant revenue reversal would not occur.

The Group recognizes revenue only when it satisfies a performance obligation by transferring control of the promised goods or services. The transfer of control can occur over time or at a point in time. A performance obligation is satisfied over time if it meets one of the following criteria:

The counterparty simultaneously receives and consumes the benefits provided by the Group’s performance as the Group performs; or

The Group’s performance creates or enhances an asset that the counterparty controls as the asset is created or enhanced

The Group’s performance does not create an asset with an alternative use to the Group and the Group has an enforceable right to payment for performance completed to date.

The portion of the transaction price that is allocated to performance obligations satisfied at a point in time is recognized as revenue when control of the goods or services is transferred to the counterparty. If the performance obligation is satisfied over time, the portion of the transaction price allocated to that performance obligation is recognized as revenue as the performance obligation is satisfied. The Group adopts an appropriate method of measuring progress for purposes of recognizing revenue. The Group evaluates the measure of progress at the end of each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Upfront fees

Upfront payment is allocated to the performance obligations based on the Group’s best estimate of their relative stand-alone selling prices. The Group recognizes revenues from non-refundable upfront fees at a point in time when the transfer of control of the intellectual property to the counterparty occurs and the counterpary is able to use and benefit from the intellectual property.

Milestone payments

At the inception of each arrangement that includes milestone payments, the Group evaluates whether the milestones are considered highly probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is highly probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Group, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are received. The Group evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgement involved in determining whether it is highly probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Group re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Milestone payments are allocated to performance obligations based on the Group’s best estimate of their relative stand-alone selling prices unless the criteria under IFRS 15.85 are met, in which case the milestone payments are allocated entirely to the performance obligation which the milestone payments are specifically related to.

The Group assessed that achievement of all the remaining contractual milestones is highly uncertain and the related milestone payments are not included in the transaction price. Milestones are achieved when the triggering event described in the related agreement occurs.

Sales royalties

The Group recognizes revenue for a sales-based royalty promised in exchange for the sales of intellectual property only when (or as) the later of the following events occurs:

(a)the subsequent sale occurs; and
(b)the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied.

Revenue from other sources

Rental income is recognized on a time proportion basis over the lease terms. Variable lease payments that do not depend on an index or a rate are recognized as income in the accounting period in which they are incurred.

Interest income

Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.

Share-based payments

Share-based payments

The Company operates a share option scheme for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group’s operations. Employees (including directors) of the Group receive remuneration in the form of share-based payments, whereby employees render services as consideration for equity instruments (“equity-settled transactions”).

The cost of equity-settled transactions with employees for grants is measured by reference to the fair value at the date at which they are granted. The fair value is determined by an external valuer using a binomial model, further details of which are given in note 19 to the Consolidated Financial Statements.

The cost of equity-settled transactions is recognized in employee benefit expense, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled. The cumulative expense recognized for equity-settled transactions at the end of each of the Relevant Periods until the vesting date reflects the extent to which the vesting period has expired and the Group’s best estimate of the number of equity instruments that will ultimately vest. The charge or credit to the statement of profit or loss and other comprehensive income for a period represents the movement in the cumulative expense recognized as of the beginning and end of that period.

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group’s best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.

Other employee benefits

Other employee benefits

Pension schemes

The employees of the Group’s subsidiaries who operate in Mainland China are required to participate in a central pension scheme operated by the local municipal government. These subsidiaries are required to contribute a certain percentage of their payroll costs to the central pension scheme. The contributions are charged to profit or loss as they become payable in accordance with the rules of the central pension scheme.

The subsidiary in the U.S. maintains multiple qualified contributory savings plans as allowed under Section 401(k) of the Internal Revenue Code in the U.S. These plans are defined contribution plans covering substantially all its qualifying employees and provide for voluntary contributions by employees, subject to certain limits. The contributions are made by both the employees and the employer. The employees’ contributions are primarily based on specified dollar amounts or percentages of employee compensation. The only obligation of the subsidiary in the U.S. with respect to the retirement benefits plans is to make the specified contributions under the plans.

Housing fund — Mainland China

The Group contributes on a monthly basis to a defined contribution housing fund plan operated by the local municipal government. Contributions to this plan by the Group are expensed as incurred.

Borrowing costs

Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets (i.e., assets that necessarily take a substantial period of time to get ready for their intended use or sale) are capitalized as part of the cost of those assets. The capitalization of such borrowing costs ceases when the assets are substantially ready for their intended use or sale. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs capitalized. All other borrowing costs are expensed in the period in which they are incurred. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

Foreign currencies

Foreign currencies

These consolidated financial statements are presented in United States dollars (“$”), which is the Company’s functional currency. Each entity in the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency. Foreign currency transactions recorded by the entities in the Group are initially recorded using their respective functional currency rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency rates of exchange at the end of the reporting period. Differences arising on settlement or translation of monetary items are recognized in the statement of operations and comprehensive loss.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured. The gain or loss arising on translation of a non-monetary item measured at fair value is treated in line with the recognition of the gain or loss on change in fair value of the item (i.e., translation difference on the item whose fair value gain or loss is recognized in other comprehensive income or profit or loss is also recognized in other comprehensive income or profit or loss, respectively).

In determining the exchange rate on initial recognition of the related asset, expense or income on the derecognition of a non-monetary asset or non-monetary liability relating to an advance consideration, the date of the initial transaction is the date on which the Group initially recognizes the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of the advance consideration.

The functional currencies of certain subsidiaries established in the PRC are currencies other than $. As of the end of the reporting period, the assets and liabilities of these entities are translated into $ at the exchange rates prevailing at the end of the reporting period and their statements of profit or loss and other comprehensive income are translated into $ at the weighted average exchange rates for the year.

The resulting exchange differences are recognized in other comprehensive income and accumulated in the exchange fluctuation reserve. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is recognized in the statement of profit or loss and other comprehensive income.

For the purpose of the consolidated statement of cash flows, the cash flows of the subsidiaries established in the PRC are translated into $ at the exchange rates at the dates of the cash flows. Frequently recurring cash flows of the subsidiaries established in the PRC which arise throughout the year are translated into $ at the weighted average exchange rates for the year.

v3.25.0.1
Corporate and Group Information (Tables)
12 Months Ended
Dec. 31, 2023
Corporate and Group Information [Abstract]  
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies

As of the date of this report, the Company had direct and indirect interests in its subsidiaries, all of which are private limited liability companies, the particulars of which are set out below:

 

            Percentage   
            of equity   
      Date and place of  Issued ordinary  attributable to   
      incorporation / registration  share/  the Company   
Name  Notes  and place of operations  registered capital  Direct  Indirect  Principal activities
Alpine Bioscience Ltd. (“Alpine BVI”)     British Virgin Islands 8 January 2018  One share of par value $1  100%    Investment holding
Adlai Nortye USA Inc (“Adlai US”)     The United States 30 January 2018  10,000 shares of par value $0.0001 each    100%  Clinical studies and testing, and technology development and transfer
Adlai Nortye (Switzerland) AG (“Adlai Swiss”)     Switzerland 21 June 2022  100 shares of par value CHF1’000 each    100%  Investment holding
Adlai Nortye PTE.LTD (“Adlai SGP”)     Singapore 22 April 2022  Two shars of par value $1    100%  Investment holding
Adlai Nortye (HK) Limited (“Adlai HK”)     Hong Kong 24 April 2018  HKD 0.001    100%  Investment holding

Hangzhou Adlai Nortye Biopharma Co., Ltd* (“Adlai Hangzhou”)

     the People’s Republic of China (“PRC”)/Mainland China 14 September 2004  RMB 200,000    100%  Product research and development, technology transfer and consulting services business

Shanghai Adlai Nortye Biopharma Co., Ltd* (“Adlai Shanghai”)

     the People’s Republic of China (“PRC”)/Mainland China 22 December 2021  RMB 10,000    100%  Product research and development, technology transfer and consulting services business

Hangzhou Tangchuang Weilai Technolegy Co., Ltd (“Hangzhou Tangchuang”)

     the People’s Republic of China (“PRC”)/Mainland China 2 November 2022  RMB 10,000    100%  Product research and development, technology transfer and consulting services business
*The English name of the subsidiary registered in the PRC represents the best efforts made by management of the Company to translate its Chinese name as the subsidiary does not have an official English name.
v3.25.0.1
Basis of Presentation (Tables)
12 Months Ended
Dec. 31, 2023
Basis Of Presentation Abstract  
Schedule of New and Revised IFRSs

The Group has not applied the following new and revised IFRSs that have been issued but are not yet effective in the Consolidated Financial Statements.

 

      Effective for
accounting year
beginning on or after
Amendments to IAS 1  Classification of Liabilities as current and non-current  January 1, 2024
Amendments to IFRS 16  Lease Liability in a Sale and Leaseback  January 1, 2024
Amendments to IAS 1  Non-current Liabilities with Covenants  January 1, 2024
Amendments to IAS 28 and IFRS 10  Sale or contribution of assets between an investor and its associate or joint venture  To be determined
Schedule of Principal Annual Rates of Property Plant and Equipment

Depreciation is calculated on the straight-line basis to write off the cost of each item of property, plant and equipment to its residual value over its estimated useful life. The principal annual rates used for this purpose are as follows:

 

Plant and machinery   10% to 19%
Office equipment   19% to 20%
Motor vehicles   19%
Electronic equipment   19% to 20%
Leasehold improvements   The shorter of remaining lease terms or estimated useful lives
Schedule of Estimated Useful Lives of The Right of Use Assets Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease terms and the estimated useful lives of the assets as follows:
Offices  2 to 5 years
Office equipment  2 to 5 years
v3.25.0.1
Revenue (Tables)
12 Months Ended
Dec. 31, 2023
Revenue [Abstract]  
Schedule of Analysis of Revenue

An analysis of revenue is as follows:

 

   2021   2022   2023 
   $’000   $’000   $’000 
Sales of intellectual property   45,726           
Sales of an exclusive option.   
    
    5,000 
Total   45,726    
    5,000 
v3.25.0.1
Finance Costs (Tables)
12 Months Ended
Dec. 31, 2023
Finance Costs [Abstract]  
Schedule of Analysis of Finance Costs

An analysis of finance costs is as follows:

 

   Year ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
Transaction cost for issuance of the Group’s convertible redeemable preferred shares   758    
    
 
Interest expenses on bank and other borrowings   421    295    708 
Interest expenses on lease liabilities   158    138    83 
Total   1,337    433    791 
v3.25.0.1
Income Tax (Tables)
12 Months Ended
Dec. 31, 2023
Income Tax [Abstract]  
Schedule of Income Tax Expense

The income tax expense of the company for the Relevant Periods is analyzed as follows:

 

   Year ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
Current   
    
    643 
Deferred   
    
    
 
Total   
    
    643 
Schedule of Reconciliation of the Tax Expense Applicable to Loss Before Tax at the Statutory Rate to the Tax Expense at the Effective Tax Rate

A reconciliation of the tax expense applicable to loss before tax at the statutory rate to the tax expense at the effective tax rate is as follows:

 

   Year ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
Loss before tax   (56,678)   (58,790)   (104,228)
Tax at the statutory tax rate (25%)   (14,169)   (14,698)   (26,057)
Foreign rate differential   13,240    2,933    14,711 
Expenses not deductible for tax   603    2,171    126 
Income not subject to tax   (2,890)   (4)   
 
Additional deductible allowance for qualified research and development costs   (1,109)   (1,681)   (2,338)
Unrecognized deferred tax assets   4,325    11,279    14,201 
Current income tax expense   
    
    643 
Tax charge at the Group’s effective rate   
    
    0.62%
Schedule of Deferred Tax Assets Deferred tax assets have not been recognized in respect of these tax losses as they have been incurred in subsidiaries that were loss-making in the past and it is not probable that they will generate sufficient taxable income in the foreseeable future to utilize such tax losses.
   Year ended December 31 
   2022   2023 
   $’000   $’000 
Fixed assets   (13)   2 
Capitalized R&D   5,494    11,050 
Accrued and prepaid expenses   669    (101)
ROU Assets   (72)   5 
Advertising expenses in excess of deduction limit   14    11 
Allowance against receivables   
    3 
State tax   (1)   (1)
Stock options   1,075    883 
NOL   21,758    31,408 
Subtotal   28,923    43,260 
Unrecognized deferred tax assets   (28,923)   (43,260)
Total Deferred tax   
    
 
v3.25.0.1
Property, Plant and Equipment (Tables)
12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment PROPERTY, PLANT AND EQUIPMENT
   Leasehold   Plant and   Office   Motor   Electronic     
   improvements   machinery   equipment   vehicles   equipment   Total 
   $’000   $’000   $’000   $’000   $’000   $’000 
At January 1, 2022, net of accumulated depreciation   1,601    1,842    68    12    132    3,655 
Additions   710    360    
    168    11    1,249 
Depreciation provided during the year   (416)   (412)   (31)   (19)   (53)   (931)
Disposals   
    
    
    (10)   
    (10)
Exchange realignment   (121)   (117)   (4)   
    (8)   (250)
At December 31, 2022, net of accumulated depreciation   1,774    1,673    33    151    82    3,713 
As of December 31, 2022:                              
Cost   2,532    3,386    150    199    276    6,543 
Accumulated depreciation   (758)   (1,713)   (117)   (48)   (194)   (2,830)
Net carrying amount   1,774    1,673    33    151    82    3,713 
   Leasehold   Plant and   Office   Motor   Electronic     
   improvements   machinery   equipment   vehicles   equipment   Total 
   $’000   $’000   $’000   $’000   $’000   $’000 
At January 1, 2023, net of accumulated depreciation   1,774    1,673    33    151    82    3,713 
Additions   28    27    
    127    18    200 
Depreciation provided during the year   (700)   (416)   (20)   (43)   (34)   (1,213)
Disposals   
    
    
    
    (1)   (1)
Exchange realignment   (25)   (23)   
    (3)   (2)   (53)
At Dec 31, 2023, net of accumulated depreciation   1,077    1,261    13    232    63    2,646 
As of December 31, 2023                              
Cost   2,519    3,373    148    322    228    6,590 
Accumulated depreciation   (1,442)   (2,112)   (135)   (90)   (165)   (3,944)
Net carrying amount   1,077    1,261    13    232    63    2,646 
v3.25.0.1
Leases (Tables)
12 Months Ended
Dec. 31, 2023
Leases [Line Items]  
Schedule of Carrying Amounts of the Group's Right-of-Use Assets and the Movements

The carrying amounts of the Group’s right-of-use assets and the movements during the Relevant Periods are as follows:

 

   Offices   Office
equipment
   Total 
   $’000   $’000   $’000 
As of January 1, 2022   2,725    209    2,934 
Additions   463    
    463 
Depreciation provided during the year   (961)   (129)   (1,090)
Exchange realignment   (141)   (4)   (145)
As of December 31, 2022   2,086    76    2,162 

 

   Offices   Office
equipment
   Total 
   $’000   $’000   $’000 
As of January 1, 2023   2,086    76    2,162 
Additions   
    
    
 
Depreciation provided during the year   (931)   (53)   (984)
Exchange realignment   (23)   (1)   (24)
As of December 31, 2023   1,132    22    1,154 
Schedule of Carrying Amount of Lease Liabilities and the Movements

The carrying amount of lease liabilities and the movements during the Relevant Periods are as follows:

 

   Lease
liabilities
 
   $’000 
As of January 1, 2022   (2,888)
Additions   (463)
Accretion of interest recognized during the year   (133)
Payments   1,070 
Exchange realignment   177 
As of December 31, 2022   (2,237)
As of January 1, 2023   (2,237)
Additions   
 
Accretion of interest recognized during the year   (83)
Payments   1,103 
Exchange realignment   26 
As of December 31, 2023   (1,191)
Schedule of Amounts Recognized in Profit or Loss in Relation to Leases The amounts recognized in profit or loss in relation to leases are as follows:
   Year ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
Interest on lease liabilities   158    133    83 
Depreciation charge of right-of-use assets   951    1,090    984 
Total amount recognized in profit or loss   1,109    1,223    1,067 
Lease liabilities [member]  
Leases [Line Items]  
Schedule of Carrying Amount of Lease Liabilities and the Movements
   2022   2023 
   $’000   $’000 
Analyzed into:        
Current portion   1,001    722 
Non-current portion   1,236    469 
Total   2,237    1,191 
v3.25.0.1
Prepayments, Other Receivables and Other Assets (Tables)
12 Months Ended
Dec. 31, 2023
Prepayments, Other Receivables and Other Assets [Abstract]  
Schedule of Prepayments, Other Receivables and Other Assets PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS
   As of December 31, 
   2022   2023 
   $’000   $’000 
Current:        
Prepayments (Note i)   1,912    2,337 
VAT deductible tax   100    135 
Deposits and other receivables   246    224 
    2,258    2,696 
Non-current:          
Deposits and other receivables   
    
 
Prepaid expenses   327    282 
    327    282 
Total   2,585    2,978 
v3.25.0.1
Financial Assets at FVTPL (Tables)
12 Months Ended
Dec. 31, 2023
Financial Assets At FVTPL [Abstract]  
Schedule of Financial Assets at FVTPL
   As of December 31, 
   2022   2023 
   $’000   $’000 
Current:        
Wealth management product   21,287    7 
Total   21,287    7 
v3.25.0.1
Investment at Amortized Cost (Tables)
12 Months Ended
Dec. 31, 2023
Investment at Amortized Cost [Abstract]  
Schedule of Investment at Amortized Cost
   As of December 31, 
   2022   2023 
   $’000   $’000 
Short-term investments at amortized cost   
    7,000 
Long-term investments at amortized cost   
    24,849 
Total   
    31,849 
v3.25.0.1
Other Payables and Accruals (Tables)
12 Months Ended
Dec. 31, 2023
Other Payables and Accruals [Abstract]  
Schedule of Other Payables and Accruals
   As of December 31, 
   2022   2023 
   $’000   $’000 
Other payables and accruals (Note i)   255    303 
Tax payable   
 
    773 
Payroll and bonus payables   3,622    3,814 
Total   3,877    4,890 

Note i:

 

Other payables and accruals are unsecured, non-interest-bearing and repayable on demand. The fair values of other payables and accruals at the end of each of the Relevant Periods approximated to their corresponding carrying amounts.

v3.25.0.1
Interest-Bearing Bank Borrowings (Tables)
12 Months Ended
Dec. 31, 2023
Interest-Bearing Bank Borrowings (Tables) [Line Items]  
Schedule of Interest-Bearing Bank Borrowings INTEREST-BEARING BANK BORROWINGS
   As of December 31, 
   2022   2023 
   $’000   $’000 
Non-Revolving Facility, 5.22% interest, due March 22,2023, guaranteed (Note i)   1,436    
 
Non-Revolving Facility, 4.8% interest, due April 24,2023, guaranteed (Note ii)   2,871    
 
Non Revolving Facility, 4.2% interest, due March 26, 2024, guaranteed (Note iii)   
    2,824 
Non Revolving Facility, 4.0% interest, due September 17, 2024, guaranteed  (Note v)   
    1,412 
Non Revolving Facility, 4.0% interest, due September 18, 2024, guaranteed (Note v).   
    1,412 
Non Revolving Facility, 4.0% interest, due April 15, 2024, guaranteed (Note ii)   
    4,235 
Non Revolving Facility, 6.78% interest, due November 27, 2024, guaranteed  (Note vi)   
    3,000 
Non Revolving Facility, 6.0% interest, due November 14, 2024, guaranteed (Note vii).   
    10,650 
Non Revolving Facility, 6.3% interest, due December 26, 2024, guaranteed (Note vi).   
    4,000 
Non Revolving Facility, 4.0% interest, due December 25, 2024, guaranteed (Note iv)   
    2,824 
Total   4,307    30,357 
(i)In March 2022, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 5.22% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. The non-revolving facility agreement was repaid at the maturity date of March 22, 2023.

 

(ii)In October 2022, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 20,000 and at an interest rate of 4.80% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. The non-revolving facility agreement was repaid at the maturity date of April 24, 2023.

 

In October 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 30,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors.

 

(iii)In March 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 20,000 and at an interest rate of 4.20% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. The non-revolving facility agreement was repaid at the maturity date of March 26, 2024. And in March 2024, Adlai Hangzhou repaid it at the maturity date.

 

(iv)In December 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 20,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors.
(v)In September 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. And in March 2024, Adlai Hangzhou repaid it before the maturity date.

 

In September 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. And in March 2024, Adlai Hangzhou repaid it before the maturity date.

 

(vi)In November 2023, Adlai US entered into a non-revolving facility agreement for a facility amount of USD 3,000 and at an interest rate of 6.78% per annum, guaranteed by the company.

 

In December 2023, Adlai US entered into a non-revolving facility agreement for a facility amount of USD 4,000 and at an interest rate of 6.30% per annum, guaranteed by the company.

 

(vii)In December 2023, the company entered into a non-revolving facility agreement for a facility amount of USD 10,650 and at an interest rate of 6.00% per annum, guaranteed by Adlai Hangzhou.
Interest-Bearing Bank Borrowings [Member]  
Interest-Bearing Bank Borrowings (Tables) [Line Items]  
Schedule of Interest-Bearing Bank Borrowings
   Bank 
borrowings
   Total 
   $’000   $’000 
As of January 1, 2022   10,457    10,457 
Additions   7,897    7,897 
Repayments   (13,316)   (13,316)
Effect of foreign exchange rate changes   (731)   (731)
As of December 31, 2022   4,307    4,307 
Additions   50,234    50,234 
Repayments   (24,069)   (24,069)
Effect of foreign exchange rate changes   (115)   (115)
As of December 31, 2023   30,357    30,357 
v3.25.0.1
Financial Liabilities At Fvtpl (Tables)
12 Months Ended
Dec. 31, 2023
Financial Liabilities At Fvtpl [Abstract]  
Schedule of Movements of The Group’s Financial Liabilities at FVTPL

The movements of the Group’s financial liabilities at FVTPL are set out as follows:

 

   Series B   Series C   Series D     
   Preferred   Preferred   Preferred     
   Shares   Shares   Shares   Total 
   $’000   $’000   $’000   $’000 
                 
At January 1, 2022   92,187    97,726    107,650    297,563 
Change in fair value   (1,803)   (594)   (4,798)   (7,195)
At December 31, 2022   90,384    97,132    102,852    290,368 
Change in fair value   13,943    15,207    10,021    39,171 
Conversion into ordinary shares upon IPO   (104,327)   (112,339)   (112,873)   (329,539)
At December 31, 2023   
    
    
    
 
Schedule of Significant Unobservable Inputs to the Valuation of Financial Instruments

Set out below is a summary of significant unobservable inputs to the valuation of financial instruments together with a quantitative sensitivity analysis as of December 31, 2022:

 

   As of
December 31,
 
   2022 
Fair value of ordinary shares of the Company  $6.15 
Risk-free interest rate (Note i)   4.68%
Expected term   0.44 years 
Volatility (Note ii)   52.86%
v3.25.0.1
Ordinary Shares (Tables)
12 Months Ended
Dec. 31, 2023
Ordinary Shares [Abstract]  
Schedule of Ordinary Shares

Issued and fully paid:

 

   Number of   Ordinary 
   shares   Shares 
       $’000 
As of 1 January 2023   25,440,000    3 
Issuance of ordinary shares   12,717,391    1 
Conversion of Series A convertible preferred shares   14,560,000    1 
Conversion of Financial liabilities at FVTPL   42,983,414    5 
As at 31 December 2023   95,700,805    10 
v3.25.0.1
Share Incentive Plan (Tables)
12 Months Ended
Dec. 31, 2023
Share Incentive Plan [Abstract]  
Schedule of Compensation Expense over the Vesting Period for each Separately Vesting Portion of the Awards

Accordingly, the Group measured the fair value of the awards as of the grant date and recognizes the amount as a compensation expense over the vesting period for each separately vesting portion of the awards.

 

               Weighted     
       Weighted   Weighted   Average     
       Average   Average   Remaining   Aggregate 
       Exercise   Grant Fair   Contractual   intrinsic 
   Number of   Price   Value   Life   value 
   awards   $ per share   $ per share   (in years)   $ 
Balances, January 1, 2022   7,635,444    1.72    1.36    9.11    26,950 
Options granted   1,957,208    2.20    3.56    9.26      
Options forfeited/cancelled   (82,550)   2.11    2.68    8.79      
Options exercised   
    
    
          
Balances, December 31, 2022   9,510,102    1.82    1.79    8.34    41,218 
Options granted   499,114    2.20    4.47    9.49      
Options forfeited/cancelled   (50,116)   2.30    5.36    9.51      
Options exercised   
    
    
          
Balances, December 31, 2023   9,959,100    1.83    1.91    7.44    11,596 
Vested but not exercisable as of December 31, 2022   4,980,069    1.59    1.15    8.00      
Vested but not exercisable as of December 31, 2023   5,400,955    1.75    1.69    7.28      
Schedule of Inputs to the Model Used The following table lists the inputs to the model used:
   Jan 1,   Apr 1,   July 1,   Oct 1,   Apr 21,   Dec 6, 
   2022   2022   2022   2022   2023   2023 
Dividend yield (%)   0.00    0.00    0.00    0.00    0.00    0.00 
Expected volatility (%)   48.73    48.78    48.88    48.82    49.68    49.90 
Risk-free interest rate (%)   1.66    2.52    3.03    3.98    3.98    4.30 
Expected life of options (year)   10.00    10.00    10.00    10.00    10.00    10.00 
v3.25.0.1
Notes to the Consolidated Statements of Cash Flows (Tables)
12 Months Ended
Dec. 31, 2023
Notes to the Consolidated Statements of Cash Flows [Abstract]  
Schedule of Changes in Liabilities Arising from Financing Activities Changes in liabilities arising from financing activities
   Financial   New bank             
   instrument   loans and       Payable     
   measured at   other   Lease   for issue     
   FVTPL   borrowings   liabilities   costs   Total 
   $’000   $’000   $’000   $’000   $’000 
At January 1, 2021   153,283    8,309    3,635    
    165,227 
Interest expense   
    422    160    
    582 
Transaction costs for the issuance of convertible redeemable preferred shares   
    
    
    758    758 
Additions   97,370    12,410    
    
    109,780 
Disposal   
    
    
    
    
 
Payment                         
 – financing cash flows   
    (10,430)   (966)   (758)   (12,154)
 – operating cash flows   
    
    
    
    
 
Interest paid   
    (427)   
    
    (427)
Change in fair value   46,910    
    
    
    46,910 
Exchange adjustment   
    184    59    
    243 
At December 31, 2021   297,563    10,468    2,888    
    310,919 
Interest expense   
    295    133    
    433 
Transaction costs for the issuance of convertible redeemable preferred shares   
    
    
    
    
 
Additions   
    7,897    463    
    8,360 
Disposal   
    
    
    
    
 
Payment                         
 – financing cash flows   
    (13,316)   (936)   
    (14,252)
 – operating cash flows   
    
    
    
    
 
Interest paid   
    (290)   (134)   
    (424)
Change in fair value   (7,195)   
    
    
    (7,195)
Exchange adjustment   
    (741)   (177)   
    (917)
At December 31, 2022   290,368    4,313    2,237    
    296,918 
Interest expense   
    708    83    
    791 
Transaction costs for the issuance of convertible redeemable preferred shares   
    
    
    
    
 
Additions   
    50,234    
    
    50,234 
Conversion into ordinary shares   (329,539)   
    
    
    (329,539)
Payment                         
 – financing cash flows   
    (24,069)   (1,020)   
    (25,089)
 – operating cash flows   
    
    
    
    
 
Interest paid   
    (602)   (83)   
    (685)
Change in fair value   39,171    
    
    
    39,171 
Exchange adjustment   
    (115)   (26)   
    (141)
At December 31, 2023   
    30,469    1,191    
    31,660 
Schedule of Investment Activities Investment activities
   Dual currency       Wealth     
   structured   investments at   management     
   deposit   amortized cost   product   Total 
   $’000   $’000   $’000   $’000 
Year ended December 31, 2021                
purchase   (17,000)   (17,965)   (46,269)   (81,234)
disposal   9,500    17,965    
    27,465 
interest received   28    4    
    32 
Year ended December 31, 2022                    
purchase   (14,900)   
    (44,080)   (58,980)
disposal   22,439    
    65,618    88,057 
interest received   19    
    531    550 
Year ended December 31, 2023                    
purchase   
    (31,849)   (7)   (31,856)
disposal   
    
    21,039    21,039 
interest received   
    
    62    62 
v3.25.0.1
Related Party Transactions (Tables)
12 Months Ended
Dec. 31, 2023
Related Party Transactions [Abstract]  
​Schedule of Related Parties
Name of related parties   Nature of relationship
Mr. Yang Lu   The chief executive officer and chairman of our board of directors and ultimate significant shareholder of the Company
v3.25.0.1
Financial Instruments by Category (Tables)
12 Months Ended
Dec. 31, 2023
Financial Instruments by Category [Abstract]  
Schedule of Categories of Financial Instruments

The carrying amounts of each of the categories of financial instruments of the Group as of the end of each of the Relevant Periods are as follows:

 

   As of December 31, 
   2022   2023 
   $’000   $’000 
Financial assets:        
Financial assets at FVTPL:        
Dual currency structured deposit   
    
 
Wealth management product   21,287    7 
Total   21,287    7 
Other financial assets:          
Financial assets included in prepayments, other receivables and other assets   2,585    2,978 
Cash and cash equivalents   42,758    91,492 
Short-term investments at amortized cost.   
    7,000 
Long-term investments at amortized cost   
    24,849 
Total   45,343    126,319 
Financial liabilities:          
Trade payables   13,098    14,348 
Financial liabilities included in other payables and accruals   3,877    4,890 
Interest-bearing bank and other borrowings   4,307    30,357 
Total   21,282    49,595 
Financial liabilities at FVTPL:          
Financial instruments measured at FVTPL   290,368    
 
Total   290,368    
 
v3.25.0.1
Fair Value and Fair Value Hierarchy of Financial Instruments (Tables)
12 Months Ended
Dec. 31, 2023
Fair Value and Fair Value Hierarchy of Financial Instruments [Abstract]  
Schedule of Carrying Amounts and Fair Values of the Group's Financial Instruments

The carrying amounts and fair values of the Group’s financial instruments, other than those with carrying amounts that reasonably approximate to fair values, are as follows:

 

   As of December 31, 2022   As of December 31, 2023 
   Carrying       Carrying     
   amount   Fair value   amount   Fair value 
   $’000   $’000   $’000   $’000 
Financial assets                
Dual currency structured deposit   
    
    
    
 
Wealth management product   21,287    21,287    7    7 
Total.   21,287    21,287    7    7 
Financial liabilities                    
Financial liabilities at FVTPL   290,368    290,368    
    
 
Total.   290,368    290,368    
    
 
Schedule of Fair Value Measurement Hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group’s financial instruments:

   Fair value measurement using 
   Quoted prices   Significant   Significant     
   in active   observable   unobservable     
   markets   inputs   inputs     
   (Level 1)   (Level 2)   (Level 3)   Total 
   $’000   $’000   $’000   $’000 
Financial assets                
Dual currency structured deposit   
    
    
    
 
Wealth management product   21,287    
    
    21,287 
Total.   21,287    
    
    21,287 
Financial liabilities             290,368    290,368 
Financial liabilities at FVTPL   
    
    290,368    290,368 
   Fair value measurement using 
   Quoted prices   Significant   Significant     
   in active   observable   unobservable     
   markets   inputs   inputs     
   (Level 1)   (Level 2)   (Level 3)   Total 
Financial assets                
Dual currency structured deposit   
    
    
    
 
Wealth management product   7    
    
    7 
Total   7    
    
    7 
v3.25.0.1
Financial Risk Management Objectives and Policies (Tables)
12 Months Ended
Dec. 31, 2023
Financial Risk Management Objectives and Policies [Abstract]  
Schedule of Exchange Rate

The following table demonstrates the sensitivity at the end of each of the Relevant Periods to a reasonably possible change in the $ and RMB exchange rate, with all other variables held constant, of the Group’s profit before tax (due to changes in the fair values of monetary assets and liabilities).

 

   Increase/   Increase/     
   (decrease) in   (decrease)   Increase/ 
   $/RMB   in net   (decrease) 
   rate%   loss   in equity 
       $’000   $’000 
At December 31, 2021            
If the $ strengthens against the RMB   5    
    2,398 
If the $ weakens against the RMB   (5)   
    (2,651)

 

   Increase/   Increase/     
   (decrease) in   (decrease)   Increase/ 
   $/RMB   in net   (decrease) 
   rate%   loss   in equity 
       $’000   $’000 
At December 31, 2022            
If the $ strengthens against the RMB   5    
    (1,939)
If the $ weakens against the RMB   (5)   
    4,081 

 

   Increase/   Increase/     
   (decrease) in   (decrease)   Increase/ 
   $/RMB   in net   (decrease) 
   rate%   loss   in equity 
       $’000   $’000 
As of December 31, 2023            
If the $ strengthens against the RMB   5    (1,010)   (943)
If the $ weakens against the RMB   (5)   1,116    1,042 
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments

The maturity profile of the Group’s financial liabilities as of the end of each Relevant Periods, based on the contractual undiscounted payments, is as follows:

 

   As of December 31, 2022 
       Less than             
   On demand   1 year   1 to 5 years   Over 5 years   Total 
   $’000   $’000   $’000   $’000   $’000 
Financial liabilities at FVTPL   
    290,368    
    
    290,368 
Trade and bills payables   13,098    
    
    
    13,098 
Financial liabilities included in other payables and accruals   3,877    
    
    
    3,877 
Interest-bearing bank borrowings   
    4,307    
    
    4,307 
Total   16,975    294,675    
    
    311,650 

 

   As of December 31, 2023 
       Less than             
   On demand   1 year   1 to 5 years   Over 5 years   Total 
   $’000   $’000   $’000   $’000   $’000 
Financial liabilities at FVTPL   
    
    
    
    
 
Trade and bills payables   14,348    
    
    
    14,348 
Financial liabilities included in other payables and accruals   4,890    
    
    
    4,890 
Interest-bearing bank borrowings   
    30,357    
    
    30,357 
Total   19,238    30,357    
    
    49,595 
Schedule of Asset Liability Ratios

The asset-liability ratios as of the end of each of the Relevant Periods are as follows:

 

   As of December 31, 
   2022   2023 
   $’000   $’000 
Total assets   72,594    130,189 
Total liabilities   313,887    50,786 
Asset-liability ratio (Note i)   0.23    2.56 

Note i:

 

The asset-liability ratio is calculated by dividing total assets by total liabilities.

v3.25.0.1
Condensed Financial Information of the Parent Company (Tables)
12 Months Ended
Dec. 31, 2023
Condensed Financial Information of the Parent Company [Abstract]  
Parent Company Balance Sheets

PARENT COMPANY BALANCE SHEETS

 

   December 31, 
   2022   2023 
   $’000   $’000 
ASSETS        
Current assets        
Cash and cash equivalents   12,194    63,150 
Prepayments, other receivables and other assets   36    44 
short-term investments at amortized cost   
    7,000 
Total current assets   12,230    70,194 
Non-current assets          
Due from related parties   115,743    123,102 
Investment in subsidiaries   94,300    129,711 
Total non-current assets   210,043    252,813 
Total assets   222,273    323,007 
LIABILITIES          
Current liabilities          
Accounts payable   888    976 
Other payables and accruals.   
    53 
Due to related parties   
    40 
Interest payables   
    10,650 
Non-current liabilities due within one year        
 
Financial liabilities at FVTPL   290,368    
 
Total current liabilities   291,260    11,719 
Non-current liabilities          
Long-term loans   
    
 
Financial liabilities at FVTPL   
    
 
Total non-current liabilities   
    
 
Total liabilities   291,260    11,719 
Ordinary shares (par value of $0.0001 per share; 442,456,586 shares authorized; 40,440,000 shares issued and outstanding as of December 31, 2022; and nil outstanding as of December 31, 2023)   4    
 
Class A Ordinary shares (par value of $0.0001 per share; nil outstanding as of December 31,2022; and 93,710,805 shares outstanding as of December 31, 2023)   
    9 
Class B Ordinary shares (par value of $0.0001 per share; nil outstanding as of December 31,2022; and 16,990,000 shares outstanding as of December 31, 2023)   
    2 
Series A convertible preferred shares (par value of US$0.0001 per share; 14,560,000 and nil shares authorized, issued and outstanding as of   10,980    
 
Additional paid-in capital   6,415    438,707 
Share option reserve   11,730    16,059 
Accumulated deficit   (98,116)   (143,489)
Total shareholders’ deficit   (68,987)   311,288 
Total liabilities and shareholders’ equity   222,273    323,007 
Parent Company Statements of Income and Comprehensive Income

PARENT COMPANY STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

 

   For the Years Ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
REVENUE   
    
    
 
Other operating income, net   
    156    242 
Administrative expenses   (2,376)   (1,390)   (6,196)
Research and development expenses   
    
    
 
Total operating loss   (2,376)   (1,234)   (5,954)
Other income and gains   173    
    
 
Other expenses   
    
    
 
Investment income   3    
    
 
Fair value loss on financial liabilities at FVTPL   (46,910)   7,194    (39,171)
Finance costs   (399)   
    (249)
LOSS BEFORE TAX   (49,509)   5,960    (45,374)
Income tax expense   
    
    
 
LOSS FOR THE YEAR   (49,509)   5,960    (45,374)
TOTAL COMPREHENSIVE (LOSS)/INCOME FOR THE YEAR   (49,509)   5,960    (45,374)
Parent Company Statements of Cash Flows

PARENT COMPANY STATEMENTS OF CASH FLOWS

 

   Year ended December 31, 
   2021   2022   2023 
   $’000   $’000   $’000 
Net cash flows used in operating activities   (1,610)   (1,134)   (13,143)
Net cash flows used in investing activities   (65,798)   (35,035)   (38,082)
Net cash flows from financing activities   96,428    
    102,181 
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS   29,020    (36,169)   50,956 
Cash and cash equivalents at beginning of year   19,343    48,363    12,194 
CASH AND CASH EQUIVALENTS AT END OF YEAR   48,363    12,194    63,150 
v3.25.0.1
Corporate and Group Information - Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies (Details)
12 Months Ended
Dec. 31, 2023
Alpine Bioscience Ltd. [Member]  
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies [Line Items]  
Date and place of incorporation / registration and place of operations British Virgin Islands 8 January 2018
Issued ordinary share/ registered capital One share of par value $1
Percentage of equity attributable to the Company Direct and Indirect 100.00%
Principal activities Investment holding
Adlai Nortye USA Inc. [Member]  
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies [Line Items]  
Date and place of incorporation / registration and place of operations The United States 30 January 2018
Issued ordinary share/ registered capital 10,000 shares of par value $0.0001 each
Percentage of equity attributable to the Company Direct and Indirect 100.00%
Principal activities Clinical studies and testing, and technology development and transfer
Adlai Nortye (Switzerland) AG (“Adlai Swiss”) [Member]  
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies [Line Items]  
Date and place of incorporation / registration and place of operations Switzerland 21 June 2022
Issued ordinary share/ registered capital 100 shares of par value CHF1’000 each
Percentage of equity attributable to the Company Direct and Indirect 100.00%
Principal activities Investment holding
Adlai Nortye PTE.LTD [Member]  
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies [Line Items]  
Date and place of incorporation / registration and place of operations Singapore 22 April 2022
Issued ordinary share/ registered capital Two shars of par value $1
Percentage of equity attributable to the Company Direct and Indirect 100.00%
Principal activities Investment holding
Adlai Nortye (HK) Limited (“Adlai HK”) [Member]  
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies [Line Items]  
Date and place of incorporation / registration and place of operations Hong Kong 24 April 2018
Issued ordinary share/ registered capital HKD 0.001
Percentage of equity attributable to the Company Direct and Indirect 100.00%
Principal activities Investment holding
Hangzhou Adlai Nortye Biopharma Co., Ltd [Member]  
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies [Line Items]  
Date and place of incorporation / registration and place of operations the People’s Republic of China (“PRC”)/Mainland China 14 September 2004 [1]
Issued ordinary share/ registered capital RMB 200,000 [1]
Percentage of equity attributable to the Company Direct and Indirect 100.00% [1]
Principal activities Product research and development, technology transfer and consulting services business [1]
Shanghai Adlai Nortye Biopharma Co., Ltd [Member]  
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies [Line Items]  
Date and place of incorporation / registration and place of operations the People’s Republic of China (“PRC”)/Mainland China 22 December 2021 [1]
Issued ordinary share/ registered capital RMB 10,000 [1]
Percentage of equity attributable to the Company Direct and Indirect 100.00% [1]
Principal activities Product research and development, technology transfer and consulting services business [1]
Hangzhou Tangchuang Weilai Technolegy Co., Ltd [Member]  
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies [Line Items]  
Date and place of incorporation / registration and place of operations the People’s Republic of China (“PRC”)/Mainland China 2 November 2022
Issued ordinary share/ registered capital RMB 10,000
Percentage of equity attributable to the Company Direct and Indirect 100.00%
Principal activities Product research and development, technology transfer and consulting services business
[1] The English name of the subsidiary registered in the PRC represents the best efforts made by management of the Company to translate its Chinese name as the subsidiary does not have an official English name.
v3.25.0.1
Basis of Presentation (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Basis of Presentation [Line Items]        
Cash and cash equivalents $ 91,492 $ 42,758 $ 64,131 $ 24,261
Short-term investments 7,000    
Net current assets 50,878      
Cash and Cash Equivalent [Member]        
Basis of Presentation [Line Items]        
Cash and cash equivalents $ 91,492      
Computer software [member]        
Basis of Presentation [Line Items]        
Useful life measured as period of time, intangible assets other than goodwill 5 years      
v3.25.0.1
Basis of Presentation - Schedule of New and Revised IFRSs (Details)
12 Months Ended
Dec. 31, 2023
Amendments to IAS 1 [Member]  
Schedule of New and Revised IFRSs [Line Items]  
Consolidated Financial Statements Classification of Liabilities as current and non-current
Effective for accounting year beginning on or after January 1, 2024
Amendments to IFRS 16 [Member]  
Schedule of New and Revised IFRSs [Line Items]  
Consolidated Financial Statements Lease Liability in a Sale and Leaseback
Effective for accounting year beginning on or after January 1, 2024
Amendments to IAS 1 [Member]  
Schedule of New and Revised IFRSs [Line Items]  
Consolidated Financial Statements Non-current Liabilities with Covenants
Effective for accounting year beginning on or after January 1, 2024
Amendments to IAS 28 and IFRS 10 [Member]  
Schedule of New and Revised IFRSs [Line Items]  
Consolidated Financial Statements Sale or contribution of assets between an investor and its associate or joint venture
Effective for accounting year beginning on or after To be determined
v3.25.0.1
Basis of Presentation - Schedule of Principal Annual Rates of Property Plant and Equipment (Details)
12 Months Ended
Dec. 31, 2023
Schedule of Principal Annual Rates of Property Plant and Equipment [Line Items]  
property, plant and equipment The shorter of remaining lease terms or estimated useful lives
Plant and machinery [member] | Top of range [member]  
Schedule of Principal Annual Rates of Property Plant and Equipment [Line Items]  
Depreciation rate, property, plant and equipment 10.00%
Plant and machinery [member] | Bottom of range [member]  
Schedule of Principal Annual Rates of Property Plant and Equipment [Line Items]  
Depreciation rate, property, plant and equipment 19.00%
Office equipment [Member] | Top of range [member]  
Schedule of Principal Annual Rates of Property Plant and Equipment [Line Items]  
Depreciation rate, property, plant and equipment 19.00%
Office equipment [Member] | Bottom of range [member]  
Schedule of Principal Annual Rates of Property Plant and Equipment [Line Items]  
Depreciation rate, property, plant and equipment 20.00%
Motor vehicles [Member]  
Schedule of Principal Annual Rates of Property Plant and Equipment [Line Items]  
Depreciation rate, property, plant and equipment 19.00%
Electronic Equipment [Member] | Top of range [member]  
Schedule of Principal Annual Rates of Property Plant and Equipment [Line Items]  
Depreciation rate, property, plant and equipment 19.00%
Electronic Equipment [Member] | Bottom of range [member]  
Schedule of Principal Annual Rates of Property Plant and Equipment [Line Items]  
Depreciation rate, property, plant and equipment 20.00%
v3.25.0.1
Basis of Presentation - Schedule of Estimated Useful Lives of The Right of Use Assets (Details)
12 Months Ended
Dec. 31, 2023
Top of range [member] | Offices [Member]  
Schedule of Estimated Useful Lives of The Right of Use Assets [Line Items]  
Estimated useful lives 2 years
Top of range [member] | Office equipment [member]  
Schedule of Estimated Useful Lives of The Right of Use Assets [Line Items]  
Estimated useful lives 2 years
Bottom of range [member] | Offices [Member]  
Schedule of Estimated Useful Lives of The Right of Use Assets [Line Items]  
Estimated useful lives 5 years
Bottom of range [member] | Office equipment [member]  
Schedule of Estimated Useful Lives of The Right of Use Assets [Line Items]  
Estimated useful lives 5 years
v3.25.0.1
Revenue (Details)
¥ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
CNY (¥)
Revenue [Line Items]        
Revenue $ 5,000 $ 45,726  
Further performance obligation 0      
Non-refundable upfront fees (in Yuan Renminbi) | ¥       ¥ 295,000
Milestone payments     45,726  
Revenue     45,726  
Sales of Exclusive Option [Member]        
Revenue [Line Items]        
Revenue 5,000  
Performance obligations satisfied at point in time [member] | Sales of Exclusive Option [Member]        
Revenue [Line Items]        
Revenue $ 5,000      
v3.25.0.1
Revenue - Schedule of Analysis of Revenue (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue [Line Items]      
Revenue $ 5,000 $ 45,726
Sales of intellectual property [Member]      
Revenue [Line Items]      
Revenue     45,726
Sales of an exclusive option [Member]      
Revenue [Line Items]      
Revenue $ 5,000
v3.25.0.1
Finance Costs - Schedule of Analysis of Finance Costs (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Schedule Of Analysis Of Finance Costs Abstract      
Transaction cost for issuance of the Group’s convertible redeemable preferred shares $ 758
Interest expenses on bank and other borrowings 708 295 421
Interest expenses on lease liabilities 83 138 158
Total $ 791 $ 433 $ 1,337
v3.25.0.1
Income Tax (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
United States [Member]    
Income Tax [Line Items]    
Federal tax rate 21.00%  
State income tax rate 9.00%  
Accumulated tax losses $ 54,168 $ 46,201
Percentage of taxable income annual limitation to offset against future taxable profits 80.00%  
China [Member]    
Income Tax [Line Items]    
Corporate income tax rate 25.00%  
Accumulated tax losses $ 102,647 $ 83,103
China [Member] | Bottom of Range [Member]    
Income Tax [Line Items]    
Extension of unused tax losses expiry term 5 years  
Unused tax losses expiry term 5 years  
China [Member] | Top of Range [Member]    
Income Tax [Line Items]    
Extension of unused tax losses expiry term 10 years  
Unused tax losses expiry term 10 years  
v3.25.0.1
Income Tax - Schedule of Income Tax Expense (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax [Abstract]      
Current $ 643
Deferred
Total $ 643
v3.25.0.1
Income Tax - Schedule of Reconciliation of the Tax Expense Applicable to Loss Before Tax at the Statutory Rate to the Tax Expense at the Effective Tax Rate (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Schedule of Reconciliation of the Tax Expense Applicable to Loss Before Tax at the Statutory Rate to the Tax Expense at the Effective Tax Rate [Abstract]      
Loss before tax $ (104,228) $ (58,790) $ (56,678)
Tax at the statutory tax rate (26,057) (14,698) (14,169)
Foreign rate differential 14,711 2,933 13,240
Expenses not deductible for tax 126 2,171 603
Income not subject to tax (4) (2,890)
Additional deductible allowance for qualified research and development costs (2,338) (1,681) (1,109)
Unrecognized deferred tax assets 14,201 11,279 4,325
Current income tax expense $ 643
Tax charge at the Group’s effective rate 0.62%
v3.25.0.1
Income Tax - Schedule of Reconciliation of the Tax Expense Applicable to Loss Before Tax at the Statutory Rate to the Tax Expense at the Effective Tax Rate (Parentheticals) (Details)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Schedule of Reconciliation of the Tax Expense Applicable to Loss Before Tax at the Statutory Rate to the Tax Expense at the Effective Tax Rate [Abstract]      
Statutory tax rate 25.00% 25.00% 25.00%
v3.25.0.1
Income Tax - Schedule of Deferred Tax Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Schedule of Deferred Tax Assets [Line Items]    
Subtotal $ 43,260 $ 28,923
Unrecognized deferred tax assets (43,260) (28,923)
Total Deferred tax
Fixed assets [Member]    
Schedule of Deferred Tax Assets [Line Items]    
Subtotal 2 (13)
Capitalized R&D [Member]    
Schedule of Deferred Tax Assets [Line Items]    
Subtotal 11,050 5,494
Accrued and prepaid expenses [Member]    
Schedule of Deferred Tax Assets [Line Items]    
Subtotal (101) 669
ROU Assets [Member]    
Schedule of Deferred Tax Assets [Line Items]    
Subtotal 5 (72)
Advertising expenses in excess of deduction limit [Member]    
Schedule of Deferred Tax Assets [Line Items]    
Subtotal 11 14
Allowance against receivables [Member]    
Schedule of Deferred Tax Assets [Line Items]    
Subtotal 3
State tax [Member]    
Schedule of Deferred Tax Assets [Line Items]    
Subtotal (1) (1)
Stock options [Member]    
Schedule of Deferred Tax Assets [Line Items]    
Subtotal 883 1,075
NOL [Member]    
Schedule of Deferred Tax Assets [Line Items]    
Subtotal $ 31,408 $ 21,758
v3.25.0.1
Dividends (Details)
Dec. 31, 2023
USD ($)
Dividends [Abstract]  
Dividends declared
v3.25.0.1
Loss Per Share Attributable To Ordinary Equity Holders of The Parent (Details) - shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Earnings per share [line items]      
Weighted average common shares outstanding, basic 43,342,068 25,440,000 25,440,000
Dilutive shares   64,300,522 62,967,406
Convertible Instruments [Member]      
Earnings per share [line items]      
Dilutive shares   57,543,414 57,543,414
Share Options [Member]      
Earnings per share [line items]      
Dilutive shares 3,869,554 6,757,108 5,423,992
v3.25.0.1
Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) [Line Items]    
Balance $ 3,713 $ 3,655
Additions 200 1,249
Depreciation provided during the year (1,213) (931)
Disposals (1) (10)
Exchange realignment (53) (250)
Balance 2,646 3,713
Cost 6,590 6,543
Accumulated depreciation (3,944) (2,830)
Net carrying amount 2,646 3,713
Leasehold improvements [Member]    
Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) [Line Items]    
Balance 1,774 1,601
Additions 28 710
Depreciation provided during the year (700) (416)
Disposals
Exchange realignment (25) (121)
Balance 1,077 1,774
Cost 2,519 2,532
Accumulated depreciation (1,442) (758)
Net carrying amount 1,077 1,774
Plant and machinery [Member]    
Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) [Line Items]    
Balance 1,673 1,842
Additions 27 360
Depreciation provided during the year (416) (412)
Disposals
Exchange realignment (23) (117)
Balance 1,261 1,673
Cost 3,373 3,386
Accumulated depreciation (2,112) (1,713)
Net carrying amount 1,261 1,673
Office equipment [Member]    
Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) [Line Items]    
Balance 33 68
Additions
Depreciation provided during the year (20) (31)
Disposals
Exchange realignment (4)
Balance 13 33
Cost 148 150
Accumulated depreciation (135) (117)
Net carrying amount 13 33
Motor vehicles [Member]    
Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) [Line Items]    
Balance 151 12
Additions 127 168
Depreciation provided during the year (43) (19)
Disposals (10)
Exchange realignment (3)
Balance 232 151
Cost 322 199
Accumulated depreciation (90) (48)
Net carrying amount 232 151
Electronic equipment [Member]    
Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) [Line Items]    
Balance 82 132
Additions 18 11
Depreciation provided during the year (34) (53)
Disposals (1)
Exchange realignment (2) (8)
Balance 63 82
Cost 228 276
Accumulated depreciation (165) (194)
Net carrying amount $ 63 $ 82
v3.25.0.1
Leases (Details)
12 Months Ended
Dec. 31, 2023
Bottom of Range [Member]  
Leases [Line Items]  
IFRS Lessee, Operating Lease, Term of Contract 2 years
Top of Range [Member]  
Leases [Line Items]  
IFRS Lessee, Operating Lease, Term of Contract 5 years
v3.25.0.1
Leases - Schedule of Carrying Amounts of the Group's Right-of-Use Assets and the Movements (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Leases [Line Items]      
As of Beginning Balance $ 2,162 $ 2,934  
Additions 463  
Depreciation provided during the year (984) (1,090) $ (951)
Exchange realignment (24) (145)  
As of Ending Balance 1,154 2,162 2,934
Offices [Member]      
Leases [Line Items]      
As of Beginning Balance 2,086 2,725  
Additions 463  
Depreciation provided during the year (931) (961)  
Exchange realignment (23) (141)  
As of Ending Balance 1,132 2,086 2,725
Office equipment [Member]      
Leases [Line Items]      
As of Beginning Balance 76 209  
Additions  
Depreciation provided during the year (53) (129)  
Exchange realignment (1) (4)  
As of Ending Balance $ 22 $ 76 $ 209
v3.25.0.1
Leases - Schedule of Carrying Amount of Lease Liabilities and the Movements (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
$’000      
As of beginning $ (2,237) $ (2,888)  
Additions (463)  
Accretion of interest recognized during the year (83) (133) $ (158)
Payments 1,103 1,070 966
Exchange realignment 26 177  
As of ending $ (1,191) $ (2,237) $ (2,888)
v3.25.0.1
Leases - Schedule of Carrying Amount of Lease Liabilities and the Movements (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Analyzed into:      
Current portion $ 722 $ 1,001  
Non-current portion 469 1,236  
Total $ 1,191 $ 2,237 $ 2,888
v3.25.0.1
Leases - Schedule of Amounts Recognized in Profit or Loss in Relation to Leases (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Leases [Abstract]      
Interest on lease liabilities $ 83 $ 133 $ 158
Depreciation charge of right-of-use assets 984 1,090 951
Total amount recognized in profit or loss $ 1,067 $ 1,223 $ 1,109
v3.25.0.1
Prepayments, Other Receivables and Other Assets - Schedule of Prepayments, Other Receivables and Other Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Schedule Of Prepayments Other Receivables And Other Assets Abstract    
Prepayments $ 2,337 $ 1,912
VAT deductible tax 135 100
Deposits and other receivables 224 246
Total 2,696 2,258
Deposits and other receivables
Prepaid expenses 282 327
Total 282 327
Total $ 2,978 $ 2,585
v3.25.0.1
Financial Assets at FVTPL (Details)
12 Months Ended
Dec. 31, 2022
Wealth Management Product [Member]  
Financial Assets At FVTPL [Line Items]  
Financial instruments redeemable term 3 months
v3.25.0.1
Financial Assets at FVTPL - Schedule of Financial Assets at FVTPL (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Financial Assets at FVTPL - Schedule of Financial Assets at FVTPL (Details) [Line Items]    
Total $ 7 $ 21,287
Wealth management product [Member]    
Financial Assets at FVTPL - Schedule of Financial Assets at FVTPL (Details) [Line Items]    
Total $ 7 $ 21,287
v3.25.0.1
Investment at Amortized Cost (Details)
12 Months Ended
Dec. 31, 2023
Minimum [Member]  
Investment at Amortized Cost [Line Items]  
Short-term investment at amortized cost, original maturities 3 months
Long-term investment at amortized cost, original maturities 1 year
Maximum [Member]  
Investment at Amortized Cost [Line Items]  
Short-term investment at amortized cost, original maturities 1 year
v3.25.0.1
Investment at Amortized Cost - Schedule of Investment at Amortized Cost (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Schedule of Investment at Amortized Cost [Abstract]    
Short-term investments at amortized cost $ 7,000
Long-term investments at amortized cost 24,849
Total $ 31,849
v3.25.0.1
Other Payables and Accruals - Schedule of Other Payables and Accruals (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Schedule Of Other Payables And Accruals Abstract    
Other payables and accruals [1] $ 303 $ 255
Tax payable 773
Payroll and bonus payables 3,814 3,622
Total $ 4,890 $ 3,877
[1] Other payables and accruals are unsecured, non-interest-bearing and repayable on demand. The fair values of other payables and accruals at the end of each of the Relevant Periods approximated to their corresponding carrying amounts.
v3.25.0.1
Interest-Bearing Bank Borrowings (Details)
¥ in Thousands, $ in Thousands
Dec. 31, 2023
USD ($)
Dec. 31, 2023
CNY (¥)
Nov. 30, 2023
USD ($)
Oct. 31, 2023
CNY (¥)
Sep. 30, 2023
CNY (¥)
Mar. 31, 2023
CNY (¥)
Dec. 31, 2022
USD ($)
Oct. 31, 2022
CNY (¥)
Mar. 31, 2022
CNY (¥)
Interest-Bearing Bank Borrowings (Details) [Line Items]                  
Facility amount | $ $ 30,357           $ 4,307    
Undrawn borrowing facilities (in Dollars) | $              
Hangzhou Adlai Nortye Biopharma Co., Ltd [Member] | Non-Revolving Facility Agreement, 5.22% Interest, Due March 22,2023, Guaranteed [Member]                  
Interest-Bearing Bank Borrowings (Details) [Line Items]                  
Facility amount | ¥                 ¥ 10,000
Interest rate                 5.22%
Hangzhou Adlai Nortye Biopharma Co., Ltd [Member] | Non-Revolving Facility Agreement, 4.8% Interest, Maturity Due April 24,2023, Guaranteed [Member]                  
Interest-Bearing Bank Borrowings (Details) [Line Items]                  
Facility amount | ¥       ¥ 30,000       ¥ 20,000  
Interest rate       4.00%       4.80%  
Hangzhou Adlai Nortye Biopharma Co., Ltd [Member] | Non Revolving Facility Agreement, 4.2 Interest Maturity Due March 26, 2024 Guaranteed [Member]                  
Interest-Bearing Bank Borrowings (Details) [Line Items]                  
Facility amount | ¥   ¥ 20,000       ¥ 20,000      
Interest rate 4.00% 4.00%       4.20%      
Hangzhou Adlai Nortye Biopharma Co., Ltd [Member] | Non Revolving Facility Agreement, 4.0 Interest Maturity Due September 17, 2024 Guaranteed [Member]                  
Interest-Bearing Bank Borrowings (Details) [Line Items]                  
Facility amount | ¥         ¥ 10,000        
Interest rate         4.00%        
Hangzhou Adlai Nortye Biopharma Co., Ltd [Member] | Non Revolving Facility Agreement, 4.0 Interest Maturity Due September 18, 2024 Guaranteed [Member]                  
Interest-Bearing Bank Borrowings (Details) [Line Items]                  
Facility amount | ¥         ¥ 10,000        
Interest rate         4.00%        
Hangzhou Adlai Nortye Biopharma Co., Ltd [Member] | Non Revolving Facility Agreement, 6.78 Interest Maturity Due November 27, 2024 Guaranteed [Member]                  
Interest-Bearing Bank Borrowings (Details) [Line Items]                  
Facility amount | $     $ 3,000            
Interest rate     6.78%            
Hangzhou Adlai Nortye Biopharma Co., Ltd [Member] | Non Revolving Facility Agreement, 6.3 Interest Maturity Due December 26, 2024 Guaranteed [Member]                  
Interest-Bearing Bank Borrowings (Details) [Line Items]                  
Facility amount | $ $ 4,000                
Interest rate 6.30% 6.30%              
Hangzhou Adlai Nortye Biopharma Co., Ltd [Member] | Non Revolving Facility Agreement, 6.0 Interest Maturity Due November 14, 2024 Guaranteed [Member]                  
Interest-Bearing Bank Borrowings (Details) [Line Items]                  
Facility amount | $ $ 10,650                
Interest rate 6.00% 6.00%              
v3.25.0.1
Interest-Bearing Bank Borrowings - Schedule of Interest-Bearing Bank Borrowings (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest-bearing bank borrowings $ 30,357 $ 4,307
Non-Revolving Facility, 5.22% interest, due March 22,2023, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest-bearing bank borrowings [1] 1,436
Non-Revolving Facility, 4.8% interest, due April 24,2023, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest-bearing bank borrowings [2] 2,871
Non Revolving Facility, 4.2% interest, due March 26, 2024, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest-bearing bank borrowings [3] 2,824
Non Revolving Facility, 4.0% interest, due September 17, 2024, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest-bearing bank borrowings [4] 1,412
Non Revolving Facility, 4.0% interest, due September 18, 2024, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest-bearing bank borrowings [4] 1,412
Non Revolving Facility, 4.0% interest, due April 15, 2024, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest-bearing bank borrowings [2] 4,235
Non Revolving Facility, 6.78% interest, due November 27, 2024, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest-bearing bank borrowings [5] 3,000
Non Revolving Facility, 6.0% interest, due November 14, 2024, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest-bearing bank borrowings [6] 10,650
Non Revolving Facility, 6.3% interest, due December 26, 2024, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest-bearing bank borrowings [5] 4,000
Non Revolving Facility, 4.0% interest, due December 25, 2024, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest-bearing bank borrowings [7] $ 2,824
[1] In March 2022, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 5.22% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. The non-revolving facility agreement was repaid at the maturity date of March 22, 2023.
[2] In October 2022, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 20,000 and at an interest rate of 4.80% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. The non-revolving facility agreement was repaid at the maturity date of April 24, 2023. In October 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 30,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors.
[3] In March 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 20,000 and at an interest rate of 4.20% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. The non-revolving facility agreement was repaid at the maturity date of March 26, 2024. And in March 2024, Adlai Hangzhou repaid it at the maturity date.
[4] In September 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. And in March 2024, Adlai Hangzhou repaid it before the maturity date. In September 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. And in March 2024, Adlai Hangzhou repaid it before the maturity date.
[5] In November 2023, Adlai US entered into a non-revolving facility agreement for a facility amount of USD 3,000 and at an interest rate of 6.78% per annum, guaranteed by the company. In December 2023, Adlai US entered into a non-revolving facility agreement for a facility amount of USD 4,000 and at an interest rate of 6.30% per annum, guaranteed by the company.
[6] In December 2023, the company entered into a non-revolving facility agreement for a facility amount of USD 10,650 and at an interest rate of 6.00% per annum, guaranteed by Adlai Hangzhou.
[7] In December 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 20,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors.
v3.25.0.1
Interest-Bearing Bank Borrowings - Schedule of Interest-Bearing Bank Borrowings (Parentheticals) (Details)
Dec. 31, 2023
Dec. 31, 2022
Non-Revolving Facility, 5.22% interest, due March 22,2023, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest rate (as a percent) [1] 5.22% 5.22%
Non-Revolving Facility, 4.8% interest, due April 24,2023, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest rate (as a percent) [2] 4.80% 4.80%
Non Revolving Facility, 4.2% interest, due March 26, 2024, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest rate (as a percent) [3] 4.20% 4.20%
Non Revolving Facility, 4.0% interest, due September 17, 2024, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest rate (as a percent) [4] 4.00% 4.00%
Non Revolving Facility, 4.0% interest, due September 18, 2024, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest rate (as a percent) [4] 4.00% 4.00%
Non Revolving Facility, 4.0% interest, due April 15, 2024, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest rate (as a percent) [2] 4.00% 4.00%
Non Revolving Facility, 6.78% interest, due November 27, 2024, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest rate (as a percent) [5] 6.78% 6.78%
Non Revolving Facility, 6.0% interest, due November 14, 2024, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest rate (as a percent) [6] 6.00% 6.00%
Non Revolving Facility, 6.3% interest, due December 26, 2024, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest rate (as a percent) [5] 6.30% 6.30%
Non Revolving Facility, 4.0% interest, due December 25, 2024, guaranteed [Member]    
Schedule of Interest-Bearing Bank Borrowings [Line Items]    
Interest rate (as a percent) [7] 4.00% 4.00%
[1] In March 2022, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 5.22% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. The non-revolving facility agreement was repaid at the maturity date of March 22, 2023.
[2] In October 2022, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 20,000 and at an interest rate of 4.80% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. The non-revolving facility agreement was repaid at the maturity date of April 24, 2023. In October 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 30,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors.
[3] In March 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 20,000 and at an interest rate of 4.20% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. The non-revolving facility agreement was repaid at the maturity date of March 26, 2024. And in March 2024, Adlai Hangzhou repaid it at the maturity date.
[4] In September 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. And in March 2024, Adlai Hangzhou repaid it before the maturity date. In September 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 10,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors. And in March 2024, Adlai Hangzhou repaid it before the maturity date.
[5] In November 2023, Adlai US entered into a non-revolving facility agreement for a facility amount of USD 3,000 and at an interest rate of 6.78% per annum, guaranteed by the company. In December 2023, Adlai US entered into a non-revolving facility agreement for a facility amount of USD 4,000 and at an interest rate of 6.30% per annum, guaranteed by the company.
[6] In December 2023, the company entered into a non-revolving facility agreement for a facility amount of USD 10,650 and at an interest rate of 6.00% per annum, guaranteed by Adlai Hangzhou.
[7] In December 2023, Adlai Hangzhou entered into a non-revolving facility agreement for a facility amount of RMB 20,000 and at an interest rate of 4.00% per annum, guaranteed by Mr. Yang Lu, the chief executive officer and chairman of our board of directors.
v3.25.0.1
Interest-Bearing Bank Borrowings - Schedule of Interest-Bearing Bank Borrowings (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Interest-Bearing Bank Borrowings - Schedule of Interest-Bearing Bank Borrowings (Details) [Line Items]      
Beginning Balance $ 4,307 $ 10,457  
Additions 50,234 7,897 $ 12,411
Repayments (24,069) (13,316)  
Effect of foreign exchange rate changes (115) (731)  
Ending Balance 30,357 4,307 10,457
Short-term borrowings [member]      
Interest-Bearing Bank Borrowings - Schedule of Interest-Bearing Bank Borrowings (Details) [Line Items]      
Beginning Balance 4,307 10,457  
Additions 50,234 7,897  
Repayments (24,069) (13,316)  
Effect of foreign exchange rate changes (115) (731)  
Ending Balance $ 30,357 $ 4,307 $ 10,457
v3.25.0.1
Financial Liabilities At Fvtpl (Details)
$ / shares in Units, ¥ in Thousands, $ in Thousands
1 Months Ended 12 Months Ended
Jul. 31, 2021
shares
May 31, 2020
shares
Jun. 30, 2018
$ / shares
shares
Dec. 31, 2023
USD ($)
Integer
$ / shares
shares
Dec. 31, 2015
CNY (¥)
Dec. 31, 2022
$ / shares
Jun. 30, 2018
CNY (¥)
Financial Liabilities at Fvtpl [Line Items]              
Increased amount | $       $ 91,780      
Preferred shares, par value | $ / shares       $ 0.0001   $ 0.0001  
Minimum period for qualified IPO       2 years      
Controlling interest, percentage       50.00%      
Threshold period to make remedy after the occurrence of material breach       30 days      
Adlai Hangzhou [Member] | Series A Investors [Member]              
Financial Liabilities at Fvtpl [Line Items]              
Increased amount | ¥         ¥ 70,000    
Adlai Hangzhou [Member] | Series B Convertible Loans [Member] | Series B Onshore Investors [Member]              
Financial Liabilities at Fvtpl [Line Items]              
Total consideration amount | ¥             ¥ 165,000
Hangzhou Adlai Nortye Biopharma Co., Ltd [Member] | Series B Convertible Loans [Member] | Series B Onshore Investors [Member]              
Financial Liabilities at Fvtpl [Line Items]              
Interest rate             15.00%
Series A Convertible Preferred Shares [Member]              
Financial Liabilities at Fvtpl [Line Items]              
Preferred shares, par value | $ / shares       $ 0.0001   $ 0.0001  
Series A Convertible Preferred Shares [Member] | Adlai Hangzhou [Member]              
Financial Liabilities at Fvtpl [Line Items]              
Converted equity interests     14,560,000        
Series A Convertible Preferred Shares [Member] | Hangzhou Adlai Nortye Biopharma Co., Ltd [Member]              
Financial Liabilities at Fvtpl [Line Items]              
Preferred shares, par value | $ / shares     $ 0.0001        
Series B Convertible Redeemable Preferred Shares [Member] | Series B Offshore Investors [Member]              
Financial Liabilities at Fvtpl [Line Items]              
Total consideration amount | $       $ 27,000      
Shares subscribed       6,907,896      
Series B Convertible Redeemable Preferred Shares [Member] | Series C Investors [Member]              
Financial Liabilities at Fvtpl [Line Items]              
Increased amount | $       $ 63,700      
Shares subscribed       14,653,013      
Series B Convertible Redeemable Preferred Shares [Member] | Series D Investors [Member]              
Financial Liabilities at Fvtpl [Line Items]              
Increased amount | $       $ 97,370      
Shares subscribed       14,722,505      
Series B Convertible Redeemable Preferred Shares [Member] | China Equities HK Limited [Member]              
Financial Liabilities at Fvtpl [Line Items]              
Number of Shares issued 100,000            
Series B Convertible Redeemable Preferred Shares [Member] | Hangzhou Adlai Nortye Biopharma Co., Ltd [Member] | Series B Onshore Investors [Member]              
Financial Liabilities at Fvtpl [Line Items]              
Preferred shares, par value | $ / shares     $ 0.0001        
Series B Convertible Redeemable Preferred Shares [Member] | Hangzhou Adlai Nortye Biopharma Co., Ltd [Member] | Series B Convertible Loans [Member] | Series B Onshore Investors [Member]              
Financial Liabilities at Fvtpl [Line Items]              
Convertible Loans issued     6,600,000        
Convertible aggregate loan   6,600,000          
Series C and Series D Convertible Redeemable Preferred Shares [Member]              
Financial Liabilities at Fvtpl [Line Items]              
Return on investment       100.00%      
Interest rate on investment per annum       10.00%      
Next Equity Financing Warrant [Member] | Series B Investors [Member]              
Financial Liabilities at Fvtpl [Line Items]              
Preferred shares, par value | $ / shares     $ 0.0001        
Exercise price per share, percentage     95.00%        
If Group Fails to Meet Committed Business Objectives [Member]              
Financial Liabilities at Fvtpl [Line Items]              
Preferred shares percentage       70.00%      
Minimum number of products to be promoted | Integer       3      
Threshold period to promote the products to next clinical stage from closing date       18 months      
Minimum period for qualified IPO       2 years      
Pre-public offering market capitalization | $       $ 650,000      
Vote for ordinary share       1      
v3.25.0.1
Financial Liabilities At Fvtpl - Schedule of Movements of The Group’s Financial Liabilities at FVTPL (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Schedule of Movements of the Group’s Financial Liabilities at FVTPL [Line Items]      
Beginning, Balance $ 290,368 $ 297,563  
Change in fair value 39,171 (7,195) $ 46,910
Conversion into ordinary shares upon IPO (329,539)    
Ending, Balance 290,368 297,563
Series B Convertible Redeemable Preferred Shares [Member]      
Schedule of Movements of the Group’s Financial Liabilities at FVTPL [Line Items]      
Beginning, Balance 90,384 92,187  
Change in fair value 13,943 (1,803)  
Conversion into ordinary shares upon IPO (104,327)    
Ending, Balance 90,384 92,187
Series C Convertible Redeemable Preferred Shares [Member]      
Schedule of Movements of the Group’s Financial Liabilities at FVTPL [Line Items]      
Beginning, Balance 97,132 97,726  
Change in fair value 15,207 (594)  
Conversion into ordinary shares upon IPO (112,339)    
Ending, Balance 97,132 97,726
Series D Convertible Redeemable Preferred Shares [Member]      
Schedule of Movements of the Group’s Financial Liabilities at FVTPL [Line Items]      
Beginning, Balance 102,852 107,650  
Change in fair value 10,021 (4,798)  
Conversion into ordinary shares upon IPO (112,873)    
Ending, Balance $ 102,852 $ 107,650
v3.25.0.1
Financial Liabilities At Fvtpl - Schedule of Significant Unobservable Inputs to the Valuation of Financial Instruments (Details)
Dec. 31, 2022
Fair value of ordinary shares of the Company [Member]  
Schedule of Significant Unobservable Inputs to the Valuation of Financial Instruments [Line Items]  
Fair value of ordinary shares of the Company 6.15
Risk-free interest rate [Member]  
Schedule of Significant Unobservable Inputs to the Valuation of Financial Instruments [Line Items]  
Risk-free interest rate 4.68%
Expected term [Member]  
Schedule of Significant Unobservable Inputs to the Valuation of Financial Instruments [Line Items]  
Expected term 5 months 8 days
Volatility [Member]  
Schedule of Significant Unobservable Inputs to the Valuation of Financial Instruments [Line Items]  
Volatility 52.86%
v3.25.0.1
Ordinary Shares (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2023
Dec. 31, 2022
Ordinary Shares (Details) [Line Items]      
Amount of Authorized Share Capital (in Dollars)   $ 50  
Shares authorised   442,456,586 442,456,586
Par value per share (in Dollars per share)   $ 0.0001 $ 0.0001
Nortye Talent Limited [Member]      
Ordinary Shares (Details) [Line Items]      
Increase (decrease) in number of shares outstanding 9,000,000    
Nortye International Limited [Member]      
Ordinary Shares (Details) [Line Items]      
Increase (decrease) in number of shares outstanding 6,000,000    
Ordinary Shares [Member]      
Ordinary Shares (Details) [Line Items]      
Shares authorised   442,456,586  
Authorized share capital [Member]      
Ordinary Shares (Details) [Line Items]      
Shares authorised   500,000,000  
v3.25.0.1
Ordinary Shares - Schedule of Ordinary Shares (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
shares
Schedule of Ordinary Shares [Line Items]  
Number of shares, as of 1 January 2023 | shares 40,440,000
Issuance of ordinary shares | $ $ 91,780
Conversion of Financial liabilities at FVTPL | $ $ 329,539
Number of shares, as at 31 December 2023 | shares
Ordinary shares [member]  
Schedule of Ordinary Shares [Line Items]  
Ordinary shares, as of 1 January 2023 | $ $ 3
Issuance of ordinary shares | $ 1
Conversion of Series A convertible preferred shares | $ 1
Conversion of Financial liabilities at FVTPL | $ 5
Ordinary shares, as at 31 December 2023 | $ $ 10
Issued capital [member]  
Schedule of Ordinary Shares [Line Items]  
Number of shares, as of 1 January 2023 | shares 25,440,000
Issuance of ordinary shares | shares 12,717,391
Conversion of Series A convertible preferred shares | shares 14,560,000
Conversion of Financial liabilities at FVTPL | shares 42,983,414
Number of shares, as at 31 December 2023 | shares 95,700,805
v3.25.0.1
Share Incentive Plan (Details)
1 Months Ended 12 Months Ended
Dec. 06, 2023
Apr. 21, 2023
Oct. 01, 2022
Jul. 01, 2022
Apr. 01, 2022
Jan. 01, 2022
Oct. 01, 2021
Jul. 05, 2021
shares
May 31, 2021
Nov. 01, 2020
Sep. 08, 2020
Jun. 15, 2017
$ / shares
Jun. 15, 2017
¥ / shares
Apr. 30, 2023
$ / shares
shares
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Dec. 30, 2021
May 28, 2021
shares
Share Incentive Plan (Details) [Line Items]                                      
Aggregate number of ordinary shares (in Shares)                                     15,000,000
Nortye International Limited [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Ordinary share issued (in Shares)                                 6,000,000    
Nortye Talent Limited [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Ordinary share issued (in Shares)                                 9,000,000    
Share Incentive Scheme [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Contractual term                       5 5            
Share-based payment expenses (in Dollars) | $                             $ 81,000    
Share Incentive Plan [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Contractual term 10 10 10 10 10 10                          
Share-based payment expenses (in Dollars) | $                             $ 4,330,000 $ 6,082,000      
Aggregate number of ordinary shares (in Shares)                             15,000,000 15,000,000     11,000,000
Fair market percentage                                     100.00%
Ordinary shares (in Shares)               15,000,000                      
Option granted                             499,114 1,957,208      
Option plan (in Shares)                             5,040,900 5,489,898      
Fair value (in Dollars) | $                             $ 2,231,000 $ 6,913,000      
Outstanding award                             9,959,100 9,510,102   7,635,444  
Issued captial (in Shares)                             9,959,100 9,510,102      
Additional share capital (in Dollars) | $                             $ 1,000 $ 1,000      
Share Incentive Plan [Member] | Nortye International Limited [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Ordinary share issued (in Shares)               6,000,000                      
Share Incentive Plan [Member] | Nortye Talent Limited [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Ordinary share issued (in Shares)               9,000,000                      
Share Incentive Plan [Member] | Top of range [member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Aggregate number of ordinary shares (in Shares)                                     4,000,000
Share Incentive Plan 2023 [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Aggregate number of ordinary shares (in Shares)                           15,000,000          
Management and Employees [Member] | Share Incentive Scheme [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Exercise price per share | ¥ / shares                         ¥ 7            
Vesting period                       4 years 4 years            
Management and Employees [Member] | Share Incentive Scheme [Member] | Top of range [member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Granted shares                       1,220,000 1,220,000            
Management [Member] | Share Incentive Scheme [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Price per share (in Dollars per share) | $ / shares                       $ 0.083              
Employees [Member] | Share Incentive Scheme [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Price per share (in Dollars per share) | $ / shares                       $ 0.0765              
Employees [Member] | Share Incentive Plan 2020 [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Exercise price per share | $ / shares                           $ 2.2          
Option granted                           352,500          
Executives, Employees and Consultants [Member] | Share Incentive Plan [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Granted shares             412,000   3,348,483 2,560,730 1,435,000                
Certain New Employees [Member] | Share Incentive Plan [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Option granted 121,200         83,500                          
Certain Employees and Managers [Member] | Share Incentive Plan [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Option granted 25,414         376,172                          
Certain New Employees, Promoted Employees and Senior Managers [Member] | Share Incentive Plan [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Option granted         1,077,800                            
Three Consultants [Member] | Share Incentive Plan [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Option granted         33,336                            
Five New Employees [Member] | Share Incentive Plan [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Option granted     179,200 207,200                              
Ifrs Share-Based Payment Arrangement, Tranche One [Member] | Share Incentive Scheme [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Vesting percentage                       25.00% 25.00%            
Ifrs Share-Based Payment Arrangement, Tranche Two [Member] | Share Incentive Scheme [Member]                                      
Share Incentive Plan (Details) [Line Items]                                      
Vesting percentage                       75.00% 75.00%            
v3.25.0.1
Share Incentive Plan - Schedule of Compensation Expense over the Vesting Period for each Separately Vesting Portion of the Awards (Details) - Share Incentive Plan [Member]
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2021
USD ($)
$ / shares
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
$ / shares
Share Incentive Plan - Schedule of Compensation Expense over the Vesting Period for each Separately Vesting Portion of the Awards (Details) [Line Items]      
Number of awards, outstanding 7,635,444 9,510,102  
Weighted Average Exercise Price, outstanding $ 1.72 $ 1.82  
Weighted Average Granted Fair Value, outstanding $ 1.36 $ 1.79  
Weighted Average Remaining Contractual Life, outstanding 9 years 1 month 9 days 7 years 5 months 8 days 8 years 4 months 2 days
Aggregate Intrinsic Value, outstanding (in Dollars) | $ $ 26,950 $ 41,218  
Number of awards, Options granted   499,114 1,957,208
Weighted Average Exercise Price, Options granted   $ 2.2 $ 2.2
Weighted Average Granted Fair Value, Options granted   $ 4.47 $ 3.56
Weighted Average Remaining Contractual Life, Options granted   9 years 5 months 26 days 9 years 3 months 3 days
Number of awards, Vested but not exercisable   5,400,955 4,980,069
Weighted Average Exercise Price, Vested but not exercisable   $ 1.75 $ 1.59
Weighted Average Granted Fair Value, Vested but not exercisable   $ 1.69 $ 1.15
Weighted Average Remaining Contractual Life, Vested but not exercisable   7 years 3 months 10 days 8 years
Number of awards, Options forfeited/cancelled   (50,116) (82,550)
Weighted Average Exercise Price, Options forfeited/cancelled   $ 2.3 $ 2.11
Weighted Average Granted Fair Value, Options forfeited/cancelled   $ 5.36 $ 2.68
Weighted Average Remaining Contractual Life, Options forfeited/cancelled   9 years 6 months 3 days 8 years 9 months 14 days
Number of awards, Options exercised  
Weighted Average Exercise Price, Options exercised  
Weighted Average Granted Fair Value, Options exercised  
Number of awards, outstanding   9,959,100 9,510,102
Weighted Average Exercise Price, outstanding   $ 1.83 $ 1.82
Weighted Average Granted Fair Value, outstanding   $ 1.91 $ 1.79
Aggregate Intrinsic Value, outstanding (in Dollars) | $   $ 11,596 $ 41,218
v3.25.0.1
Share Incentive Plan - Schedule of Inputs to the Model Used (Details) - Share Incentive Plan [Member]
Dec. 06, 2023
Apr. 21, 2023
Oct. 01, 2022
Jul. 01, 2022
Apr. 01, 2022
Jan. 01, 2022
Share Incentive Plan - Schedule of Inputs to the Model Used (Details) [Line Items]            
Dividend yield (%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Expected volatility (%) 49.90% 49.68% 48.82% 48.88% 48.78% 48.73%
Risk-free interest rate (%) 4.30% 3.98% 3.98% 3.03% 2.52% 1.66%
Expected life of options (year) 10 10 10 10 10 10
v3.25.0.1
Notes to the Consolidated Statements of Cash Flows (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Notes to the Consolidated Statements of Cash Flows [Abstract]      
Non-cash additions to right-of-use assets
Non-cash additions to lease liabilities
v3.25.0.1
Notes to the Consolidated Statements of Cash Flows - Schedule of Changes in Liabilities Arising from Financing Activities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Schedule of Changes in Liabilities Arising from Financing Activities [Line Items]      
Balance at beginning $ 296,918 $ 310,919 $ 165,227
Interest expense 791 433 582
Conversion into ordinary shares (329,539)    
Transaction costs for the issuance of convertible redeemable preferred shares 758
Additions 50,234 8,360 109,780
Disposal  
Payment- financing cash flows (25,089) (14,252) (12,154)
Payment– operating cash flows
Interest paid (685) (424) (427)
Change in fair value 39,171 (7,195) 46,910
Exchange adjustment (141) (917) 243
Balance at end 31,660 296,918 310,919
Financial instrument measured at FVTPL [Member]      
Schedule of Changes in Liabilities Arising from Financing Activities [Line Items]      
Balance at beginning 290,368 297,563 153,283
Interest expense
Conversion into ordinary shares (329,539)    
Transaction costs for the issuance of convertible redeemable preferred shares
Additions 97,370
Disposal  
Payment- financing cash flows
Payment– operating cash flows
Interest paid
Change in fair value 39,171 (7,195) 46,910
Exchange adjustment
Balance at end 290,368 297,563
New bank loans and other borrowings [Member]      
Schedule of Changes in Liabilities Arising from Financing Activities [Line Items]      
Balance at beginning 4,313 10,468 8,309
Interest expense 708 295 422
Conversion into ordinary shares    
Transaction costs for the issuance of convertible redeemable preferred shares
Additions 50,234 7,897 12,410
Disposal  
Payment- financing cash flows (24,069) (13,316) (10,430)
Payment– operating cash flows
Interest paid (602) (290) (427)
Change in fair value
Exchange adjustment (115) (741) 184
Balance at end 30,469 4,313 10,468
Lease liabilities [Member]      
Schedule of Changes in Liabilities Arising from Financing Activities [Line Items]      
Balance at beginning 2,237 2,888 3,635
Interest expense 83 133 160
Conversion into ordinary shares    
Transaction costs for the issuance of convertible redeemable preferred shares
Additions 463
Disposal  
Payment- financing cash flows (1,020) (936) (966)
Payment– operating cash flows
Interest paid (83) (134)
Change in fair value
Exchange adjustment (26) (177) 59
Balance at end 1,191 2,237 2,888
Payable for issue costs [Member]      
Schedule of Changes in Liabilities Arising from Financing Activities [Line Items]      
Balance at beginning
Interest expense
Conversion into ordinary shares    
Transaction costs for the issuance of convertible redeemable preferred shares 758
Additions
Disposal  
Payment- financing cash flows (758)
Payment– operating cash flows
Interest paid
Change in fair value
Exchange adjustment
Balance at end
v3.25.0.1
Notes to the Consolidated Statements of Cash Flows - Schedule of Investment Activities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Schedule of Investment Activities [Line Items]      
purchase $ (31,856) $ (58,980) $ (81,234)
disposal 21,039 88,057 27,465
interest received 62 550 32
Dual Currency Structured Deposit [Member]      
Schedule of Investment Activities [Line Items]      
purchase (14,900) (17,000)
disposal 22,439 9,500
interest received 19 28
Investments at Amortized Cost [Member]      
Schedule of Investment Activities [Line Items]      
purchase (31,849) (17,965)
disposal 17,965
interest received 4
Wealth Management Product [Member]      
Schedule of Investment Activities [Line Items]      
purchase (7) (44,080) (46,269)
disposal 21,039 65,618
interest received $ 62 $ 531
v3.25.0.1
Related Party Transactions (Details) - CNY (¥)
Dec. 31, 2023
Dec. 31, 2022
Related Party Transactions [Abstract]    
Non-revolving facility agreements ¥ 90,000 ¥ 40,000
v3.25.0.1
Related Party Transactions - ​Schedule of Related Parties (Details)
12 Months Ended
Dec. 31, 2023
Mr. Yang Lu [Member]  
Schedule of Related Parties [Line Items]  
Nature of relationship The chief executive officer and chairman of our board of directors and ultimate significant shareholder of the Company
v3.25.0.1
Financial Instruments by Category - Schedule of Categories of Financial Instruments (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Financial assets at fair value through profit or loss, category [member]    
Financial assets at FVTPL:    
Financial assets $ 7 $ 21,287
Financial assets at amortised cost, category [member]    
Financial assets at FVTPL:    
Financial assets 126,319 45,343
Financial assets at amortised cost, category [member] | Financial liabilities at amortised cost, category [member]    
Financial liabilities:    
Financial liabilities 49,595 21,282
Financial assets at amortised cost, category [member] | Financial liabilities at fair value through profit or loss, category [member]    
Financial liabilities:    
Financial liabilities 290,368
Financial liabilities included in other payables and accruals [Member] | Financial assets at amortised cost, category [member] | Financial liabilities at amortised cost, category [member]    
Financial liabilities:    
Financial liabilities 4,890 3,877
Interest-bearing bank and other borrowings [Member] | Financial assets at amortised cost, category [member] | Financial liabilities at amortised cost, category [member]    
Financial liabilities:    
Financial liabilities 30,357 4,307
Financial instruments measured at FVTPL [Member] | Financial assets at amortised cost, category [member] | Financial liabilities at amortised cost, category [member]    
Financial liabilities:    
Financial liabilities 290,368
Dual currency structured deposit [Member] | Financial assets at fair value through profit or loss, category [member]    
Financial assets at FVTPL:    
Financial assets
Wealth management product [Member] | Financial assets at fair value through profit or loss, category [member]    
Financial assets at FVTPL:    
Financial assets 7 21,287
Financial assets included in prepayments, other receivables and other assets [Member] | Financial assets at fair value through profit or loss, category [member]    
Financial assets at FVTPL:    
Financial assets 2,978 2,585
Cash and cash equivalents [Member] | Financial assets at fair value through profit or loss, category [member]    
Financial assets at FVTPL:    
Financial assets 91,492 42,758
Short-term investments at amortized cost. [Member] | Financial assets at fair value through profit or loss, category [member]    
Financial assets at FVTPL:    
Financial assets 7,000
Long-term investments at amortized cost [Member] | Financial assets at fair value through profit or loss, category [member]    
Financial assets at FVTPL:    
Financial assets 24,849
Trade payables [Member] | Financial assets at amortised cost, category [member] | Financial liabilities at amortised cost, category [member]    
Financial liabilities:    
Financial liabilities $ 14,348 $ 13,098
v3.25.0.1
Fair Value and Fair Value Hierarchy of Financial Instruments - Schedule of Carrying Amounts and Fair Values of the Group's Financial Instruments (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Financial assets    
Financial assets, Carrying amount $ 7 $ 21,287
Financial assets, Fair value 7 21,287
Financial liabilities    
Financial liabilities, Carrying amount 290,368
Financial liabilities, Fair value 290,368
Financial liabilities at FVTPL [Member]    
Financial liabilities    
Financial liabilities, Carrying amount 290,368
Financial liabilities, Fair value 290,368
Dual Currency Structured Deposit [Member] | Financial assets at fair value through profit or loss, category [member]    
Financial assets    
Financial assets, Carrying amount
Financial assets, Fair value
Wealth management product [Member] | Financial assets at fair value through profit or loss, category [member]    
Financial assets    
Financial assets, Carrying amount 7 21,287
Financial assets, Fair value $ 7 $ 21,287
v3.25.0.1
Fair Value and Fair Value Hierarchy of Financial Instruments - Schedule of Fair Value Measurement Hierarchy (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Financial assets    
Financial assets $ 7 $ 21,287
Financial liabilities 290,368
Financial liabilities at FVTPL [Member]    
Financial assets    
Financial liabilities   290,368
Level 1 of fair value hierarchy [member]    
Financial assets    
Financial assets 7 21,287
Level 1 of fair value hierarchy [member] | Financial liabilities at FVTPL [Member]    
Financial assets    
Financial liabilities  
Level 2 of fair value hierarchy [member]    
Financial assets    
Financial assets
Level 2 of fair value hierarchy [member] | Financial liabilities at FVTPL [Member]    
Financial assets    
Financial liabilities  
Level 3 of fair value hierarchy [member]    
Financial assets    
Financial assets
Financial liabilities   290,368
Level 3 of fair value hierarchy [member] | Financial liabilities at FVTPL [Member]    
Financial assets    
Financial liabilities   290,368
Dual Currency Structured Deposit [Member] | Financial assets at fair value through profit or loss, category [member]    
Financial assets    
Financial assets
Dual Currency Structured Deposit [Member] | Level 1 of fair value hierarchy [member] | Financial assets at fair value through profit or loss, category [member]    
Financial assets    
Financial assets
Dual Currency Structured Deposit [Member] | Level 2 of fair value hierarchy [member] | Financial assets at fair value through profit or loss, category [member]    
Financial assets    
Financial assets
Dual Currency Structured Deposit [Member] | Level 3 of fair value hierarchy [member] | Financial assets at fair value through profit or loss, category [member]    
Financial assets    
Financial assets
Wealth Management Product [Member] | Financial assets at fair value through profit or loss, category [member]    
Financial assets    
Financial assets 7 21,287
Wealth Management Product [Member] | Level 1 of fair value hierarchy [member] | Financial assets at fair value through profit or loss, category [member]    
Financial assets    
Financial assets 7 21,287
Wealth Management Product [Member] | Level 2 of fair value hierarchy [member] | Financial assets at fair value through profit or loss, category [member]    
Financial assets    
Financial assets
Wealth Management Product [Member] | Level 3 of fair value hierarchy [member] | Financial assets at fair value through profit or loss, category [member]    
Financial assets    
Financial assets
v3.25.0.1
Financial Risk Management Objectives and Policies - Schedule of Exchange Rate (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Schedule of Exchange Rate [Line Items]      
Increase/ (decrease) in net loss - If the $ strengthens against the RMB $ (1,010)
Increase/ (decrease) in net loss - If the $ weakens against the RMB $ 1,116
Currency risk [member]      
Schedule of Exchange Rate [Line Items]      
Increase/(decrease) in $/RMB rate - If the $ strengthens against the RMB 5.00% 5.00% 5.00%
Increase (decrease) in equity - If the $ strengthens against the RMB $ (943) $ (1,939) $ 2,398
Increase/(decrease) in $/RMB rate - If the $ weakens against the RMB (5.00%) (5.00%) (5.00%)
Increase (decrease) in equity - If the $ weakens against the RMB $ 1,042 $ 4,081 $ (2,651)
v3.25.0.1
Financial Risk Management Objectives and Policies - Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total $ 49,595 $ 311,650
Financial Liabilities at FVTPL [Member]    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total  
On demand    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total 19,238 16,975
On demand | Financial Liabilities at FVTPL [Member]    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total  
Less than 1 year    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total 30,357 294,675
Less than 1 year | Financial Liabilities at FVTPL [Member]    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total  
1 to 5 years    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total
1 to 5 years | Financial Liabilities at FVTPL [Member]    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total  
Over 5 years    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total
Over 5 years | Financial Liabilities at FVTPL [Member]    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total  
Financial Liabilities at FVTPL [Member]    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total   290,368
Financial Liabilities at FVTPL [Member] | On demand    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total  
Financial Liabilities at FVTPL [Member] | Less than 1 year    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total   290,368
Financial Liabilities at FVTPL [Member] | 1 to 5 years    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total  
Financial Liabilities at FVTPL [Member] | Over 5 years    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total  
Trade and Bills Payables [Member]    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total 14,348 13,098
Trade and Bills Payables [Member] | On demand    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total 14,348 13,098
Trade and Bills Payables [Member] | Less than 1 year    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total
Trade and Bills Payables [Member] | 1 to 5 years    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total
Trade and Bills Payables [Member] | Over 5 years    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total
Financial Liabilities Included in Other Payables and Accruals [Member]    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total 4,890 3,877
Financial Liabilities Included in Other Payables and Accruals [Member] | On demand    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total 4,890 3,877
Financial Liabilities Included in Other Payables and Accruals [Member] | Less than 1 year    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total
Financial Liabilities Included in Other Payables and Accruals [Member] | 1 to 5 years    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total
Financial Liabilities Included in Other Payables and Accruals [Member] | Over 5 years    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total
Interest-Bearing Bank Borrowings [Member]    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total 30,357 4,307
Interest-Bearing Bank Borrowings [Member] | On demand    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total
Interest-Bearing Bank Borrowings [Member] | Less than 1 year    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total 30,357 4,307
Interest-Bearing Bank Borrowings [Member] | 1 to 5 years    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total
Interest-Bearing Bank Borrowings [Member] | Over 5 years    
Schedule of Financial Liabilities of Each Relevant Periods, Based on the Contractual Undiscounted Payments [Line Items]    
Total
v3.25.0.1
Financial Risk Management Objectives and Policies - Schedule of Asset Liability Ratios (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Schedule of Asset Liability Ratios [Abstract]    
Total assets $ 130,189 $ 72,594
Total liabilities $ 50,786 $ 313,887
Asset-liability ratio [1] 2.56 0.23
[1] The asset-liability ratio is calculated by dividing total assets by total liabilities.
v3.25.0.1
Subsequent Events (Details) - Subsequent Events [Member]
¥ in Thousands, $ in Thousands
1 Months Ended
Feb. 29, 2024
USD ($)
Apr. 30, 2024
CNY (¥)
Mar. 31, 2024
CNY (¥)
Feb. 29, 2024
CNY (¥)
Subsequent Events [Line Items]        
Registered Capital     ¥ 100,000  
Hangzhou Hongxi Business Management Co., Ltd [Member]        
Subsequent Events [Line Items]        
Proceeds from contributed capital     70,000  
Hangzhou Adlai Nortye Biopharma Co., Ltd [Member]        
Subsequent Events [Line Items]        
Repayment of debt   ¥ 30,000 40,000  
Proceeds from contributed capital     20,000  
Hangzhou Adlai Nortye Biopharma Co., Ltd [Member] | Non-Revolving Facility [Member]        
Subsequent Events [Line Items]        
Facility amount     ¥ 60,000 ¥ 20,000
Interest rate 4.00%   3.50% 4.00%
Borrowings, maturity August 2, 2024   November 28, 2024  
Repayment of debt     ¥ 30,000  
Hangzhou Adlai Nortye Biopharma Co., Ltd [Member] | Mr. Yang Lu and Adlai Shanghai [Member] | Non-Revolving Facility [Member]        
Subsequent Events [Line Items]        
Facility amount       ¥ 30,000
Interest rate 4.00%     4.00%
Borrowings, maturity March 4, 2024      
Adlai Nortye USA Inc. [Member] | Non-Revolving Facility [Member]        
Subsequent Events [Line Items]        
Facility amount | $ $ 3,000      
Interest rate 6.57%     6.57%
Borrowings, maturity February 26, 2025      
Hangzhou Tangchuang Weilai Technolegy Co., Ltd [Member]        
Subsequent Events [Line Items]        
Registered capital percentage     30.00%  
v3.25.0.1
Condensed Financial Information of the Parent Company (Details)
12 Months Ended
Dec. 31, 2023
Condensed Financial Information of the Parent Company [Abstract]  
Percentage of Net Assets. 25.00%
v3.25.0.1
Condensed Financial Information of the Parent Company - Schedule of Parent Company Balance Sheets (Details) - Separate [member] - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Current assets        
Cash and cash equivalents $ 63,150 $ 12,194 $ 48,363 $ 19,343
Prepayments, other receivables and other assets 44 36    
short-term investments at amortized cost 7,000    
Total current assets 70,194 12,230    
Non-current assets        
Investment in subsidiaries 129,711 94,300    
Total non-current assets 252,813 210,043    
Total assets 323,007 222,273    
Current liabilities        
Accounts payable 976 888    
Other payables and accruals. 53    
Interest payables 10,650    
Non-current liabilities due within one year      
Financial liabilities at FVTPL 290,368    
Total current liabilities 11,719 291,260    
Non-current liabilities        
Long-term loans    
Financial liabilities at FVTPL    
Total non-current liabilities    
Total liabilities 11,719 291,260    
Additional paid-in capital 438,707 6,415    
Share option reserve 16,059 11,730    
Accumulated deficit (143,489) (98,116)    
Total shareholders’ (deficit)/equity 311,288 (68,987)    
Total liabilities and shareholders’ (deficit)/equity 323,007 222,273    
Related Party [Member]        
Non-current assets        
Due from related parties 123,102 115,743    
Current liabilities        
Due to related parties 40    
Ordinary Shares [Member]        
Non-current liabilities        
Ordinary shares 4    
Class A Ordinary Shares [Member]        
Non-current liabilities        
Ordinary shares 9    
Class B Ordinary Shares [Member]        
Non-current liabilities        
Ordinary shares 2    
Series A Convertible Preferred Shares [Member]        
Non-current liabilities        
Ordinary shares $ 10,980    
v3.25.0.1
Condensed Financial Information of the Parent Company - Schedule of Parent Company Balance Sheets (Parentheticals) (Details) - Separate [member] - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Ordinary Shares [Member]    
Schedule of Parent Company Balance Sheets [Line Items]    
Par value per share (in Dollars per share) $ 0.0001 $ 0.0001
Shares authorized 442,456,586 442,456,586
Shares issued   40,440,000
Shares outstanding   40,440,000
Class A Ordinary Shares [Member]    
Schedule of Parent Company Balance Sheets [Line Items]    
Par value per share (in Dollars per share) $ 0.0001 $ 0.0001
Shares outstanding 93,710,805  
Class B Ordinary Shares [Member]    
Schedule of Parent Company Balance Sheets [Line Items]    
Par value per share (in Dollars per share) $ 0.0001 0.0001
Shares outstanding 16,990,000  
Series A Convertible Preferred Shares [Member]    
Schedule of Parent Company Balance Sheets [Line Items]    
Par value per share (in Dollars per share) $ 0.0001 $ 0.0001
Shares authorized   14,560,000
Shares issued   14,560,000
Shares outstanding   14,560,000
v3.25.0.1
Condensed Financial Information of the Parent Company - Schedule of Parent Company Statements of Income and Comprehensive Income (Details) - Separate [member] - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Condensed Income Statements, Captions [Line Items]      
REVENUE
Other operating income, net 242 156
Administrative expenses (6,196) (1,390) (2,376)
Research and development expenses
Total operating loss (5,954) (1,234) (2,376)
Other income and gains 173
Other expenses
Investment income 3
Fair value loss on financial liabilities at FVTPL (39,171) 7,194 (46,910)
Finance costs (249) (399)
LOSS BEFORE TAX (45,374) 5,960 (49,509)
Income tax expense
LOSS FOR THE YEAR (45,374) 5,960 (49,509)
TOTAL COMPREHENSIVE LOSS FOR THE YEAR $ (45,374) $ 5,960 $ (49,509)
v3.25.0.1
Condensed Financial Information of the Parent Company - Schedule of Parent Company Statements of Cash Flows (Details) - Separate [member] - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Condensed Cash Flow Statements, Captions [Line Items]      
Net cash flows used in operating activities $ (13,143) $ (1,134) $ (1,610)
Net cash flows used in investing activities (38,082) (35,035) (65,798)
Net cash flows from financing activities 102,181 96,428
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS 50,956 (36,169) 29,020
Cash and cash equivalents at beginning of year 12,194 48,363 19,343
CASH AND CASH EQUIVALENTS AT END OF YEAR $ 63,150 $ 12,194 $ 48,363

Adlai Nortye (NASDAQ:ANL)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Adlai Nortye.
Adlai Nortye (NASDAQ:ANL)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Adlai Nortye.